10-Q

UNITED STATESSECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

Or

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                 to                

Commission file number: 001-36048

ENVISION HEALTHCARE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	45-0832318
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification Number)

6200 S. Syracuse Way, Suite 200
Greenwood Village, CO	80111
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 303-495-1200

Former name, former address and former fiscal year, if changed since last report:

Not applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o
Non-accelerated filer x	Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date:

At November 3, 2014, the registrant had 183,524,958 shares of common stock, par value $0.01 per share, outstanding.

ENVISION HEALTHCARE HOLDINGS, INC.

TABLE OF CONTENTS

		Page Number
	PART I — FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (unaudited):
	Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013	3
	Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2014 and 2013	4
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013	5
	Notes to Unaudited Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	49
Item 4.	Controls and Procedures	50
	PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	50
Item 1A.	Risk Factors	50
Item 5.	Other Information	73
Item 6.	Exhibits	73
Signatures		74

1

ENVISION HEALTHCARE HOLDINGS, INC.

EXPLANATORY NOTE

Unless the context indicates otherwise, any reference in this report to “EVHC,” “the “Company,” “we,” “our,” or “us” refer to Envision Healthcare Holdings, Inc. and its direct and indirect subsidiaries.

2

ENVISION HEALTHCARE HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	September 30, 2014			December 31,2013
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	247,170		$	204,712
Insurance collateral	27,899			29,619
Trade and other accounts receivable, net	913,413			801,146
Parts and supplies inventory	23,983			23,376
Prepaids and other current assets	51,950			23,430
Total current assets	1,264,415			1,082,283
Non-current assets:
Property, plant and equipment, net	203,405			194,715
Intangible assets, net	543,226			513,698
Insurance collateral	8,663			12,716
Goodwill	2,536,156			2,435,670
Other long-term assets	38,629			60,935
Total assets	$	4,594,494		$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable	$	52,072		$	52,588
Accrued liabilities	413,685			350,936
Current deferred tax liabilities	36,383			35,487
Current portion of long-term debt and capital lease obligations	12,235			12,318
Total current liabilities	514,375			451,329
Long-term debt and capital lease obligations	2,029,095			1,895,381
Long-term deferred tax liabilities	151,225			151,130
Insurance reserves	167,628			175,427
Other long-term liabilities	16,707			16,997
Total liabilities	2,879,030			2,690,264
Commitments and contingencies
Equity:
Common stock ($0.01 par value; 2,000,000,000 shares authorized, 183,381,792 and 180,382,885 issued and outstanding as of September 30, 2014 and December 31, 2013, respectively)	1,834			1,804
Preferred stock ($0.01 par value; 200,000,000 shares authorized, none issued and outstanding as of September 30, 2014 and December 31, 2013)	—			—
Additional paid-in capital	1,609,244			1,575,417
Retained earnings	93,950			18,341
Accumulated other comprehensive income (loss)	(1,611		)	(839		)
Total Envision Healthcare Holdings, Inc. equity	1,703,417			1,594,723
Noncontrolling interest	12,047			15,030
Total equity	1,715,464			1,609,753
Total liabilities and equity	$	4,594,494		$	4,300,017

The accompanying notes are an integral part of these financial statements.

3

ENVISION HEALTHCARE HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except share and per share amounts, unaudited)

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Revenue, net of contractual discounts	$	1,989,957		$	1,691,208		$	5,802,153		$	4,986,261
Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue	1,150,329			955,888			3,239,867			2,743,467
Compensation and benefits	819,353			677,797			2,330,021			1,963,546
Operating expenses	129,535			110,387			364,885			313,145
Insurance expense	27,527			26,974			90,091			78,647
Selling, general and administrative expenses	22,851			40,733			65,820			86,521
Depreciation and amortization expense	36,796			35,175			108,786			104,552
Restructuring charges	366			1,319			4,906			4,988
Income from operations	113,901			63,503			275,358			192,068
Interest income from restricted assets	175			2			507			634
Interest expense, net	(25,742		)	(46,772		)	(84,793		)	(148,526		)
Realized gains (losses) on investments	(466		)	158			648			276
Other income (expense), net	(660		)	(52		)	(3,432		)	(13,022		)
Loss on early debt extinguishment	—			(29,519		)	(66,397		)	(29,641		)
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208			(12,680		)	121,891			1,789
Income tax benefit (expense)	(34,437		)	4,949			(49,700		)	(3,932		)
Income (loss) before equity in earnings of unconsolidated subsidiary	52,771			(7,731		)	72,191			(2,143		)
Equity in earnings of unconsolidated subsidiary	72			68			185			230
Net income (loss)	52,843			(7,663		)	72,376			(1,913		)
Less: Net (income) loss attributable to noncontrolling interest	(67		)	—			3,233			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776		$	(7,663	)	$	75,609		$	(1,913	)
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic	$	0.29		$	(0.05	)	$	0.42		$	(0.01	)
Diluted	$	0.28		$	(0.05	)	$	0.40		$	(0.01	)
Weighted-average common shares outstanding:
Basic	182,564,837			157,282,885			181,502,232			139,969,940
Diluted	190,184,323			157,282,885			189,707,609			139,969,940
Comprehensive income (loss):
Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
Other comprehensive income (loss), net of tax:
Unrealized holding gains (losses) during the period	(310		)	(133		)	(1,012		)	(582		)
Unrealized gains (losses) on derivative financial instruments	(74		)	236			240			(42		)
Total other comprehensive income (loss), net of tax	(384		)	103			(772		)	(624		)
Comprehensive income (loss)	52,459			(7,560		)	71,604			(2,537		)
Less: Comprehensive (income) loss attributable to noncontrolling interest	(67		)	—			3,233			—
Comprehensive income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,392		$	(7,560	)	$	74,837		$	(2,537	)

The accompanying notes are an integral part of these financial statements.

4

ENVISION HEALTHCARE HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, unaudited)

	Nine months endedSeptember 30,
	2014			2013
Cash Flows from Operating Activities
Net income (loss)	$	72,376		$	(1,913	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	116,133			118,683
(Gain) loss on disposal of property, plant and equipment	(2,094		)	(55		)
Equity-based compensation expense	3,612			3,186
Excess tax benefits from equity-based compensation	(38,520		)	(3,168		)
Loss on early debt extinguishment	66,397			29,641
Equity in earnings of unconsolidated subsidiary	(185		)	(230		)
Dividends received	430			556
Deferred income taxes	1,456			4,319
Payment of dissenting shareholder settlement	—			(13,717		)
Changes in operating assets/liabilities, net of acquisitions:
Trade and other accounts receivable, net	(92,537		)	(126,506		)
Parts and supplies inventory	(574		)	(489		)
Prepaids and other current assets	(10,959		)	(8,997		)
Accounts payable and accrued liabilities	85,008			22,520
Insurance accruals	(6,539		)	1,795
Net cash provided by (used in) operating activities	194,004			25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities	(52,654		)	(2,615		)
Sales and maturities of available-for-sale securities	40,425			7,616
Purchases of property, plant and equipment	(55,659		)	(45,493		)
Proceeds from sale of property, plant and equipment	2,299			396
Acquisition of businesses, net of cash received	(199,261		)	(27,358		)
Net change in insurance collateral	2,021			(2,121		)
Other investing activities	(1,774		)	(456		)
Net cash provided by (used in) investing activities	(264,603		)	(70,031		)
Cash Flows from Financing Activities
Issuance of common stock	—			1,112,017
Borrowings under the Term Loan	—			150,000
Borrowings under the ABL Facility	50,000			345,440
Proceeds from issuance of senior notes	740,625			—
Repayments of the Term Loan	(6,686		)	(10,028		)
Repayments of the ABL Facility	(50,000		)	(470,440		)
Repayments of PIK Notes and senior notes	(607,750		)	(450,000		)
Payment for debt extinguishment premiums	(37,630		)	(12,386		)
Debt issuance costs	(2,221		)	(5,011		)
Equity issuance costs	—			(63,420		)
Proceeds from stock options exercised	7,405			—
Excess tax benefits from equity-based compensation	38,520			3,168
Shares repurchased for tax withholdings	(14,430		)	—
Proceeds from noncontrolling interest	250			—
Payment of dissenting shareholder settlement	—			(38,336		)
Net change in bank overdrafts	—			1,686
Other financing activities	(5,026		)	(355		)
Net cash provided by (used in) financing activities	113,057			562,335
Change in cash and cash equivalents	42,458			517,929
Cash and cash equivalents, beginning of period	204,712			57,832
Cash and cash equivalents, end of period	$	247,170		$	575,761

The accompanying notes are an integral part of these financial statements.

5

1.General

Basis of Presentation of Financial Statements

Envision Healthcare Holdings, Inc., formerly known as CDRT Holding Corporation, is organized as a holding company that operates through various subsidiaries.  Envision Healthcare Corporation, formerly known as Emergency Medical Services Corporation, (“Corporation”) is a wholly-owned subsidiary of the Company.

The accompanying interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) to reflect the consolidated financial position, results of operations and cash flows of the Company for interim reporting, and accordingly, do not include all of the disclosures required for annual financial statements.

In the opinion of management, the consolidated financial statements of the Company include all normal recurring adjustments necessary for a fair presentation of the periods presented. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.  For further information on the Company’s significant accounting policies and other information, see the Company’s consolidated financial statements, including the accounting policies and notes thereto for the year ended December 31, 2013, which includes all disclosures required by GAAP, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

On July 29, 2013, the Company effected a 9.3 for 1.0 stock split of its common stock, resulting in 132,082,885 shares of common stock issued, not including 504,197 treasury shares. The accompanying consolidated financial statements give retroactive effect to the stock split for all periods presented.

On August 13, 2013, the Company’s registration statement (the “Registration Statement”) for an initial public offering of its common stock, par value $0.01 per share (“Common Stock”) was declared effective.  On February 5, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $30.50 per share.  On July 10, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $34.00 per share.  On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company.  The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices.  See Note 2 for further information on the Company’s public offerings and its equity.

The Company’s business is conducted primarily through two operating subsidiaries, EmCare Holdings, Inc. (“EmCare”), its facility-based and post-acute care physician services segment, and American Medical Response, Inc. (“AMR”), its healthcare transportation services segment.

2.Summary of Significant Accounting Policies

Consolidation

The consolidated financial statements of the Company include all of its wholly-owned subsidiaries, including Corporation, EmCare and AMR and their respective subsidiaries and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

Insurance Collateral

Insurance collateral is comprised of investments in U.S. Treasuries and marketable equity and debt securities held by the Company’s captive insurance subsidiary that supports the Company’s insurance program and reserves, as well as cash deposits with third parties. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. These investments are designated as available-for-sale and reported at fair value with the related temporary unrealized gains and losses reported as a separate component of accumulated other comprehensive income, net of deferred income tax. Declines in the fair value of a marketable investment security which are determined to be other-than-temporary are recognized in the statements of operations, thus establishing a new cost basis for such investment. Investment income earned on these investments is reported as interest income from restricted assets in the statements of operations.

6

Realized gains and losses are determined based on an average cost basis.

Insurance collateral also includes a receivable from insurers of $1.8 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively, for liabilities in excess of the Company’s self-insured retention.

Trade and Other Accounts Receivable, net

The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee-for-service charges as of December 31, 2013 was equal to approximately 87% and 89% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014			December 31, 2013
Gross trade accounts receivable	$	4,691,710		$	3,841,672
Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
Trade accounts receivable, net	913,385			800,135
Other receivables, net	28			1,011
Trade and other accounts receivable, net	$	913,413		$	801,146

Other receivables primarily represent employee advances and other miscellaneous receivables.

Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. The Company continuously compares actual cash collected on a date of service basis to the revenue recorded for that period and records any  adjustment necessary for an overage or deficit in these allowances based on actual collections.

AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated based on historical write-off experience.

Business Combinations

Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

7

Insurance Reserves

Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first one million dollars to three million dollars of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims are discounted at a rate of 1.5%.

The Company’s most recent actuarial valuation was completed in September 2014. As a result of this and previous actuarial valuations, the Company recorded a decrease in its provision for insurance liabilities of $0.7 million and an increase in its provision for insurance liabilities of $6.6 million during the three and nine months ended September 30, 2014, respectively, as compared to increases of $1.6 million and $1.2 million for the three and nine months ended September 30, 2013, related to reserves for losses in prior years.

The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively.

Equity Structure and Public Offerings

On August 13, 2013, the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “SEC”) for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 per share, for an aggregate offering price of $1,110.9 million, and the offering terminated. At the closing, the Company received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with the Company (“Consulting Agreement”) which was recorded in the third quarter of 2013 to selling, general and administrative expenses in the statements of operations (see Note 13).

Net proceeds from the initial public offering were used to (i) redeem in full the Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million of aggregate principal amount of the senior unsecured notes due 2019 and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

On February 5, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by investment funds sponsored by, or affiliated with, CD&R (the “CD&R Affiliates”) to the underwriters pursuant to their option to purchase additional shares at $30.50 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

On July 10, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by the CD&R Affiliates to the underwriters pursuant to their option to purchase additional shares at $34.00 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

8

On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company.  The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices.  The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders.

Financial Instruments and Concentration of Credit Risk

The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, long-term debt and other long-term liabilities constitute financial instruments. Based on management’s estimates, the carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value as of September 30, 2014 and December 31, 2013. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2014 and 2013, the Company derived approximately 31% and 28%, respectively, of its revenue from Medicare and Medicaid, 66% and 68%, respectively, from insurance providers and contracted payors, and 3% and 4%, respectively, directly from patients.

The Company estimates the fair value of its fixed rate senior notes based on an analysis in which the Company evaluates market conditions, related securities, various public and private offerings, and other publicly available information (Level 2, as defined below). The estimated fair value of the senior notes as of September 30, 2014 was approximately $738.8 million with a carrying amount of $750.0 million.

Fair Value Measurement

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include corporate bonds and derivatives.

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

9

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	24,998	$	—	$	—	$	24,998
Liabilities:
Contingent consideration	—		—		2,000		2,000
Fuel hedge	—		22		—		22
Interest rate swap	—		1,991		—		1,991

	December 31, 2013
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	12,710	$	517	$	—	$	13,227
Fuel hedge	—		672		—		672
Liabilities:
Contingent consideration	—		—		7,734		7,734
Interest rate swap	—		3,135		—		3,135

The contingent consideration balance classified as a Level 3 liability has decreased by $5.7 million since December 31, 2013 primarily due to payments made, offset by an increase of $2.0 million from recent acquisitions.

During the nine months ended September 30, 2014 and 2013, there were no transfers in and out of Level 1 and Level 2 fair value measurements.

Revenue Recognition

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies at EmCare and fees for stand-by services, special event services and community subsidies at AMR.

The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within its care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

The Company has historically reported Medicare and Medicaid managed care in the line “Commercial insurance and managed care”. Medicare managed care and Medicaid managed care have been reclassified into the Medicare and Medicaid lines in the current period and all prior periods have been conformed to current period presentation.  Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

10

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Fee-for-service revenue, net of contractual discounts:
Medicare	$	265,300		$	231,517		$	816,040		$	732,153
Medicaid	70,343			52,089			236,784			196,952
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
Self-pay	728,598			644,141			2,205,326			1,961,170
Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
Subsidies and fees	189,116			171,481			554,653			446,679
Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate decreased the contractual discount and uncompensated care provisions (increased net revenue) by approximately $1.1 million for the three months ended September 30, 2014 and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $2.7 million for the nine months ended September 30, 2014, and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $1.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards.  ASU 2014-09 is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period.  Early application is not permitted.  The Company has not yet determined the effects, if any, that adoption of ASU 2014-09 may have on its consolidated financial position or results of operations.

3.Basic and Diluted Net Income (Loss) Per Share

The Company presents both basic earnings per share (“EPS”) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing “Net income (loss) attributable to Envision Healthcare Holdings, Inc.” by the “Weighted-average common shares outstanding” for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised. The potential dilution from stock awards was computed using the treasury stock method based on the average market value of the Company’s common stock. The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation (in thousands, except share and per share amounts).

11

	Three months endedSeptember 30,					Nine months endedSeptember 30,
	2014		2013			2014		2013
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776	$	(7,663	)	$	75,609	$	(1,913	)
Weighted-average common shares outstanding — common stock:
Basic	182,564,837		157,282,885			181,502,232		139,969,940
Dilutive impact of stock awards outstanding	7,619,486		—			8,205,377		—
Diluted	190,184,323		157,282,885			189,707,609		139,969,940
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic	$	0.29	$	(0.05	)	$	0.42	$	(0.01	)
Diluted	$	0.28	$	(0.05	)	$	0.40	$	(0.01	)

The Company had a net loss for the three and nine months ended September 30, 2013; therefore, the effect of stock awards to purchase common stock of 6,088,252 and 8,663,107, respectively, is excluded from the computations of diluted loss per share since the effect is anti-dilutive. As of September 30, 2014 and 2013, there were no stock awards of common stock outstanding excluded from the weighted-average common shares outstanding above.

4.Acquisitions

2014 Acquisitions

Phoenix Physicians, LLC (“Phoenix Physicians”). On June 17, 2014, the Company acquired the stock of Phoenix Physicians for a total purchase price of $169.5 million paid in cash (the “Phoenix Physicians Acquisition”).  Phoenix Physicians, in part through management services agreements with professional entities, is engaged in providing medical practices support and emergency department management and staffing services to hospitals, physicians and healthcare facilities in Florida. The Company has accounted for the acquisition of Phoenix Physicians using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. All of the goodwill is tax deductible and assigned to the EmCare segment.

The allocation of the purchase price is in the table below, which is subject to adjustment based upon the completion of purchase price allocations (in thousands):

Cash	$	7,052
Accounts receivable	16,748
Prepaid and other current assets	17,268
Property, plant, and equipment	92
Acquired intangible assets	56,000
Goodwill	98,402
Accounts payable	(1,073		)
Accrued liabilities	(11,039		)
Insurance reserves	(14,000		)
Total purchase price	$	169,450

During the three months ended September 30, 2014, the Company made a purchase price allocation adjustment that increased goodwill and other current assets by $1.6 million and $16.9 million, respectively, with a corresponding increase to accrued liabilities and insurance reserves of $4.5 million and $14.0 million, respectively, to record the transfer of risk of the malpractice claims liability.

The following unaudited pro forma operating results give effect to the Phoenix Physicians Acquisition, as if it had been completed as of January 1, 2013. These pro forma amounts are not necessarily indicative of the operating results that would have occurred if these transactions had occurred on such date. The pro forma adjustments are based on certain assumptions that the Company believes are reasonable.

12

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
	(in thousands)
Net revenue	$	34,076	$	28,647	$	98,346	$	84,576
Net income	1,833		733		3,943		1,714

The Company’s statements of operations for the three months and nine months ended September 30, 2014 include net revenue of $34.1 million and $37.6 million, respectively, and net income of $1.8 million and $2.1 million, respectively, attributable to Phoenix Physicians.

Other 2014 Acquisitions. The Company completed the acquisitions of Life Line Ambulance Service, Inc., an emergency medical transportation service provider with operations in Arizona, on February 6, 2014, MedStat EMS, Inc., an emergency and non-emergency medical ground transportation service provider with operations in Mississippi, on March 7, 2014, and Streamlined Medical Solutions, LLC, a healthcare technology company which has developed proprietary software to enhance patient direct admission and referral management processes, on May 21, 2014 for total aggregate purchase consideration of approximately $38.0 million paid in cash.

The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $12.1 million. The total purchase price for these acquisitions was allocated to goodwill of $7.1 million, $6.9 million of which is tax deductible goodwill, other acquired intangible assets of $27.1 million, and net current assets of $3.8 million, which are subject to adjustment based upon the completion of purchase price allocations.

2013 Acquisitions

During the year ended December 31, 2013, indirect, wholly-owned subsidiaries of the Company completed the acquisitions of CMORx, LLC and Loya Medical Services, PLLC, which provide clinical management software, each of T.M.S. Management Group, Inc. and Transportation Management Services of Brevard, Inc. (collectively, “TMS”), two related corporations that leverage the provision of non-emergency medical transportation services by third-party transportation service providers, Jackson Emergency Consultants, which provides facility based physician staffing in northern Florida, and other smaller acquisitions for a combined purchase price of $34.2 million paid in cash.

The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $5.4 million. The total purchase price for these acquisitions was allocated to goodwill of $20.8 million, all of which is tax deductible goodwill, other acquired intangible assets of $14.9 million, and net current liabilities of $1.5 million. The allocation of purchase price for the 2013 acquisitions is subject to adjustment based upon the completion of purchase price allocations, except for the allocation of the TMS purchase price which is complete as of September 30, 2014.

5.Insurance Collateral

Insurance collateral consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Available-for-sale securities:
U.S. Treasuries	$	1,198	$	2,100
Corporate bonds /Fixed income	8,426		6,372
Corporate equity	15,374		4,755
Total available-for-sale securities	24,998		13,227
Insurance receivable	1,796		1,300
Cash deposits and other	9,768		27,808
Total insurance collateral	$	36,562	$	42,335

13

Amortized cost basis and aggregate fair value of the Company’s available-for-sale securities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	1,191	$	10	$	(3	)	$	1,198
Corporate bonds /Fixed income	8,439		3		(16		)	8,426
Corporate equity	15,982		—		(608		)	15,374
Total available-for-sale securities	$	25,612	$	13	$	(627	)	$	24,998

	December 31, 2013
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	2,064	$	37	$	(1	)	$	2,100
Corporate bonds /Fixed income	6,384		26		(38		)	6,372
Corporate equity	4,399		500		(144		)	4,755
Total available-for-sale securities	$	12,847	$	563	$	(183	)	$	13,227

As of September 30, 2014, available-for-sale securities included U.S. Treasuries and corporate bonds /fixed income securities of $1.7 million with contractual maturities within one year, $7.4 million with contractual maturities extending longer than one year through five years and $0.5 million with contractual maturities extending longer than five years through and including ten years. Actual maturities may differ from contractual maturities as a result of the Company’s ability to sell these securities prior to maturity.

The Company’s temporarily impaired investment securities available-for-sale as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014					December 31, 2013
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
U.S. Treasuries:
Less than 12 months	$	—	$	—		$	132	$	(1	)
12 months or more	132		(3		)	—		—
Corporate bonds /Fixed income:
Less than 12 months	6,531		(13		)	2,768		(18		)
12 months or more	1,335		(3		)	2,178		(20		)
Corporate equity:
Less than 12 months	15,374		(608		)	—		—
12 months or more	—		—			2,553		(144		)
Total	$	23,372	$	(627	)	$	7,631	$	(183	)

The Company evaluates the investment securities available-for-sale on a quarterly basis to determine whether declines in the fair value of these securities are other-than-temporary.  This quarterly evaluation consists of reviewing the fair value of the security compared to the carrying amount, the historical volatility of the price of each security, and any industry and company specific factors related to each security.

The Company is not aware of any specific factors indicating that the underlying issuers of the U.S. Treasuries and corporate bonds /fixed income securities would not be able to pay interest as it becomes due or repay the principal amount at maturity.  Therefore, the Company believes that the changes in the estimated fair values of these debt securities are related to temporary market fluctuations.  Additionally, the Company is not aware of any specific factors which indicate the unrealized losses on the investments in corporate equity securities are due to anything other than temporary market fluctuations.

The Company realized net losses of $0.5 million and net gains of $0.6 million on the sale and maturities of available-for-sale securities for the three and nine months ended September 30, 2014, respectively, and net gains of $0.2 million and $0.3 million on the sale and maturities of available-for-sale securities for both the three and nine months ended September 30, 2013, respectively.

14

6.Accrued Liabilities

Accrued liabilities were as follows as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Accrued wages and benefits	$	186,983	$	161,398
Accrued paid time-off	30,115		25,713
Current portion of self-insurance reserves	73,719		73,738
Accrued restructuring	6,200		5,682
Current portion of compliance and legal	3,928		2,000
Accrued billing and collection fees	3,057		2,954
Accrued incentive compensation	33,297		19,570
Accrued income taxes	8,015		—
Accrued interest	12,812		6,898
Other	55,559		52,983
Total accrued liabilities	$	413,685	$	350,936

7.Debt and Capital Lease Obligations

Senior Unsecured Notes due 2019

On May 25, 2011, Corporation issued $950 million of senior unsecured notes due 2019 (“2019 Notes”). During the second quarter of 2012, the Company’s captive insurance subsidiary purchased $15.0 million of the 2019 Notes through an open market transaction and currently holds none of the 2019 Notes subsequent to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014.

On December 30, 2013, the Company redeemed $332.5 million in aggregate principal amount of the 2019 Notes of which $5.2 million was held by the Company’s captive insurance subsidiary at a redemption price of 108.125%, plus accrued and unpaid interest of $2.2 million. During the fourth quarter of 2013, the Company recorded a loss on early debt extinguishment of $38.7 million related to premiums and unamortized debt issuance costs from the partial redemption of the 2019 Notes.

On June 18, 2014, the Company redeemed $617.5 million in aggregate principal amount of the 2019 Notes of which $9.8 million was held by the Company’s captive insurance subsidiary at a redemption price of 106.094%, plus accrued and unpaid interest of $2.4 million. During the second quarter of 2014, the Company recorded a loss on early debt extinguishment of $66.4 million related to premiums, financing fees paid to the creditors of the unsecured senior notes due 2022, and unamortized debt issuance costs from the redemption of the 2019 Notes.

Senior Secured Credit Facilities

On May 25, 2011, Corporation entered into $1.8 billion of senior secured credit facilities (“Senior Secured Credit Facilities”) that consisted of a $1.44 billion senior secured term loan facility due 2018 (the “Term Loan Facility”) and a $350 million asset-backed revolving credit facility due 2016 (the “ABL Facility”). The Senior Secured Credit Facilities are secured by substantially all of the assets of the Company.

Term Loan Facility

Prior to February 7, 2013, loans under the Term Loan Facility bore interest at the Company’s election at a rate equal to (i) the highest of (x) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“Term Loan LIBOR”) and (y) 1.50%, plus, in each case, 3.75%, or (ii) the base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month Term Loan LIBOR (adjusted for maximum reserves) plus 1.00% per annum and (x) 2.50%, plus, in each case, 2.75%.

On February 7, 2013, Corporation, the borrower under the Term Loan Facility, entered into a First Amendment (the “Term Loan Amendment”) to the credit agreement governing the Term Loan Facility (as amended, the “Term Loan Credit Agreement”). Under the Term Loan Amendment, the Company incurred an additional $150 million in incremental borrowings under the Term Loan Facility, the proceeds of which were used to pay down the ABL Facility. In addition, the rate at which the loans under the Term Loan Credit Agreement bear interest was amended to equal (i) the higher of (x) the rate for deposits in U.S. dollars in the London Interbank Market (adjusted for maximum reserves) for the applicable interest period (“LIBOR”) and (y) 1.00%, plus, in each case, 3.00% (with a step-down to 2.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00), or (ii) the alternate base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% and (z) 2.00%, plus, in each case, 2.00% (with a step-down to 1.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00). The Company recorded a loss on early debt extinguishment of $0.1 million related to unamortized debt issuance costs as a result of this modification.

15

The credit agreement governing the Term Loan Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on the incurrence of debt, liens, fundamental changes, restrictions on subsidiary distributions, transactions with affiliates, further negative pledge, asset sales, restricted payments, investments and acquisitions, repayment of certain junior debt (including the senior notes) or amendments of junior debt documents related thereto and line of business. The negative covenants are subject to the customary exceptions.

ABL Facility

Prior to February 27, 2013, loans under the ABL Facility bore interest at the Company’s election at a rate equal to (i) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“ABL LIBOR”), plus an applicable margin that ranges from 2.25% to 2.75% based on the average available loan commitments, or (ii) the base rate, which is the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) the overnight federal funds rate plus 0.5% and (z) the one-month ABL LIBOR plus 1.0% per annum, plus, in each case, an applicable margin that ranges from 1.25% to 1.75% based on the average available loan commitments.

On February 27, 2013, Corporation entered into a First Amendment (the “ABL Amendment”) to the credit agreement governing the ABL Facility (as amended, the “ABL Credit Agreement”), under which the Company increased its commitments under the ABL Facility to $450 million and extended the term to 2018. In addition, the rate at which the loans under the ABL Credit Agreement bear interest was amended to equal (i) LIBOR plus, (x) 2.00% in the event that average daily excess availability is less than or equal to 33% of availability, (y) 1.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (z) 1.50% in the event that average daily excess availability is greater than 66% of availability, or (ii) the alternate base rate, which will be the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) 0.50% in excess of the overnight federal funds rate and (z) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% plus, in each case, (A) 1.00% in the event that average daily excess availability is less than or equal to 33% of availability, (B) 0.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (C) 0.50% in the event that average daily excess availability is greater than 66% of availability.

The ABL Facility bears a commitment fee that ranges from 0.500% to 0.375%, payable quarterly in arrears, based on the utilization of the ABL Facility. The ABL Facility also bears customary letter of credit fees.

As of September 30, 2014, letters of credit outstanding which impact the available credit under the ABL Facility were $130.2 million and the maximum available under the ABL Facility was $319.8 million.

The credit agreement governing the ABL Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on indebtedness, dividends and distributions, investments, acquisitions, prepayments or redemptions of junior indebtedness, amendments of junior indebtedness, transactions with affiliates, asset sales, mergers, consolidations and sales of all or substantially all assets, liens, negative pledge clauses, changes in fiscal periods, changes in line of business and hedging transactions. The negative covenants are subject to the customary exceptions and also permit the payment of dividends and distributions, investments, permitted acquisitions and payments or redemptions of junior indebtedness upon satisfaction of a “payment condition.” The payment condition is deemed satisfied upon 30-day average excess availability exceeding agreed upon thresholds and, in certain cases, the absence of specified events of default and compliance with a fixed charge coverage ratio of 1.0 to 1.0.

In the second quarter of 2013, the Company recorded $5.0 million of debt issuance expense related to the Term Loan Amendment and ABL Amendment.

16

Senior PIK Toggle Notes

On October 1, 2012, the Company issued $450 million of Senior PIK Toggle Notes due 2017 (the “PIK Notes”) and used the proceeds from the offering to pay an extraordinary dividend to its stockholders, pay debt issuance costs and make certain payments to members of management with rollover options in the Company.

On August 30, 2013, the Company redeemed all of the PIK Notes at a redemption price equal to 102.75% of the aggregate principal amount of the PIK Notes, plus accrued and unpaid interest of $17.2 million. During the third quarter of 2013, the Company recorded a loss on early debt extinguishment of $29.5 million related to premiums and unamortized debt issuance costs from the redemption of the PIK Notes.

Senior Unsecured Notes due 2022

On June 18, 2014, Corporation issued $750.0 million of senior unsecured notes due 2022 (“2022 Notes”) the proceeds of which were used to redeem the 2019 Notes and for other general corporate purposes. The Company paid $9.4 million in financing fees to the creditors of the 2022 Notes which was recorded to loss on early debt extinguishment in the second quarter of 2014.

The 2022 Notes have a fixed interest rate of 5.125%, payable semi-annually on January 1 and July 1 with the principal due at maturity on July 1, 2022. The 2022 Notes are general unsecured obligations of the Company and are guaranteed by each of the Company’s domestic subsidiaries, except for any of the Company’s subsidiaries subject to regulation as an insurance company, including the Company’s captive insurance subsidiary.

The Company may redeem the 2022 Notes, in whole or in part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus the applicable make-whole premium. The Company may redeem the 2022 Notes, in whole or in part, at any time (i) on and after July 1, 2017 and prior to July 1, 2018, at a price equal to 103.844% of the principal amount of the 2022 Notes, (ii) on or after July 1, 2018 and prior to July 1, 2019, at a price equal to 102.563% of the principal amount of the 2022 Notes, (iii) on or after July 1, 2019 and prior to July 1, 2020, at a price equal to 101.281% of the principal amount of the 2022 Notes, and (iv) on or after July 1, 2020, at a price equal to 100.000% of the principal amount of the 2022 Notes, in each case, plus accrued and unpaid interest, if any, to the redemption date. In addition, at any time prior to July 1, 2017, the Company at its option may redeem up to 40% of the aggregate principal amount of the 2022 Notes with the proceeds of certain equity offerings at a redemption price of 105.125%, plus accrued and unpaid interest, if any, to the applicable redemption date.

The indenture governing the 2022 Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: incur additional indebtedness or issue certain preferred shares; pay dividends on, redeem or repurchase stock or make other distributions in respect of its capital stock; repurchase, prepay or redeem subordinated indebtedness; make investments; create restrictions on the ability of the Company’s restricted subsidiaries to pay dividends to the Company or make other intercompany transfers; create liens; transfer or sell assets; consolidate, merge or sell or otherwise dispose of all or substantially all of its assets; enter into certain transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries. Upon the occurrence of certain events constituting a change of control, the Company is required to make an offer to repurchase all of the 2022 Notes (unless otherwise redeemed) at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any to the repurchase date. If the Company sells assets under certain circumstances, it must use the proceeds to make an offer to purchase the 2022 Notes at a price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to the date of purchase.

Debt and capital lease obligations consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,2014			December 31,2013
Senior unsecured notes due 2019	$	—		$	607,750
Senior unsecured notes due 2022	750,000			—
Senior secured term loan due 2018 (4.00% at September 30, 2014 and December 31, 2013)	1,292,917			1,302,945
Discount on senior secured term loan	(3,567		)	(4,217		)
ABL Facility	—			—
Notes due at various dates from 2014 to 2022 with interest rates from 6% to 10%	731			852
Capital lease obligations due at various dates from 2014 to 2018	1,249			369
Total	2,041,330			1,907,699
Less current portion	(12,235		)	(12,318		)
Total long-term debt and capital lease obligations	$	2,029,095		$	1,895,381

17

8.Derivative Instruments and Hedging Activities

The Company manages its exposure to changes in fuel prices and interest rates and, from time to time, uses highly effective derivative instruments to manage well-defined risk exposures. The Company monitors its positions and the credit ratings of its counterparties and does not anticipate non-performance by the counterparties. The Company does not use derivative instruments for speculative purposes.

At September 30, 2014, the Company was party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.63 to $3.76 per gallon. The Company purchases the diesel fuel at the market rate and periodically settles with its counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 0.6 million gallons, which represents approximately 25.2% of the Company’s total estimated usage during the periods hedged, through December 2014. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability and an asset associated with the fair value of the fuel hedge in the amount of less than $0.1 million and $0.7 million, respectively, as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify less than $0.1 million of deferred loss from accumulated other comprehensive income as the related fuel hedge transactions mature. Settlement of hedge agreements are included in operating expenses and resulted in net receipts from the counterparty of $0.1 million for each of the three months ended September 30, 2014 and 2013, respectively, and $0.4 million for each of the nine months ended September 30, 2014 and 2013, respectively.

In October 2011, the Company entered into interest rate swap agreements which mature on August 31, 2015. The swap agreements are with major financial institutions and effectively convert a total of $400 million in variable rate debt to fixed rate debt with an effective rate of 4.49%. The Company will continue to make interest payments based on the variable rate associated with the debt (based on LIBOR, but not less than 1.0%) and will periodically settle with its counterparties for the difference between the rate paid and the fixed rate. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability associated with the fair value of the interest rate swap in the amount of $2.0 million and $3.1 million as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify $2.0 million of deferred loss from accumulated other comprehensive income to interest expense as the related interest rate swap transactions mature. Settlement of interest rate swap agreements are included in interest expense and resulted in net payments to the counterparties of $0.5 million for each of the three months ended September 30, 2014 and 2013, respectively, and $1.5 million for each of the nine months ended September 30, 2014 and 2013, respectively.

9.Changes in Accumulated Other Comprehensive Income (Loss) by Component

The following table summarizes the changes in the Company’s accumulated other comprehensive income (loss) (“AOCI”) by component as of September 30, 2014 and December 31, 2013 (in thousands).  All amounts are after tax.

	Fuel hedge			Interest rate swap			Unrealized holding gains on available-for-sale securities			Total
Balance as of January 1, 2013	$	1,057		$	(2,861	)	$	1,591		(213		)
Other comprehensive income (loss) before reclassifications	(396		)	(336		)	(598		)	(1,330		)
Amounts reclassified from accumulated other comprehensive income (loss)	(241		)	1,239			(294		)	704
Net current-period other comprehensive income (loss)	(637		)	903			(892		)	(626		)
Balance as of December 31, 2013	$	420		$	(1,958	)	$	699		$	(839	)
Other comprehensive income (loss) before reclassifications	(501		)	38			(608		)	(1,071		)
Amounts reclassified from accumulated other comprehensive income (loss)	(226		)	929			(404		)	299
Net current-period other comprehensive income (loss)	(727		)	967			(1,012		)	(772		)
Balance as of September 30, 2014	$	(307	)	$	(991	)	$	(313	)	$	(1,611	)

18

The following table shows the line item on the statements of operations affected by reclassifications out of AOCI (in thousands):

	Amount reclassified from AOCI
	Three months endedSeptember 30,						Nine months endedSeptember 30,
Details about AOCI components	2014			2013			2014			2013			Statements of Operations
Gains and losses on cash flow hedges:
Fuel Hedge	$	86		$	106		$	362		$	326		Operating expenses
Interest rate swap	(496		)	(502		)	(1,489		)	(1,489		)	Interest expense, net
	(410		)	(396		)	(1,127		)	(1,163		)	Total before tax
	153			149			424			437			Tax benefit (expense)
	$	(257	)	$	(247	)	$	(703	)	$	(726	)	Net of tax
Unrealized holding gains on available-for-sale securities	$	(466	)	$	158		$	648		$	276		Realized gains (losses) on investments
	(466		)	158			648			276			Total before tax
	176			(59		)	(244		)	(104		)	Tax benefit (expense)
	$	(290	)	$	99		$	404		$	172		Net of tax

10.Restructuring Charges

The Company recorded restructuring charges of $0.4 million and $4.9 million during the three and nine months ended September 30, 2014, respectively, and $1.3 million and $5.0 million during the three and nine months ended September 30, 2013, respectively, related primarily to continuing efforts to re-align AMR’s operations and billing functions.  Payments currently under this plan are expected to be complete by March 2015.

	AMR
	Lease and
	other contract
	termination						EmCare			EVHC
	costs			Severance			Severance			Severance			Total
							(in thousands)
Balance as of January 1, 2013	$	8,122		$	3,015		$	773		$	408		$	12,318
Incurred	1,876			2,890			913			20			5,699
Paid	(6,989		)	(3,765		)	(1,204		)	(377		)	(12,335		)
Balance as of December 31, 2013	$	3,009		$	2,140		$	482		$	51		$	5,682
Incurred	3,265			512			729			400			4,906
Paid	(1,712		)	(1,296		)	(929		)	(451		)	(4,388		)
Balance as of September 30, 2014	$	4,562		$	1,356		$	282		$	—		$	6,200

11.Equity Based Compensation

Upon completion of the Company’s initial public offering, the previous stock compensation plan (“Stock Compensation Plan”) terminated and the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (“Omnibus Incentive Plan”) was adopted pursuant to which options and awards with respect to a total of 16,708,289 shares of Common Stock are available for grant. As of September 30, 2014, a total of 16,539,527 shares remained available for grant under the Omnibus Incentive Plan. Awards under the Omnibus Incentive Plan include both performance and non-performance based awards. As of September 30, 2014, no grants of performance based awards under the Omnibus Incentive Plan had been made. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. No participant may be granted in any calendar year awards covering more than 2.5 million shares of Common Stock or 1.5 million performance awards up to a maximum dollar value of $5.0 million. Non-performance based awards have time-based vesting and performance-based awards vest upon achievement of certain company-wide objectives. All options have 10 year terms.

Awards previously granted under the Stock Compensation Plan were unaffected by the termination of the Stock Compensation Plan; however no future grants will be made under the Stock Compensation Plan.

A compensation charge of $1.1 million and $1.1 million was recorded for the three months ended September 30, 2014 and 2013, respectively, and $3.6 million and $3.2 million was recorded for the nine months ended September 30, 2014 and 2013, respectively.

19

12.Commitments and Contingencies

Lease Commitments

The Company leases various facilities and equipment under operating lease agreements. Rental expense incurred under these leases was $11.3 million and $11.3 million for the three months ended September 30, 2014 and 2013, respectively and $34.0 million and $33.6 million for the nine months ended September 30, 2014 and 2013, respectively.

The Company also records certain leasehold improvements and vehicles under capital leases. Assets under capital leases are capitalized using inherent interest rates at the inception of each lease. Capital leases are collateralized by the underlying assets.

Services

The Company is subject to the Medicare and Medicaid fraud and abuse laws which prohibit, among other things, any false claims, or any bribe, kickback or rebate in return for the referral of Medicare and Medicaid patients. Violation of these prohibitions may result in civil and criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Management has implemented policies and procedures that management believes will assure that the Company is in substantial compliance with these laws and regulations but there can be no assurance the Company will not be found to have violated certain of these laws and regulations. From time to time, the Company receives requests for information from government agencies pursuant to their regulatory or investigational authority. Such requests can include subpoenas or demand letters for documents to assist the government agencies in audits or investigations. The Company is cooperating with the government agencies conducting these investigations and is providing requested information to the government agencies. Other than the proceedings described below, management believes that the outcome of any of these investigations would not have a material adverse effect on the Company.

Letters of Credit

As of September 30, 2014 and December 31, 2013, the Company had $130.2 million and $129.9 million, respectively, in outstanding letters of credit.

Other Legal Matters

In December 2006, AMR received a subpoena from the U.S. Department of Justice (“DOJ”). The subpoena requested copies of documents for the period from January 2000 through the present. The subpoena required AMR to produce a broad range of documents relating to the operations of certain AMR affiliates in New York. The Company produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited the Company to respond to the identified areas of concern. The Company reviewed the information provided by the government and provided its response. On May 20, 2011, AMR entered into a settlement agreement with the DOJ and a Corporate Integrity Agreement (“CIA”) with the Office of Inspector General of the Department of Health and Human Services (“OIG”) in connection with this matter. Under the terms of the settlement, AMR paid $2.7 million to the federal government. In connection with the settlement, the Company entered into a CIA with a five-year period beginning May 20, 2011. Pursuant to this CIA, the Company is required to maintain a compliance program, which includes, among other elements, the appointment of a compliance officer and committee, training of employees nationwide, safeguards for its billing operations as they relate to services provided in New York, including specific training for operations and billing personnel providing services in New York, review by an independent review organization and reporting of certain reportable events. The Company entered into the settlement in order to avoid the uncertainties of litigation, and has not admitted any wrongdoing. In May 2013, a subsidiary of the Company entered into an agreement to divest substantially all the assets underlying AMR’s services in New York, although the obligations of the Company’s compliance program will remain in effect following the expected divestiture. The divesture was completed on July 1, 2013.

Four different putative class action lawsuits have been filed against AMR and certain subsidiaries in California alleging violations of California wage and hour laws.  On April 16, 2008, Laura Bartoni commenced a suit in the Superior Court for the State of California, County of Alameda; on July 8, 2008, Vaughn Banta filed suit in the Superior Court of the State of California, County of Los Angeles; on January 22, 2009, Laura Karapetian filed suit in the Superior Court of the State of California, County of Los Angeles: and on March 11, 2010, Melanie Aguilar filed suit in Superior Court of the State of California, County of Los Angeles.  The Banta, Aguilar and Karapetian cases have been coordinated in the Superior Court for the State of California, County of Los Angeles, and the Aguilar and Karapetian cases have subsequently been consolidated into a single action.  In these cases, the plaintiffs allege principally that the AMR entities failed to pay wages, including overtime wages, in compliance with California law, and failed to provide required meal breaks, rest breaks or pay premium compensation for missed breaks.  The plaintiffs sought to certify classes on these claims and are seeking lost wages, various penalties, and attorneys’ fees under California law.  The Court has certified classes in the consolidated Karapetian /Aguilar case on claims alleging that AMR has not provided meal periods in compliance with the law as to dispatchers and call takers, that AMR has an unlawful time round policy, and that AMR has an unlawful practice of setting rates for those employees; the Court denied certification of the rest period claims of these employees.  In Banta, the Court denied certification of the meal and rest period claims as to EMTs and paramedics, a decision that is being appealed; the Court indicated that it would certify a class on overtime claims, but plaintiff’s counsel have indicated that they intend to dismiss that claim as AMR’s policy complies with a recent Court of Appeal decision.  In Bartoni, the Court denied certification on the meal and rest period claims, but certified a class on the overtime claims, as to which the Company intends to seek summary judgment. The Company is unable at this time to estimate the amount of potential damages, if any in any of these actions.

20

Merion Capital, L.P. (“Merion”), a former stockholder of Corporation, filed an action in the Delaware Court of Chancery on June 20, 2011 seeking to exercise its right to appraisal of its holdings in Corporation prior to the merger of Corporation with a wholly-owned subsidiary of the Company (the “Merger”) on May 25, 2011. During the first quarter of 2013, the Company expensed $8.4 million of legal settlement costs and $1.9 million of interest. On April 15, 2013, the Company paid $52.1 million in a settlement of Merion’s appraisal action, in which Merion agreed to release its claims against the Company.

On August 7, 2012, EmCare received a subpoena from the OIG requesting copies of documents for the period from January 1, 2007 through the present that appears to primarily be focused on EmCare’s contracts for services at hospitals that are affiliated with Health Management Associates, Inc. (“HMA”). The Company has been cooperating with the government during its investigation and, as such, continues to gather responsive documents. During the months of December 2013 and January 2014, several lawsuits filed by whistleblowers on behalf of the federal and certain state governments against HMA have been unsealed; the Company is a named defendant in two of these lawsuits. Although the federal government intervened in these lawsuits in connection with certain of the allegations against HMA, the federal government has not, at this time, disclosed whether it will intervene in these matters as they relate to the Company. The Company continues to engage in meaningful dialogue with the relevant government representatives and, at this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

On February 14, 2013, EmCare received a subpoena from the OIG requesting documents and other information relating to EmCare’s relationship with Community Health Services, Inc. (“CHS”). The Company is cooperating with the government during its investigation, has provided responsive documents, and is engaged in a meaningful dialogue with the relevant government representatives regarding additional requests. At this time, the Company is unable to determine the potential impact, if any, that will result from these investigations.

In November 2013, AMR received a subpoena from the New Hampshire Department of Insurance directed to American Medical Response of Massachusetts, Inc. The subpoena requested documents relating to ambulance services provided to approximately 150 patients residing in the state of New Hampshire who had been involved in motor vehicle accidents and who were ultimately transported by AMR. In addition, the subpoena requested information relating to any agreements for reimbursement between AMR and Progressive Insurance. We cooperated with the Department and, in March 2014, we were notified that the investigation was concluded and closed.

The Company is involved in other litigation arising in the ordinary course of business. Management believes the outcome of these legal proceedings will not have a material adverse impact on its financial condition, results of operations or liquidity.

13.Related Party Transactions

CD&R Affiliates

Stockholders Agreement

In connection with the Company’s initial public offering, the Company entered into a stockholders agreement (“Stockholders Agreement”) with CD&R Affiliates. Under the Stockholders Agreement, CD&R Affiliates were granted the right to designate for nomination for election a number of CD&R-designated directors equal to: (i) at least a majority of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 50% of the outstanding shares of Common Stock, (ii) at least 40% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 40% but less than 50% of the outstanding shares of Common Stock, (iii) at least 30% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 30% but less than 40% of the outstanding shares of Common Stock, (iv) at least 20% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 20% but less than 30% of the outstanding shares of Common Stock, and (v) at least 5% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 5% but less than 20% of the outstanding shares of Common Stock. Additionally, a CD&R-designated director will serve as the Chairman of the board of directors as long as the CD&R Affiliates own at least 30% of the outstanding shares of Common Stock. As of September 30, 2014, the CD&R Affiliates owned approximately 27.7% of the outstanding shares of Common Stock.

21

Consulting Agreement

The Company was party to the Consulting Agreement, dated May 25, 2011 (the “Consulting Agreement”), with CD&R pursuant to which CD&R provided the Company and its subsidiaries with financial, investment banking, management, advisory and other services in exchange for an annual fee of $5.0 million. The Company expensed $2.5 million for the nine months ended September 30, 2013, respectively, for this fee.

During the third quarter of 2013, the Company made a $20.0 million payment to CD&R with proceeds received from the initial public offering of Common Stock of the Company to terminate the Consulting Agreement.

Registration Rights Agreement

In connection with the closing of the Merger, the Company entered into a registration rights agreement (“Registration Rights Agreement”) with the CD&R Affiliates which grants the CD&R Affiliates specified demand and piggyback registration rights with respect to the Company’s Common Stock. Under the Registration Rights Agreement, if the Company registers Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), holders of the Common Stock, including CD&R Affiliates, have the right to require the Company’s to use reasonable best efforts to include in the Company’s registration statement shares of Common Stock held by them, subject to certain limitations and at the expense of the Company.

Indemnification Agreements

In connection with the closing of the Merger, the Company and the Company entered into separate indemnification agreements with CD&R and CD&R Affiliates (the “CD&R Entities”). Under the indemnification agreement with the CD&R Entities, Holding and the Company, subject to certain limitations, jointly and severally agreed to indemnify the CD&R Entities and certain of their affiliates against certain liabilities arising out of performance of the Consulting Agreement and certain other claims and liabilities.

Other

On November 25, 2008, the Company entered into a corporate account agreement with The Hertz Corporation pursuant to which it agreed to spend a minimum total amount of $460,000 per year for the rental of cars from The Hertz Corporation and its subsidiaries and licensees. For each of the three and nine months ended September 30, 2014 and 2013, we spent less than $1.0 million under this contract. The agreement had an initial one-year term, and renews automatically until terminated by either party. Investment funds associated with CD&R had been affiliated with Hertz Global Holdings.

Other Transactions

In connection with the closing of the Merger, Holding and Corporation entered into separate indemnification agreements with each of Richard J. Schnall, Ronald A. Williams, William A. Sanger, and Kenneth A. Giuriceo as the directors of Holding and Corporation. Under the indemnification agreements with the directors of Holding and Corporation, Holding and Corporation, subject to certain limitations, jointly and severally agreed to indemnify the directors against certain liabilities arising out of service as a director.

The executive employment agreements include indemnification provisions whereby the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

In connection with the Company’s initial public offering, the Company entered into new indemnification agreements with each of its directors. On November 11, 2013, the Company entered into an indemnification agreement with Mark V. Mactas. Under these agreements, the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

22

14.Variable Interest Entities

GAAP requires the assets, liabilities, noncontrolling interests and activities of Variable Interest Entities (“VIE”) to be consolidated if an entity’s interest in the VIE has specific characteristics including: voting rights not proportional to ownership and the right to receive a majority of expected income or absorb a majority of expected losses. In addition, the entity exposed to the majority of the risks and rewards associated with the VIE is deemed its primary beneficiary and must consolidate the entity.

UHS-EmCare JV

EmCare entered into an agreement in 2014 with Universal Health Services, Inc. to form an entity which would provide physician services to various healthcare facilities (“UHS-EmCare JV”).  UHS-EmCare JV began providing services to healthcare facilities during the second quarter of 2014 and meets the definition of a VIE.  The Company determined that, although EmCare holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

·EmCare provides management services to UHS-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of UHS-EmCare JV’s activities involve EmCare; and

·as payment for management services, EmCare is entitled to receive a base management fee from UHS-EmCare JV.

The following table summarizes the UHS-EmCare JV assets and liabilities as of September 30, 2014, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,
	2014
Current assets	$	18,021
Current liabilities	8,773

HCA-EmCare JV

EmCare entered into an agreement in 2011 with an indirect wholly-owned subsidiary of HCA Holdings Inc. to form an entity which would provide physician services to various healthcare facilities (“HCA-EmCare JV”). HCA-EmCare JV began providing services to healthcare facilities during the first quarter of 2012 and meets the definition of a VIE. The Company determined that, although EmCare only holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

·EmCare provides management services to HCA-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of HCA-EmCare JV’s activities involve EmCare; and

·as payment for management services, EmCare is entitled to receive a base management fee from HCA-EmCare JV as well as a bonus management fee.

The following table summarizes the HCA-EmCare JV assets and liabilities as of September 30, 2014 and December 31, 2013, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,		December 31,
	2014		2013
Current assets	$	137,992	$	88,479
Current liabilities	31,294		22,005

15.Segment Information

The Company is organized around two separately managed business units: facility-based and post-acute care physician services and healthcare transportation services, which have been identified as operating segments. The facility-based and post-acute care physician services reportable segment provides physician services to hospitals primarily for emergency department, anesthesiology, hospitalist/inpatient, radiology, teleradiology and surgery services. It also offers physician-led care management solutions outside the hospital. The healthcare transportation services reportable segment focuses on providing a full range of medical transportation services from basic patient transit to the most advanced emergency care and pre-hospital assistance. The Chief Executive Officer has been identified as the chief operating decision maker (the “CODM”) as he assesses the performance of the business units and decides how to allocate resources to the business units.

23

Net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, related party management fees, restructuring charges, and depreciation and amortization expense (“Adjusted EBITDA”) is the measure of profit and loss that the CODM uses to assess performance and make decisions. Adjusted EBITDA is not considered a measure of financial performance under GAAP and the items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the Company’s financial statements as an indicator of financial performance. Since Adjusted EBITDA is not a measure determined to be in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Pre-tax income from continuing operations represents net revenue less direct operating expenses incurred within the operating segments. The accounting policies for reported segments are the same as for the Company as a whole (see Note 2).

The Company’s operating segment results were as follows (in thousands):

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
Facility-Based Physician Services
Net revenue	$	748,080	$	605,105	$	2,082,661	$	1,729,158
Income from operations	81,246		55,706		201,325		156,802
Adjusted EBITDA	99,726		82,032		258,179		218,767
Healthcare Transportation Services
Net revenue	$	402,249	$	350,783	$	1,157,206	$	1,014,309
Income from operations	32,655		7,782		74,033		35,339
Adjusted EBITDA	52,507		39,623		138,223		109,843
Segment Totals
Net revenue	$	1,150,329	$	955,888	$	3,239,867	$	2,743,467
Income from operations	113,901		63,488		275,358		192,141
Adjusted EBITDA	152,233		121,655		396,402		328,610

24

A reconciliation of net income (loss) to Adjusted EBITDA (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
Add-back of non-operating expense (income):
Interest expense, net	25,742			46,772			84,793			148,526
Income tax expense (benefit)	34,437			(4,949		)	49,700			3,932
Loss on early debt extinguishment	—			29,519			66,397			29,641
Realized losses (gains) on investments	466			(158		)	(648		)	(276		)
Interest income from restricted assets	(175		)	(2		)	(507		)	(634		)
Equity in earnings of unconsolidated subsidiary	(72		)	(68		)	(185		)	(230		)
Other expense (income), net	660			52			3,432			13,022
Corporate operating expense	—			(15		)	—			73
Income from operations — segment totals	113,901			63,488			275,358			192,141
Add-back of operating expense (income):
Depreciation and amortization expense	36,796			35,175			108,786			104,552
Restructuring charges	366			1,319			4,906			4,988
Net loss (income) attributable to noncontrolling interest	(67		)	—			3,233			—
Interest income from restricted assets	175			2			507			634
Equity-based compensation expense	1,062			1,062			3,612			3,186
Related party management fees	—			20,609			—			23,109
Adjusted EBITDA — segment totals	152,233			121,655			396,402			328,610
Corporate operating expense	—			15			—			(73		)
Adjusted EBITDA	$	152,233		$	121,670		$	396,402		$	328,537

16.Consolidating Financial Information

Pursuant to the indenture governing the 2022 Notes, so long as any of the 2022 Notes are outstanding, the Company is required to provide condensed consolidating financial information with a separate column for (i) the Company and its subsidiaries (other than Corporation and its subsidiaries) on a combined basis, (ii) Corporation and its subsidiaries, (iii) consolidating adjustments on a combined basis, and (iv) the total consolidated amount. The consolidating adjustments column represents the elimination of any intercompany activity between EVHC (excluding Corporation and its subsidiaries) and Corporation.

25

Consolidating Balance Sheet

As of September 30, 2014

(in thousands, unaudited)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	5		$	247,165		$	—		$	247,170
Insurance collateral	—			27,899			—			27,899
Trade and other accounts receivable, net	—			913,413			—			913,413
Parts and supplies inventory	—			23,983			—			23,983
Prepaids and other current assets	27,273			54,245			(29,568		)	51,950
Total current assets	27,278			1,266,705			(29,568		)	1,264,415
Property, plant, and equipment, net	—			203,405			—			203,405
Intangible assets, net	—			543,226			—			543,226
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			8,663			—			8,663
Goodwill	—			2,536,156			—			2,536,156
Other long-term assets	—			38,629			—			38,629
Investment in wholly owned subsidiary	1,677,128			—			(1,677,128		)	—
Total assets	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494
Liabilities and Equity
Current liabilities:
Accounts payable	$	1,117		$	50,955		$	—		52,072
Accrued liabilities	—			422,941			(9,256		)	413,685
Current deferred tax liabilities	—			56,695			(20,312		)	36,383
Current portion of long-term debt and capital lease obligations	—			12,235			—			12,235
Total current liabilities	1,117			542,826			(29,568		)	514,375
Long-term debt and capital lease obligations	—			2,029,095			—			2,029,095
Long-term deferred tax liabilities	—			151,353			(128		)	151,225
Insurance reserves	—			167,628			—			167,628
Other long-term liabilities	—			16,707			—			16,707
Total liabilities	1,117			2,907,609			(29,696		)	2,879,030
Equity:
Common stock	1,834			—			—			1,834
Preferred stock	—			—			—			—
Additional paid-in capital	1,609,244			1,516,383			(1,516,383		)	1,609,244
Retained earnings	93,950			162,356			(162,356		)	93,950
Accumulated other comprehensive loss	(1,611		)	(1,611		)	1,611			(1,611		)
Total Envision Healthcare Holdings, Inc. equity	1,703,417			1,677,128			(1,677,128		)	1,703,417
Noncontrolling interest	—			12,047			—			12,047
Total equity	1,703,417			1,689,175			(1,677,128		)	1,715,464
Total liabilities and equity	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494

26

Consolidating Balance Sheet

As of December 31, 2013

(in thousands)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	81,722		$	122,990		—			$	204,712
Insurance collateral	—			29,619			—			29,619
Trade and other accounts receivable, net	—			801,146			—			801,146
Parts and supplies inventory	—			23,376			—			23,376
Prepaids and other current assets	26,860			23,925			(27,355		)	23,430
Total current assets	108,582			1,001,056			(27,355		)	1,082,283
Property, plant, and equipment, net	—			194,715			—			194,715
Intangible assets, net	—			513,698			—			513,698
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			12,716			—			12,716
Goodwill	—			2,435,670			—			2,435,670
Other long-term assets	—			60,935			—			60,935
Investment in wholly owned subsidiary	1,486,129			—			(1,486,129		)	—
Total assets	$	1,594,839		$	4,218,790		(1,513,612		)	$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable	$	116		$	52,472		—			$	52,588
Accrued liabilities	—			357,979			(7,043		)	350,936
Current deferred tax liabilities	—			55,799			(20,312		)	35,487
Current portion of long-term debt and capital lease obligations	—			12,318			—			12,318
Total current liabilities	116			478,568			(27,355		)	451,329
Long-term debt and capital lease obligations	—			1,895,381			—			1,895,381
Long-term deferred tax liabilities	—			151,258			(128		)	151,130
Insurance reserves	—			175,427			—			175,427
Other long-term liabilities	—			16,997			—			16,997
Total liabilities	116			2,717,631			(27,483		)	2,690,264
Equity:
Common stock	1,804			—			—			1,804
Preferred stock	—			—			—			—
Additional paid-in capital	1,575,417			1,402,861			(1,402,861		)	1,575,417
Retained earnings	18,341			84,107			(84,107		)	18,341
Accumulated other comprehensive loss	(839		)	(839		)	839			(839		)
Total Envision Healthcare Holdings, Inc. equity	1,594,723			1,486,129			(1,486,129		)	1,594,723
Noncontrolling interest	—			15,030			—			15,030
Total equity	1,594,723			1,501,159			(1,486,129		)	1,609,753
Total liabilities and equity	$	1,594,839		$	4,218,790		$	(1,513,612	)	$	4,300,017

27

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2014
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	1,150,329		$	—		$	1,150,329
Compensation and benefits	—			819,353			—			819,353
Operating expenses	—			129,535			—			129,535
Insurance expense	—			27,527			—			27,527
Selling, general and administrative expenses	—			22,851			—			22,851
Depreciation and amortization expense	—			36,796			—			36,796
Restructuring charges	—			366			—			366
Income (loss) from operations	—			113,901			—			113,901
Interest income from restricted assets	—			175			—			175
Interest expense, net	—			(25,742		)	—			(25,742		)
Realized gains (losses) on investments	—			(466		)	—			(466		)
Other income (expense), net	(1,433		)	773			—			(660		)
Loss on early debt extinguishment	—			—			—			—
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(1,433		)	88,641			—			87,208
Income tax benefit (expense)	697			(35,134		)	—			(34,437		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(736		)	53,507			—			52,771
Equity in net income (loss) of subsidiary	53,512			—			(53,512		)	—
Equity in earnings of unconsolidated subsidiary	—			72			—			72
Net income (loss)	52,776			53,579			(53,512		)	52,843
Less: Net (income) loss attributable to noncontrolling interest	—			(67		)	—			(67		)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776		$	53,512		$	(53,512	)	$	52,776

28

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2013
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	955,888		$	—		$	955,888
Compensation and benefits	—			677,797			—			677,797
Operating expenses	(17		)	110,404			—			110,387
Insurance expense	—			26,974			—			26,974
Selling, general and administrative expenses	2			40,731			—			40,733
Depreciation and amortization expense	—			35,175			—			35,175
Restructuring charges	—			1,319			—			1,319
Income from operations	15			63,488			—			63,503
Interest income from restricted assets	—			2			—			2
Interest expense, net	(7,641		)	(39,131		)	—			(46,772		)
Realized gains (losses) on investments	—			158			—			158
Other income (expense), net	—			(52		)	—			(52		)
Loss on early debt extinguishment	(29,519		)	—			—			(29,519		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(37,145		)	24,465			—			(12,680		)
Income tax benefit (expense)	14,765			(9,816		)	—			4,949
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(22,380		)	14,649			—			(7,731		)
Equity in net income (loss) of subsidiary	14,717			—			(14,717		)	—
Equity in earnings of unconsolidated subsidiary	—			68			—			68
Net income (loss)	(7,663		)	14,717			(14,717		)	(7,663		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(7,663	)	$	14,717		$	(14,717	)	$	(7,663	)

29

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	3,239,867		$	—		$	3,239,867
Compensation and benefits	—			2,330,021			—			2,330,021
Operating expenses	—			364,885			—			364,885
Insurance expense	—			90,091			—			90,091
Selling, general and administrative expenses	—			65,820			—			65,820
Depreciation and amortization expense	—			108,786			—			108,786
Restructuring charges	—			4,906			—			4,906
Income from operations	—			275,358			—			275,358
Interest income from restricted assets	—			507			—			507
Interest expense, net	—			(84,793		)	—			(84,793		)
Realized gains (losses) on investments	—			648			—			648
Other income (expense), net	(4,232		)	800			—			(3,432		)
Loss on early debt extinguishment	—			(66,397		)	—			(66,397		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(4,232		)	126,123			—			121,891
Income tax benefit (expense)	1,592			(51,292		)	—			(49,700		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(2,640		)	74,831			—			72,191
Equity in net income (loss) of subsidiary	78,249			—			(78,249		)	—
Equity in earnings of unconsolidated subsidiary	—			185			—			185
Net income (loss)	75,609			75,016			(78,249		)	72,376
Less: Net (income) loss attributable to noncontrolling interest	—			3,233			—			3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	75,609		$	78,249		$	(78,249	)	$	75,609

30

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	2,743,467		$	—		$	2,743,467
Compensation and benefits	—			1,963,546			—			1,963,546
Operating expenses	70			313,075			—			313,145
Insurance expense	—			78,647			—			78,647
Selling, general and administrative expenses	3			86,518			—			86,521
Depreciation and amortization expense	—			104,552			—			104,552
Restructuring charges	—			4,988			—			4,988
Income from operations	(73		)	192,141			—			192,068
Interest income from restricted assets	—			634			—			634
Interest expense, net	(30,567		)	(117,959		)	—			(148,526		)
Realized gains (losses) on investments	—			276			—			276
Other income (expense), net	—			(13,022		)	—			(13,022		)
Loss on early debt extinguishment	(29,519		)	(122		)	—			(29,641		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(60,159		)	61,948			—			1,789
Income tax benefit (expense)	23,850			(27,782		)	—			(3,932		)
Income before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(36,309		)	34,166			—			(2,143		)
Equity in net income (loss) of subsidiary	34,396			—			(34,396		)	—
Equity in earnings of unconsolidated subsidiary	—			230			—			230
Net income (loss)	(1,913		)	34,396			(34,396		)	(1,913		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(1,913	)	$	34,396		$	(34,396	)	$	(1,913	)

31

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(859	)	$	194,863		$	194,004
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(52,654		)	(52,654		)
Sales and maturities of available-for-sale securities	—			40,425			40,425
Purchase of property, plant and equipment	—			(55,659		)	(55,659		)
Proceeds from sale of property, plant and equipment	—			2,299			2,299
Acquisition of businesses, net of cash received	—			(199,261		)	(199,261		)
Net change in insurance collateral	—			2,021			2,021
Other investing activities	—			(1,774		)	(1,774		)
Net cash provided by (used in) investing activities	—			(264,603		)	(264,603		)
Cash Flows from Financing Activities
Borrowings under the ABL Facility	—			50,000			50,000
Proceeds from issuance of senior notes	—			740,625			740,625
Repayments of the Term Loan	—			(6,686		)	(6,686		)
Repayments of the ABL Facility	—			(50,000		)	(50,000		)
Repayments of PIK Notes and senior notes	—			(607,750		)	(607,750		)
Payment for debt extinguishment premiums	—			(37,630		)	(37,630		)
Debt issuance costs	—			(2,221		)	(2,221		)
Proceeds from stock options exercised	—			7,405			7,405
Excess tax benefits from equity-based compensation	—			38,520			38,520
Shares repurchased for tax withholdings	—			(14,430		)	(14,430		)
Proceeds from noncontrolling interest	—			250			250
Other financing activities	859			(5,885		)	(5,026		)
Net intercompany borrowings (payments)	(81,717		)	81,717			—
Net cash provided by (used in) financing activities	(80,858		)	193,915			113,057
Change in cash and cash equivalents	(81,717		)	124,175			42,458
Cash and cash equivalents, beginning of period	81,722			122,990			204,712
Cash and cash equivalents, end of period	$	5		$	247,165		$	247,170

32

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(38,375	)	$	64,000		$	25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(2,615		)	(2,615		)
Sales and maturities of available-for-sale securities	—			7,616			7,616
Purchase of property, plant and equipment	—			(45,493		)	(45,493		)
Proceeds from sale of property, plant and equipment	—			396			396
Acquisition of businesses, net of cash received	—			(27,358		)	(27,358		)
Net change in insurance collateral	—			(2,121		)	(2,121		)
Other investing activities	—			(456		)	(456		)
Net cash provided by (used in) investing activities	—			(70,031		)	(70,031		)
Cash Flows from Financing Activities
Issuance of common stock	1,110,900			1,117			1,112,017
Borrowings under the Term Loan	—			150,000			150,000
Borrowings under the ABL Facility	—			345,440			345,440
Repayments of the Term Loan	—			(10,028		)	(10,028		)
Repayments of the ABL Facility	—			(470,440		)	(470,440		)
Repayments of PIK Notes and senior notes	(450,000		)	—			(450,000		)
Payment for debt extinguishment premiums	(12,386		)	—			(12,386		)
Dividend paid	20,813			(20,813		)	—
Debt issuance costs	(4		)	(5,007		)	(5,011		)
Equity issuance costs	(63,420		)	—			(63,420		)
Excess tax benefits from equity-based compensation	—			3,168			3,168
Payment of dissenting shareholder settlement	—			(38,336		)	(38,336		)
Net change in bank overdrafts	—			1,686			1,686
Other financing activities	—			(355		)	(355		)
Net intercompany borrowings (payments)	(86,087		)	86,087			—
Net cash provided by (used in) financing activities	519,816			42,519			562,335
Change in cash and cash equivalents	481,441			36,488			517,929
Cash and cash equivalents, beginning of period	281			57,551			57,832
Cash and cash equivalents, end of period	$	481,722		$	94,039		$	575,761

33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements and Factors That May Affect Results

Certain statements and information herein may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Any forward-looking statements herein are made as of the date this Quarterly Report on Form 10-Q is filed with the SEC, and we undertake no duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in this Form 10-Q and in our other filings with the SEC, including the risks described in Item 1A “Risk Factors” of Part II of this Form 10-Q.

Among the factors that could cause future results to differ materially from those provided in this Quarterly Report on Form 10-Q are: decreases in our revenue and profit margin under our fee-for-service contracts due to changes in volume, payor mix and third party reimbursement rates, including from political discord in the federal budgeting process; the loss of existing contracts; failure to accurately assess costs under new contracts; difficulties in our ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; failure to implement some or all of our business strategies, including our efforts to grow our Evolution Health business and cross-sell our services; lawsuits for which we are not fully reserved; the adequacy of our insurance coverage and insurance reserves; our ability to successfully integrate strategic acquisitions; the high level of competition in the markets we serve; the cost of capital expenditures to maintain and upgrade our vehicle fleet and medical equipment; the loss of one or more members of our senior management team; our ability to maintain or implement complex information systems; disruptions in disaster recovery systems or management continuity planning; our ability to adequately protect our intellectual property and other proprietary rights or to defend against intellectual property infringement claims; challenges by tax authorities on our treatment of certain physicians as independent contractors; the impact of labor union representation; the impact of fluctuations in results due to our national contract with the Federal Emergency Management Agency (“FEMA”); potential penalties or changes to our operations, including our ability to collect accounts receivable, if we fail to comply with extensive and complex government regulation of our industry; the impact of changes in the healthcare industry, including changes due to healthcare reform; our ability to timely enroll our providers in the Medicare program; our ability to restructure our operations to comply with future changes in government regulation; the outcome of government investigations of certain of our business practices; our ability to comply with the terms of our settlement agreements with the government; our ability to generate cash flow to service our substantial debt obligations; the significant influence of the CD&R Affiliates over us; and risks related to other factors discussed in this Quarterly Report on Form 10-Q.

Words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “goal,” “objectives,” “intends,” “may,” “opportunity,” “plans,” “potential,” “near-term,” “long-term,” “projections,” “assumptions,” “projects,” “guidance,” “forecasts,” “outlook,” “target,” “trends,” “should,” “could,” “would,” “will” and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors.

Healthcare Reform

As currently enacted the Patient Protection and Affordable Care Act (the “PPACA”) changes how health care services are delivered and reimbursed, and increases access to health insurance benefits to the uninsured and underinsured population in the United States. On June 28, 2012, the U.S. Supreme Court upheld the constitutionality of the individual mandate provisions of the PPACA, but struck down the provisions that would have allowed the Department of Health and Human Services (“HHS”) to penalize states that do not implement Medicaid expansion provisions through the loss of existing federal Medicaid funding.

34

Most of the provisions of the PPACA that seek to decrease the number of uninsured became effective January 1, 2014. Based on the government’s February 2014 projection, by 2022, the PPACA will expand coverage to 25 million additional individuals. This increased coverage will occur through a combination of public program expansion and private sector health insurance and other reforms. The employer mandate, which requires firms with 50 or more full-time employees to offer health insurance or pay fines, has been delayed until January 1, 2015. For employers with 50 to 99 employees, this requirement has been further delayed until January 1, 2016.

A number of states have opted out of the Medicaid expansion, but these states could choose to implement the expansion at a later date.  It is unclear how many states will ultimately decline to implement the Medicaid expansion provisions of the law.  At this point, we cannot quantify or predict with any certainty the likely impact of the PPACA on our business model, financial condition or results of operations.

Company Overview

We are a leading provider of physician-led, outsourced medical services in the United States with more than 20,000 affiliated clinicians. We market our services on a stand-alone, multi-service and integrated basis, primarily under our EmCare and AMR brands. EmCare is a leading provider of integrated facility-based physician services, including emergency, anesthesiology, hospitalist/inpatient care, radiology, teleradiology and surgery. EmCare also offers physician-led care management solutions outside the hospital. AMR is a leading provider and manager of community based healthcare transportation services, including emergency “911”, non-emergency, managed transportation, fixed-wing ambulance and disaster response.

Key Factors and Measures We Use to Evaluate Our Business

The key factors and measures we use to evaluate our business focus on the number of patients we treat and transport and the costs we incur to provide the necessary care and transportation for each of our patients.

We evaluate our revenue net of provisions for contractual payor discounts and provisions for uncompensated care. Medicaid, Medicare and certain other payors receive discounts from our standard charges, which we refer to as contractual discounts. In addition, individuals we treat and transport may be personally responsible for a deductible or co-pay under their third party payor coverage, and most of our contracts require us to treat and transport patients who have no insurance or other third party payor coverage. Due to the uncertainty regarding collectability of charges associated with services we provide to these patients, which we refer to as uncompensated care, our net revenue recognition is based on expected cash collections. Our net revenue represents gross billings after provisions for contractual discounts and estimated uncompensated care. Provisions for contractual discounts and uncompensated care have increased historically primarily as a result of increases in gross billing rates without corresponding increases in payor reimbursement.

The table below summarizes our approximate payor mix as a percentage of both net revenue and total transports and patient encounters for the three and nine months ended September 30, 2014 and 2013. In determining the net revenue payor mix, we use cash collections in the period as an approximation of net revenue recorded. With the expansion of the Medicaid program in certain states, we would expect cash collections related to the Medicaid payor class to continue to increase over time as those collections are received.  During the second quarter of 2014, the Company determined that Medicare and Medicaid managed care programs would be better categorized in the Medicare and Medicaid payor class and has reclassified those encounters in the presentation below and conformed prior periods to current period presentation.

	Percentage of Cash Collections (Net Revenue)								Percentage of Total Volume
	Three months endedSeptember 30,				Nine months endedSeptember 30,				Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013		2014		2013		2014		2013
Medicare	20.4	%	21.2	%	22.9	%	22.5	%	29.9	%	29.9	%	30.5	%	30.2	%
Medicaid	5.5		4.8		7.4		5.0		22.3		21.3		23.0		22.0
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	54.1		52.0		49.1		52.1		31.9		30.8		30.1		30.3
Self-pay	3.6		4.0		3.4		4.3		15.9		18.0		16.4		17.5
Fees/other	7.6		7.7		7.0		5.7		—		—		—		—
Subsidies	8.8		10.3		10.2		10.4		—		—		—		—
Total	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

35

As illustrated above, Commercial insurance and managed care (excluding Medicare and Medicaid managed care) has consistently represented our largest payor group based on net revenue. Separately, given the emergency nature of many of our services, self-pay (primarily uninsured patients) has represented approximately 16% to 18% of our total patient volume, but is only 3% to 4% of our total cash collections. The decrease in self-pay as a percentage of total revenue over the past three years has been due to additional EmCare service lines with lower self-pay, including our post-acute care services.  The decrease in self-pay as a percentage of total volume has been primarily driven by Medicaid expansion evidenced by an approximate 2.3% drop in self-pay volume to 16.4% for the first nine months of 2014 as compared to a self-pay mix of approximately 18.7% in the fourth quarter of 2013.

EmCare

Of EmCare’s net revenue for the nine months ended September 30, 2014, approximately 73% was derived from our hospital contracts for emergency department staffing, 9% from contracts related to anesthesiology services, 9% from our hospitalist/inpatient services, 4% from our post-acute care services, 2% from our radiology/teleradiology services, 1% from our surgery services, and 2% from other hospital management services. Approximately 85% of EmCare’s net revenue was generated from billings to third party payors and patients for patient encounters and approximately 15% was generated from billings to hospitals and affiliated physician groups for professional services. EmCare’s key net revenue measures are:

·Patient encounters. We utilize patient encounters to evaluate net revenue and as the basis by which we measure certain costs of the business. We segregate patient encounters into four main categories—ED visits, hospitalist encounters, radiology reads, and anesthesiology cases—due to the differences in reimbursement rates for and associated costs of providing the various services. As a result of these differences, in certain analyses we weight our patient encounter numbers according to category in an effort to better measure net revenue and costs. In calculating “weighted patient encounters”, each radiology read and anesthesiology case is not counted as a full patient encounter as we apply a discount factor to reflect differences in reimbursement rates for and associated costs of providing such services.

·Number of contracts. This reflects the number of contractual relationships we have for outsourced ED staffing, anesthesiology, hospitalist/inpatient, radiology, teleradiology, surgery and other hospital management services. We analyze the change in our number of contracts from period to period based on “net new contracts,” which is the difference between total new contracts and contracts that have terminated.

·Revenue per patient encounter. This reflects the expected net revenue for each patient encounter based on gross billings less all estimated provisions for contractual discounts and uncompensated care. Net revenue per patient encounter also includes net revenue from billings to third party payors and hospitals.

The change from period to period in the number of patient encounters under our same store contracts is influenced by general community conditions as well as hospital-specific elements, many of which are beyond our direct control. The general community conditions include: (i) the timing, location and severity of influenza, allergens and other annually recurring viruses, and (ii) severe weather that affects a region’s health status and/or infrastructure. Hospital-specific elements include the timing and extent of facility renovations, hospital staffing issues and regulations that affect patient flow through the hospital.

The costs incurred in our EmCare business segment consist primarily of compensation and benefits for physicians and other professional providers, professional liability costs, and contract and other support costs. EmCare’s key cost measures include:

·Provider compensation per hour of coverage. Provider compensation per hour of coverage includes all compensation and benefit costs for all professional providers, including physicians, physician assistants and nurse practitioners, during each patient encounter. Providers include all full-time, part-time and independently contracted providers. Analyzing provider compensation per hour of coverage enables us to monitor our most significant cost in performing services under our contracts.

·Professional liability costs. These costs include provisions for estimated losses for actual claims, and claims likely to be incurred in the period, based on our past loss experience and actuarial analysis provided by a third party, as well as actual direct costs, including investigation and defense costs, claims payments, and other costs related to provider professional liability.

EmCare’s business is not as capital intensive as AMR’s and EmCare’s depreciation expense relates primarily to charges for usage of computer hardware and software, and other technologies. Amortization expense relates primarily to intangibles recorded for customer relationships.

36

AMR

Approximately 83% of AMR’s net revenue for the nine months ended September 30, 2014 was transport revenue derived from the treatment and transportation of patients, including fixed-wing air ambulance services, based on billings to third party payors, healthcare facilities and patients. The balance of AMR’s net revenue is derived from direct billings to communities and government agencies, including FEMA, for the provision of training, dispatch center and other services. AMR’s measures for transport net revenue include:

·Transports. We utilize transport data, including the number and types of transports, to evaluate net revenue and as the basis by which we measure certain costs of the business. Excluded from our transport data are transports which are outsourced /brokered through our managed transportation business.  We segregate transports into two main categories—ambulance transports (including emergency, as well as non-emergency, critical care and other inter-facility transports) and wheelchair transports—due to the differences in reimbursement and the associated costs of providing ambulance and wheelchair transports. As a result of these differences, in certain analyses we weight our transport numbers according to category in an effort to better measure net revenue and costs. In calculating “weighted transports”, each wheelchair transport is not counted as a full transport, as we apply a discount factor to reflect differences in reimbursement rates for and associated costs of providing such services.

·Net revenue per transport. Net revenue per transport reflects the expected net revenue for each transport based on gross billings less provisions for contractual discounts and estimated uncompensated care. In order to better understand the trends across service lines and in our transport rates, we analyze our net revenue per transport based on weighted transports to reflect the differences in our transportation mix.

The change from period to period in the number of transports and net revenue per transport is influenced by changes in transports in existing markets from both new and existing facilities we serve for non-emergency transports, and the effects of general community conditions for emergency transports. The general community conditions may include (i) the timing, location and severity of influenza, allergens and other annually recurring viruses, (ii) severe weather that affects a region’s health status and/or infrastructure and (iii) community-specific demographic changes.

The costs we incur in our AMR business segment consist primarily of compensation and benefits for ambulance crews and support personnel, direct and indirect operating costs to provide transportation services, and costs related to accident and insurance claims. AMR’s key cost measures include:

·Unit hours and cost per unit hour. Our measurement of a unit hour is based on a fully staffed ambulance or wheelchair van for one operating hour. We use unit hours and cost per unit hour to measure compensation-related costs and the efficiency of our deployed resources. We monitor unit hours and cost per unit hour on a combined basis, as well as on a segregated basis between ambulance and wheelchair transports.

·Operating costs per transport. Operating costs per transport is comprised of certain direct operating costs, including vehicle operating costs, medical supplies and other transport-related costs, but excluding compensation-related costs. Monitoring operating costs per transport allows us to better evaluate cost trends and operating practices of our regional and local management teams.

·Accident and insurance claims. We monitor the number and magnitude of all accident and insurance claims in order to measure the effectiveness of our risk management programs. Depending on the type of claim (workers compensation, auto, general or professional liability), we monitor our performance by utilizing various bases of measurement, such as net revenue, miles driven, number of vehicles operated, compensation dollars, and number of transports.

We have focused our risk mitigation efforts on employee training for proper patient handling techniques, development of clinical and medical equipment protocols, driving safety, implementation of equipment to reduce lifting injuries and other risk mitigation processes.

AMR’s business requires various investments in long-term assets and depreciation expense relates primarily to charges for usage of these assets, including vehicles, computer hardware and software, medical equipment, and other technologies. Amortization expense relates primarily to intangibles recorded for customer relationships.

37

Factors Affecting Operating Results

Rate Changes by Government Sponsored Programs

In February 2002, the Centers for Medicare and Medicaid Services (“CMS”) issued the Medicare Ambulance Fee Schedule Final Rule (“Ambulance Fee Schedule”) that revised Medicare policy on the coverage of ambulance transport services, effective April 1, 2002. The Ambulance Fee Schedule was the result of a mandate under the Balanced Budget Act of 1997 (“BBA”) to establish a national fee schedule for payment of ambulance transport services that would control increases in expenditures under Part B of the Medicare program, establish definitions for ambulance transport services that link payments to the type of services furnished, consider appropriate regional and operational differences and consider adjustments to account for inflation, among other provisions. The Ambulance Fee Schedule provided for a five-year phase-in of a national fee schedule, beginning April 1, 2002. While a reduced fee schedule was scheduled to go into effect in 2014, Congress extended updates preventing any reductions in payment rates for the nine months ended September 30, 2014 which has been extended until April 1, 2015.

Although we have been able to substantially mitigate the phased-in reductions of the BBA through additional fee and subsidy increases, we may not be able to continue to do so.

Medicare law requires CMS to adjust the Medicare Physician Fee Schedule (the “Physician Fee Schedule”) payment rates annually based on a formula which includes an application of the Sustainable Growth Rate (the “SGR”) that was adopted in the BBA. This formula has yielded negative updates every year beginning in 2002, although CMS was able to take administrative steps to avoid a reduction in 2003 and Congress took a series of legislative actions to prevent reductions each year from 2004 through 2013. Legislative action by Congress in December 2013 resulted in a delay of the Physician Fee Schedule SGR cuts until April 1, 2014. In the first quarter of 2014, Congress passed a bill to avoid reductions in Medicare payments to physicians due to the Physician Fee Schedule SGR until April 1, 2015.

This same bill extended the Ambulance Fee Schedule add-on payments until April 1, 2015 as well.

On August 2, 2011, the Budget Control Act of 2011 (Public Law 112-25) (the “Budget Control Act”) was enacted. Under the Budget Control Act, a Joint Select Committee on Deficit Reduction (the “Joint Committee”) was established to develop recommendations to reduce the deficit, over 10 years, by $1.2 trillion to $1.5 trillion, and was required to report its recommendations to Congress by November 23, 2011. Under the Budget Control Act, Congress was then required to consider the Joint Committee’s recommendations by December 23, 2011. If the Joint Committee failed to refer agreed upon legislation to Congress or did not meet the required savings threshold set out in the Budget Control Act, a sequestration process would be put into effect, government-wide, to reduce Federal outlays by the proposed amount. Because the Joint Committee failed to report the requisite recommendations for deficit reduction, the sequestration process was set to automatically start, impacting Medicare and certain other government programs beginning in January 2013. Congress passed the American Taxpayer Relief Act, signed into law on January 2, 2013, delaying the start of sequestration until March 1, 2013. In order to provide its contractors and providers sufficient lead time to implement the cuts in Medicare, CMS delayed implementation of Medicare cuts until April 1, 2013. As there has been no further Congressional action with respect to the sequestration, reimbursements were cut by 2% for Medicare providers, including physicians and ambulance providers, starting April 1, 2013, and cuts are scheduled annually through 2021. A subsequent round of budget sequestration cuts took effect in January 2014 further reducing Medicare provider reimbursements by another 2% for 2014. The Continuing Appropriations Resolution 2014 (Public Law 113-67), enacted December 26, 2013, extends the annual budget sequestration cuts to Medicare provider payments for an additional two years through 2023.

On November 1, 2012, CMS released the final regulation which implements Section 1202 of the Patient and Affordable Care Act. This section increases Medicaid payments for specified primary care services in both the fee-for-service and managed care settings to Medicare levels for certain primary care physicians in 2013 and 2014. This resulted in an increase to our net revenue of approximately $24.1 million and $2.5 million for the nine months ended September 30, 2014 and 2013, respectively.

Changes in Net New Contracts

Our operating results are affected directly by the number of net new contracts we have in a period, reflecting the effects of both new contracts and contract expirations. We regularly bid for new contracts, frequently in a formal competitive bidding process that often requires written responses to a request for proposal (“RFP”), and, in any fiscal period, certain of our contracts will expire. We may elect not to seek extension or renewal of a contract if we determine that we cannot do so on favorable terms. With respect to expiring contracts we would like to renew, we may be required to seek renewal through an RFP, and we may not be successful in retaining any such contracts, or retaining them on terms that are as favorable as present terms.

38

Inflation and Fuel Costs

Certain of our expenses, such as wages and benefits, insurance, fuel and equipment repair and maintenance costs, are subject to normal inflationary pressures. Fuel expense represented 13.3% and 12.8% of AMR’s operating expenses for the three and nine months ended September 30, 2014, respectively, as compared to 12.7% and 13.0% for the three and nine months ended September 30, 2013, respectively. Although we have generally been able to offset inflationary cost increases through increased operating efficiencies and successful negotiation of fees and subsidies, we can provide no assurance that we will be able to offset any future inflationary cost increases through similar efficiencies and fee changes.

Critical Accounting Policies

For a discussion of accounting policies that we consider critical to our business operations and the understanding of our results of operations that affect the more significant judgments and estimates used in the preparation of our unaudited consolidated financial statements, please refer to “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies” contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. As of September 30, 2014, there were no significant changes in our critical accounting policies or estimation procedures.

Results of Operations

Three and Nine Months ended September 30, 2014 Compared to the Three and Nine Months ended September 30, 2013

The following tables present a comparison of financial data from our unaudited consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013 for the Company and our two operating segments.

Non-GAAP Measures

Adjusted EBITDA is defined as net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, related party management fees, restructuring charges, and depreciation and amortization expense. Adjusted EBITDA is commonly used by management and investors as a performance measure. Adjusted EBITDA is not considered a measure of financial performance under GAAP and the items excluded from Adjusted EBITDA are significant components in understanding and assessing our financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in our financial statements as an indicator of financial performance. Since Adjusted EBITDA is not a measure determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

39

The following tables sets forth a reconciliation of Adjusted EBITDA to net income (loss):

Consolidated Results of Operations and as a Percentage of Net Revenue

(dollars in thousands, unaudited)

	Three months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	1,150,329		100.0	%	$	955,888		100.0	%
Compensation and benefits	819,353			71.2		677,797			70.9
Operating expenses	129,535			11.3		110,387			11.5
Insurance expense	27,527			2.4		26,974			2.8
Selling, general and administrative expenses	22,851			2.0		40,733			4.3
Equity-based compensation expense	(1,062		)	(0.1	)	(1,062		)	(0.1	)
Related party management fees	—			—		(20,609		)	(2.1	)
Interest income from restricted assets	(175		)	(0.0	)	(2		)	(0.0	)
Net income (loss) attributable to noncontrolling interest	67			0.0		—			—
Adjusted EBITDA	152,233			13.2		121,670			12.7
Equity-based compensation expense	(1,062		)	(0.1	)	(1,062		)	(0.1	)
Related party management fees	—			—		(20,609		)	(2.1	)
Depreciation and amortization expense	(36,796		)	(3.2	)	(35,175		)	(3.7	)
Restructuring charges	(366		)	(0.0	)	(1,319		)	(0.1	)
Interest expense, net	(25,742		)	(2.2	)	(46,772		)	(4.9	)
Realized gains (losses) on investments	(466		)	(0.0	)	158			0.0
Other income (expense), net	(660		)	(0.1	)	(52		)	(0.0	)
Loss on early debt extinguishment	—			—		(29,519		)	(3.1	)
Income tax benefit (expense)	(34,437		)	(3.0	)	4,949			0.5
Equity in earnings of unconsolidated subsidiary	72			0.0		68			0.0
Net income (loss) attributable to noncontrolling interest	67			0.0		—			—
Net income (loss)	$	52,843		4.6	%	$	(7,663	)	(0.8	)%

	Nine months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	3,239,867		100.0	%	$	2,743,467		100.0	%
Compensation and benefits	2,330,021			71.9		1,963,546			71.5
Operating expenses	364,885			11.3		313,145			11.4
Insurance expense	90,091			2.8		78,647			2.9
Selling, general and administrative expenses	65,820			2.0		86,521			3.1
Equity-based compensation expense	(3,612		)	(0.1	)	(3,186		)	(0.1	)
Related party management fees	—			—		(23,109		)	(0.8	)
Interest income from restricted assets	(507		)	(0.0	)	(634		)	(0.0	)
Net income (loss) attributable to noncontrolling interest	(3,233		)	(0.1	)	—			—
Adjusted EBITDA	396,402			12.2		328,537			12.0
Equity-based compensation expense	(3,612		)	(0.1	)	(3,186		)	(0.1	)
Related party management fees	—			—		(23,109		)	(0.8	)
Depreciation and amortization expense	(108,786		)	(3.4	)	(104,552		)	(3.8	)
Restructuring charges	(4,906		)	(0.2	)	(4,988		)	(0.2	)
Interest expense, net	(84,793		)	(2.6	)	(148,526		)	(5.4	)
Realized gains (losses) on investments	648			0.0		276			0.0
Other income (expense), net	(3,432		)	(0.1	)	(13,022		)	(0.5	)
Loss on early debt extinguishment	(66,397		)	(2.0	)	(29,641		)	(1.1	)
Income tax benefit (expense)	(49,700		)	(1.5	)	(3,932		)	(0.2	)
Equity in earnings of unconsolidated subsidiary	185			0.0		230			0.0
Net income (loss) attributable to noncontrolling interest	(3,233		)	(0.1	)	—			—
Net income (loss)	$	72,376		2.2	%	$	(1,913	)	(0.1	)%

40

Segment Results of Operations and as a Percentage of Net Revenue

(in thousands, unaudited)

EmCare

	Three months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	748,080		100.0	%	$	605,105		100.0	%
Compensation and benefits	589,458			78.8		475,817			78.6
Operating expenses	30,786			4.1		22,195			3.7
Insurance expense	16,750			2.2		15,662			2.6
Selling, general and administrative expenses	11,835			1.6		18,609			3.1
Interest income from restricted assets	(64		)	(0.0	)	109			0.0
Equity-based compensation expense	(478		)	(0.0	)	(457		)	(0.1	)
Related party management fees	—			—		(8,862		)	(1.5	)
Net income (loss) attributable to noncontrolling interest	67			0.0		—			—
Adjusted EBITDA	99,726			13.3		82,032			13.6	%
Depreciation and amortization expenses	(18,030		)	(2.4	)	(16,434		)	(2.7	)
Restructuring charges	25			0.0		(682		)	(0.1	)
Interest income from restricted assets	(64		)	(0.0	)	109			0.0
Equity-based compensation expense	(478		)	(0.0	)	(457		)	(0.1	)
Related party management fees	—			—		(8,862		)	(1.5	)
Net income (loss) attributable to noncontrolling interest	67			0.0		—			—
Income from operations	$	81,246		10.9	%	$	55,706		9.2	%

	Nine months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	2,082,661		100.0	%	$	1,729,158		100.0	%
Compensation and benefits	1,661,532			79.8		1,362,608			78.8
Operating expenses	80,111			3.9		68,093			3.9
Insurance expense	52,504			2.5		49,651			2.9
Selling, general and administrative expenses	35,368			1.7		41,647			2.4
Interest income from restricted assets	(174		)	(0.0	)	(301		)	(0.0	)
Equity-based compensation expense	(1,626		)	(0.1	)	(1,370		)	(0.1	)
Related party management fees	—			—		(9,937		)	(0.6	)
Net income (loss) attributable to noncontrolling interest	(3,233		)	(0.2	)	—			—
Adjusted EBITDA	258,179			12.4		218,767			12.7	%
Depreciation and amortization expenses	(50,949		)	(2.4	)	(49,423		)	(2.9	)
Restructuring charges	(872		)	(0.0	)	(934		)	(0.1	)
Interest income from restricted assets	(174		)	(0.0	)	(301		)	(0.0	)
Equity-based compensation expense	(1,626		)	(0.1	)	(1,370		)	(0.1	)
Related party management fees	—			—		(9,937		))	(0.6	)
Net income (loss) attributable to noncontrolling interest	(3,233		)	(0.2	)	—			—
Income from operations	$	201,325		9.7	%	$	156,802		9.0	%

41

Segment Results of Operations and as a Percentage of Net Revenue

(in thousands, unaudited)

AMR

	Three months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	402,249		100.0	%	$	350,783		100.0	%
Compensation and benefits	229,895			57.2		201,980			57.6
Operating expenses	98,749			24.5		88,209			25.1
Insurance expense	10,777			2.7		11,312			3.2
Selling, general and administrative expenses	11,016			2.7		22,122			6.3
Interest income from restricted assets	(111		)	(0.0	)	(111		)	(0.0	)
Equity-based compensation expense	(584		)	(0.2	)	(605		)	(0.2	)
Related party management fees	—			—		(11,747		)	(3.3	)
Adjusted EBITDA	52,507			13.1		39,623			11.3
Depreciation and amortization expenses	(18,766		)	(4.7	)	(18,741		)	(5.4	)
Restructuring charges	(391		)	(0.1	)	(637		)	(0.2	)
Interest income from restricted assets	(111		)	(0.0	)	(111		)	(0.0	)
Equity-based compensation expense	(584		)	(0.2	)	(605		)	(0.2	)
Related party management fees	—			—		(11,747		)	(3.3	)
Income from operations	$	32,655		8.1	%	$	7,782		2.2	%

	Nine months ended September 30,
	2014			% of netrevenue		2013			% of netrevenue
Net revenue	$	1,157,206		100.0	%	$	1,014,309		100.0	%
Compensation and benefits	668,489			57.8		600,938			59.2
Operating expenses	284,774			24.6		244,982			24.2
Insurance expense	37,587			3.3		28,996			2.9
Selling, general and administrative expenses	30,452			2.6		44,871			4.4
Interest income from restricted assets	(333		)	(0.0	)	(333		)	(0.0	)
Equity-based compensation expense	(1,986		)	(0.2	)	(1,816		)	(0.2	)
Related party management fees	—			—		(13,172		)	(1.3	)
Adjusted EBITDA	138,223			11.9		109,843			10.8
Depreciation and amortization expenses	(57,837		)	(5.0	)	(55,129		)	(5.4	)
Restructuring charges	(4,034		)	(0.3	)	(4,054		)	(0.4	)
Interest income from restricted assets	(333		)	(0.0	)	(333		)	(0.0	)
Equity-based compensation expense	(1,986		)	(0.2	)	(1,816		)	(0.2	)
Related party management fees	—			—		(13,172		)	(1.3	)
Income from operations	$	74,033		6.4	%	$	35,339		3.5	%

42

Three months ended September 30, 2014 compared to the Three months ended September 30, 2013

Consolidated

Our results for the three months ended September 30, 2014 reflect an increase in net revenue of $194.4 million and an increase in net income of $60.5 million compared to the three months ended September 30, 2013.  The increase in net income is attributable primarily to the decrease in interest expense from the redemption of the 2019 Notes in December of 2013 and June of 2014, the redemption of the PIK Notes in August of 2013, the re-pricing of the Term Loan Facility and ABL Facility in February of 2013 and the decrease in expenses related to the payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R of $20.0 million.

Net revenue. For the three months ended September 30, 2014, we generated net revenue of $1,150.3 million compared to $955.9 million for the three months ended September 30, 2013, representing an increase of 20.3%. The increase is attributable primarily to increases in rates and volumes on existing contracts combined with increased volume from net new contracts and acquisitions, partially offset by the impact of markets exited.

Adjusted EBITDA. For the three months ended September 30, 2014, Adjusted EBTIDA was $152.2 million, or 13.2% of net revenue, compared to $121.7 million, or 12.7% of net revenue for the three months ended September 30, 2013.

Restructuring charges. For the three months ended September 30, 2014, restructuring charges were $0.4 million, related to continuing efforts to re-align AMR and EmCare operations, compared to $1.3 million for the three months ended September 30, 2013.

Interest expense, net. For the three months ended September 30, 2014, interest expense was $25.7 million compared to $46.8 million for the three months ended September 30, 2013. The decrease was due to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014, the redemption of the PIK Notes on August 30, 2013 and the re-pricing of the Term Loan Facility and ABL Facility in February 2013, offset by the increase in interest expense from the 2022 Notes issued on June 18, 2014.

Other income (expense), net. For the three months ended September 30, 2014, other (income) expense, net was $0.7 million of expense compared to $0.1 million of expense for the three months ended September 30, 2013.

Income tax benefit (expense). For the three months ended September 30, 2014, income tax expense was $34.4 million compared to income tax benefit of $4.9 million for the three months ended September 30, 2013. Our effective tax rate was 39.5% and 39.0% for the three months ended September 30, 2014 and 2013, respectively.

EmCare

Net revenue. For the three months ended September 30, 2014, EmCare generated net revenue of $748.1 million compared to $605.1 million for the three months ended September 30, 2013, representing an increase of $143.0 million, or 23.6%. The increase was due to an increase in patient encounters from net new hospital contracts and net revenue increases in existing contracts. Net new contracts since September 30, 2013 accounted for a net revenue increase of $66.4 million for the three months ended September 30, 2014, of which $33.6 million came from net new contracts added in 2013, with the remaining increase in net revenue from those added in 2014. Net revenue under our same store contracts (contracts in existence for the entirety of both periods) increased $40.7 million, or 7.9%, for the three months ended September 30, 2014. The change was due to a 1.6% increase in revenue per weighted patient encounter and a 6.3% increase in same store weighted patient encounters. Revenue from recent acquisitions was $35.9 million during the three months ended September 30, 2014.

Compensation and benefits. For the three months ended September 30, 2014, compensation and benefits costs were $589.5 million, or 78.8% of net revenue, compared to $475.8 million, or 78.6% of net revenue, for the three months ended September 30, 2013. Provider compensation costs increased $81.4 million from net new contract additions and acquisitions and $21.4 million from same store contracts.  Non-provider compensation and total benefits costs increased by $10.9 million for the three months ended September 30, 2014 compared to the three months ended September 30, 2013 due primarily to organic growth.

Operating expenses. For the three months ended September 30, 2014, operating expenses were $30.8 million, or 4.1% of net revenue, compared to $22.2 million, or 3.7% of net revenue, for the three months ended September 30, 2013.

Insurance expense. For the three months ended September 30, 2014, professional liability insurance expense was $16.8 million, or 2.2% of net revenue, compared to $15.7 million, or 2.6% of net revenue, for the three months ended September 30, 2013. We recorded an increase of prior year insurance provisions of $0.6 million during the three months ended September 30, 2014 compared to a decrease of $0.1 million for the three months ended September 30, 2013.

43

Selling, general and administrative. For the three months ended September 30, 2014, selling, general, and administrative expense was $11.8 million, or 1.6% of net revenue, compared to $18.6 million, or 3.1% of net revenue, for the three months ended September 30, 2013.  The decrease is attributable primarily to the decrease in expenses related to the allocation of $8.6 million to EmCare with respect to the payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R.

Depreciation and amortization. For the three months ended September 30, 2014, depreciation and amortization expense was $18.0 million, or 2.4% of net revenue, compared to $16.4 million, or 2.7% of net revenue, for the three months ended September 30, 2013.

AMR

Net revenue. For the three months ended September 30, 2014, AMR generated net revenue of $402.2 million compared to $350.8 million for the three months ended September 30, 2013, representing an increase of $51.4 million, or 14.7%. The increase in net revenue was due primarily to an increase in net revenue per weighted transport of 1.1%, or $3.8 million, primarily from increased managed transportation revenue which has no associated transport volume and increased rates in existing markets and an increase of 13.6%, or $47.6 million, in weighted transport volume. Weighted transports increased 95,100 from the same quarter last year. The change was due to an increase of 67,500 weighted transports from our entry into new markets and recent acquisitions and an increase of 4.9%, or 33,400 weighted transports, in existing markets, offset by a decrease of 5,800 weighted transports from exited markets.

Compensation and benefits. For the three months ended September 30, 2014, compensation and benefits costs were $229.9 million, or 57.2% of net revenue, compared to $202.0 million, or 57.6% of net revenue, for the three months ended September 30, 2013. The increase was primarily due to additional compensation and benefits costs from new markets and recent acquisitions.  As a percentage of net revenue, the decrease primarily relates to our recent managed transportation acquisitions in which we do not directly employ the providers and therefore; such provider costs are included within operating expenses.  Ambulance crew wages per ambulance unit hour increased by approximately 1.0%, or $1.3 million, and ambulance unit hours increased period over period by 11.9%, or $13.9 million. Non-crew compensation increased $8.3 million for the three months ended September 30, 2014 compared to the three months ended September 30, 2013 due to increased costs associated with the net impact from markets entered and exited and increased costs from recent acquisitions. Total benefits related costs increased $4.4 million for the three months ended September 30, 2014 compared to the three months ended September 30, 2013 due primarily to the impact from markets entered and recent acquisitions.

Operating expenses. For the three months ended September 30, 2014, operating expenses were $98.7 million, or 24.5% of net revenue, compared to $88.2 million, or 25.1% of net revenue, for the three months ended September 30, 2013.  The change was due primarily to increased costs of $1.4 million associated with the net impact from markets entered and exited, increased costs of $7.9 million primarily from recent managed transportation acquisitions, and increased other miscellaneous net operating costs of $2.2 million offset by decreased costs associated with our existing managed transportation business of $1.0 million.

Insurance expense. For the three months ended September 30, 2014, insurance expense was $10.8 million, or 2.7% of net revenue, compared to $11.3 million, or 3.2% of net revenue, for the three months ended September 30, 2013. We recorded a decrease of prior year insurance provisions of $1.3 million during the three months ended September 30, 2014 compared to an increase of $1.7 million during the three months ended September 30, 2013.

Selling, general and administrative. For the three months ended September 30, 2014, selling, general, and administrative expense was $11.0 million, or 2.7% of net revenue, compared to $22.1 million, or 6.3% of net revenue, for the three months ended September 30, 2013.  The decrease is attributable primarily to the decrease in expenses related to the allocation of $11.4 million to AMR with respect to the payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R

Depreciation and amortization. For the three months ended September 30, 2014, depreciation and amortization expense was $18.8 million, or 4.7% of net revenue, compared to $18.7 million, or 5.4% of net revenue, for the three months ended September 30, 2013.

Nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

Consolidated

Our results for the nine months ended September 30, 2014 reflect an increase in net revenue of $496.4 million and an increase in net income of $74.3 million compared to the nine months ended September 30, 2013. The increase in net income is attributable primarily to the decrease in interest expense from the redemption of the 2019 Notes in December of 2013 and June of 2014, the redemption of the PIK Notes in August of 2013, the re-pricing of the Term Loan Facility and ABL Facility in February of 2013, and the decrease in expenses related to the dissenting shareholder lawsuit that was settled in 2013 and the $20.0 million payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R, offset by the loss on early debt extinguishment of the 2019 Notes in June of 2014.

44

Net revenue. For the nine months ended September 30, 2014, we generated net revenue of $3,239.9 million compared to $2,743.5 million for the nine months ended September 30, 2013, representing an increase of 18.1%. The increase is attributable primarily to increases in rates and volumes on existing contracts combined with increased volume from net new contracts and acquisitions, partially offset by the impact of markets exited.

Adjusted EBITDA. For the nine months ended September 30, 2014, Adjusted EBTIDA was $396.4 million, or 12.2% of net revenue, compared to $328.5 million, or 12.0% of net revenue for the nine months ended September 30, 2013.

Restructuring charges. For the nine months ended September 30, 2014, restructuring charges were $4.9 million, related to continuing efforts to re-align AMR and EmCare operations, compared to $5.0 million for the nine months ended September 30, 2013.

Interest expense, net. For the nine months ended September 30, 2014, interest expense was $84.8 million compared to $148.5 million for the nine months ended September 30, 2013. The decrease was due to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014, the redemption of the PIK Notes on August 30, 2013, and the re-pricing of the Term Loan Facility and ABL Facility in February 2013, offset by the increase in interest expense from the 2022 Notes issued on June 18, 2014.

Other income (expense), net. For the nine months ended September 30, 2014, other income (expense), net was $3.4 million of expense compared to $13.0 million of expense for the nine months ended September 30, 2013. We recorded $8.4 million of expense during the nine months ended September 30, 2013 related to a settlement with a prior shareholder regarding its appraisal action over its holdings in Corporation prior to the Merger on May 25, 2011.

Income tax benefit (expense). For the nine months ended September 30, 2014, income tax expense was $49.7 million compared to $3.9 million for the nine months ended September 30, 2013. Our effective tax rate was 40.8% and 219.8% for the nine months ended September 30, 2014 and 2013, respectively. Our effective tax rate for the nine months ended September 30, 2013 was impacted by the settlement with a prior shareholder regarding its appraisal action over its holdings in the Company prior to the Merger, which was not deductible for tax purposes.

EmCare

Net revenue. For the nine months ended September 30, 2014, EmCare generated net revenue of $2,082.7 million compared to $1,729.2 million for the nine months ended September 30, 2013, representing an increase of $353.5 million, or 20.4%. The increase was due to an increase in patient encounters from net new hospital contracts and net revenue increases in existing contracts. Net new contracts since September 30, 2013 accounted for a net revenue increase of $236.9 million for the nine months ended September 30, 2014, of which $165.8 million came from net new contracts added in 2013, with the remaining increase in net revenue from those added in 2014. Net revenue under our same store contracts (contracts in existence for the entirety of both periods) increased $73.6 million, or 5.2%, for the nine months ended September 30, 2014. The change was due to a 2.0% increase in revenue per weighted patient encounter and a 3.2% increase in same store weighted patient encounters. Revenue from recent acquisitions was $43.0 million during the nine months ended September 30, 2014.

Compensation and benefits. For the nine months ended September 30, 2014, compensation and benefits costs were $1,661.5 million, or 79.8% of net revenue, compared to $1,362.6 million, or 78.8% of net revenue, for the nine months ended September 30, 2013. Provider compensation costs increased $229.3 million from net new contract additions and acquisitions and $42.0 million from same store contracts.  Non-provider compensation and total benefits costs increased by $27.6 million for the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 due primarily to organic growth.

Operating expenses. For the nine months ended September 30, 2014, operating expenses were $80.1 million, or 3.9% of net revenue, compared to $68.1 million, or 3.9% of net revenue, for the nine months ended September 30, 2013.

Insurance expense. For the nine months ended September 30, 2014, professional liability insurance expense was $52.5 million, or 2.5% of net revenue, compared to $49.7 million, or 2.9% of net revenue, for the nine months ended September 30, 2013. We recorded an increase of prior year insurance provisions of $3.5 million during the nine months ended September 30, 2014 compared to an increase of $1.5 million for the nine months ended September 30, 2013.

45

Selling, general and administrative. For the nine months ended September 30, 2014, selling, general, and administrative expense was $35.4 million, or 1.7% of net revenue, compared to $41.6 million, or 2.4% of net revenue, for the nine months ended September 30, 2013. The decrease is attributable primarily to the decrease in expenses related to the allocation of $8.6 million to EmCare with respect to the payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R.

Depreciation and amortization. For the nine months ended September 30, 2014, depreciation and amortization expense was $50.9 million, or 2.4% of net revenue, compared to $49.4 million, or 2.9% of net revenue, for the nine months ended September 30, 2013.

AMR

Net revenue. For the nine months ended September 30, 2014, AMR generated net revenue of $1,157.2 million compared to $1,014.3 million for the nine months ended September 30, 2013, representing an increase of $142.9 million, or 14.1%. The increase in net revenue was due primarily to an increase in net revenue per weighted transport of 3.4%, or $34.1 million, primarily from increased managed transportation revenue which has no associated transport volume and increased rates in existing markets and an increase of 10.7%, or $108.8 million, in weighted transport volume. Weighted transports increased 224,700 compared to the nine months ended September 30, 2013. The change was due to an increase of 201,300 weighted transports from our entry into new markets and recent acquisitions and an increase of 2.7%, or 55,100 weighted transports, in existing markets, offset by a decrease of 31,700 weighted transports from exited markets.

Compensation and benefits. For the nine months ended September 30, 2014, compensation and benefits costs were $668.5 million, or 57.8% of net revenue, compared to $600.9 million, or 59.2% of net revenue, for the nine months ended September 30, 2013. The increase was primarily due to additional compensation and benefits costs from new markets and recent acquisitions.  As a percentage of net revenue, the decrease primarily relates to our recent managed transportation acquisitions in which we do not directly employ the providers and therefore; such provider costs are included within operating expenses.  Ambulance crew wages per ambulance unit hour increased by approximately 0.5%, or $1.7 million, and ambulance unit hours increased period over period by 10.2%, or $35.1 million. Non-crew compensation increased $23.5 million for the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 due to increased costs associated with the net impact from markets entered and exited and increased costs from recent acquisitions. Total benefits related costs increased $7.3 million for the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 due primarily to the impact from markets entered and recent acquisitions.

Operating expenses. For the nine months ended September 30, 2014, operating expenses were $284.8 million, or 24.6% of net revenue, compared to $245.0 million, or 24.2% of net revenue, for the nine months ended September 30, 2013. The change was due primarily to increased costs of $6.4 million associated with the net impact from markets entered and exited, increased costs of $33.4 million primarily from recent managed transportation acquisitions, and increased costs of other miscellaneous net operating costs of $3.8 million, offset by decreased costs associated with our existing managed transportation business of $3.8 million.

Insurance expense. For the nine months ended September 30, 2014, insurance expense was $37.6 million, or 3.3% of net revenue, compared to $29.0 million, or 2.9% of net revenue, for the nine months ended September 30, 2013. We recorded an increase of prior year insurance provisions of $3.1 million during the nine months ended September 30, 2014 compared to a decrease of $0.3 million during the nine months ended September 30, 2013.

Selling, general and administrative. For the nine months ended September 30, 2014, selling, general, and administrative expense was $30.5 million, or 2.6% of net revenue, compared to $44.9 million, or 4.4% of net revenue, for the nine months ended September 30, 2013. The decrease was due to the receipt of $1.9 million in reimbursement of costs associated with certain exit activities and the decrease in expenses related to the allocation of $11.4 million to AMR with respect to the payment made in 2013 to CD&R to terminate the Consulting Agreement with CD&R.

Depreciation and amortization. For the nine months ended September 30, 2014, depreciation and amortization expense was $57.8 million, or 5.0% of net revenue, compared to $55.1 million, or 5.4% of net revenue, for the nine months ended September 30, 2013. The increase was due primarily to technology and fleet-related additions and an increase in amortizable intangible assets from recent acquisitions.

Liquidity and Capital Resources

Our primary source of liquidity is cash flows provided by the operating activities of our subsidiaries. The Company and its subsidiaries also have the ability to use the ABL Facility, described below, to supplement cash flows provided by our operating activities if we decide to do so for strategic or operating reasons. Our liquidity needs are primarily to service long-term debt and to fund working capital requirements, capital expenditures related to the acquisition of vehicles and medical equipment, technology-related assets and insurance-related deposits.

46

On May 25, 2011, Corporation issued $950 million of the 2019 Notes and entered into the $1.8 billion Senior Secured Credit Facilities, that consisted of a $1.44 billion Term Loan Facility and a $350 million ABL Facility which are further described in Note 7 of the accompanying unaudited consolidated financial statements.

2019 Notes

During the second quarter of 2012, the Company’s captive insurance subsidiary purchased $15.0 million of the 2019 Notes through an open market transaction and currently holds none of the 2019 Notes subsequent to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014.

On December 30, 2013, the Company redeemed $332.5 million in aggregate principal amount of the 2019 Notes of which $5.2 million was held by the Company’s captive insurance subsidiary at a redemption price of 108.125%, plus accrued and unpaid interest of $2.2 million. During the fourth quarter of 2013, the Company recorded a loss on early debt extinguishment of $38.7 million related to premiums and unamortized debt issuance costs from the partial redemption of the 2019 Notes.

On June 18, 2014, the Company redeemed $617.5 million in aggregate principal amount of the 2019 Notes of which $9.8 million was held by the Company’s captive insurance subsidiary at a redemption price of 106.094%, plus accrued and unpaid interest of $2.4 million. During the second quarter of 2014, the Company recorded a loss on early debt extinguishment of $66.4 million related to premiums, financing fees paid to the creditors of the 2022 Notes, and unamortized debt issuance costs from the redemption of the 2019 Notes.

Term Loan Facility

On February 7, 2013, Corporation, the borrower under the Term Loan Facility, entered into the Term Loan Amendment to the Term Loan Credit Agreement. Under the Term Loan Amendment, the Company incurred an additional $150 million in incremental borrowings under the Term Loan Facility, the proceeds of which were used to pay down the ABL Facility. In addition, the rate at which the loans under the Term Loan Credit Agreement bear interest was amended to equal (i) the higher of (x) LIBOR and (y) 1.00%, plus, in each case, 3.00% (with a step-down to 2.75% in the event that we meet a consolidated first lien net leverage ratio of 2.50:1.00), or (ii) the alternate base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% and (z) 2.00%, plus, in each case, 2.00% (with a step-down to 1.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00).

ABL Facility

On February 27, 2013, Corporation entered into the ABL Credit Agreement, under which the Company increased its commitments under the ABL Facility to $450 million and extended the term to 2018. In addition, the rate at which the loans under the ABL Credit Agreement bear interest was amended to equal (i) LIBOR plus, (x) 2.00% in the event that average daily excess availability is less than or equal to 33% of availability, (y) 1.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (z) 1.50% in the event that average daily excess availability is greater than 66% of availability, or (ii) the alternate base rate, which will be the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) 0.50% in excess of the overnight federal funds rate and (z) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% plus, in each case, (A) 1.00% in the event that average daily excess availability is less than or equal to 33% of availability, (B) 0.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (C) 0.50% in the event that average daily excess availability is greater than 66% of availability.

The ABL Facility provides for up to $450 million of senior secured first priority borrowings, subject to a borrowing base of $450.0 million as of September 30, 2014. The ABL Facility is available to fund working capital and for general corporate purposes. As of September 30, 2014, we had available borrowing capacity of $319.8 million and $130.2 million of letters of credit issued under the ABL Facility.

While the ABL Facility generally does not contain financial maintenance covenants, a springing fixed charge coverage ratio of not less than 1.0 to 1.0 will be tested if our excess availability (as defined in the credit agreement governing the ABL Facility) falls below specified thresholds at any time. If we require additional financing to meet cyclical increases in working capital needs, to fund acquisitions or unanticipated capital expenditures, we may need to access the financial markets.

47

The credit agreements governing the ABL Facility and the Term Loan Facility contain significant covenants, including prohibitions on our ability to incur certain additional indebtedness and to make certain investments and to pay dividends.

PIK Notes

On October 1, 2012, the Company issued $450 million aggregate principal amount of the PIK Notes.

On August 30, 2013, the Company redeemed the PIK Notes in full with a portion of the net proceeds of the Company’s initial public offering, at a redemption price equal to 102.75% of the aggregate principal amount of the PIK Notes, plus accrued and unpaid interest of $17.2 million. During the third quarter of 2013, the Company recorded a loss on early debt extinguishment of $29.5 million related to premiums and unamortized debt issuance costs from the redemption of the PIK Notes.

2022 Notes

On June 18, 2014, Corporation issued $750.0 million in aggregate principal amount of the 2022 Notes the proceeds of which were used to redeem the outstanding 2019 Notes and for other general corporate purposes.

The indenture governing the 2022 Notes contain significant covenants, including prohibitions on our ability to incur certain additional indebtedness and to make certain investments and to pay dividends.

We may from time to time repurchase or otherwise retire or extend our debt and/or take other steps to reduce our debt or otherwise improve our financial position. These actions may include open market debt repurchases, negotiated repurchases, other retirements of outstanding debt, and/or opportunistic refinancing of debt. The amount of debt that may be repurchased or otherwise retired or refinanced, if any, will depend on market conditions, trading levels of our debt, our cash position, compliance with debt covenants and other considerations. Our affiliates may also purchase our debt from time to time, through open market purchases or other transactions. In such cases, our debt may not be retired, in which case we would continue to pay interest in accordance with the terms of the debt, and we would continue to reflect the debt as outstanding in our consolidated statements of financial position.

Initial Public Offering

On August 13, 2013, the Company’s Registration Statement was declared effective by the SEC for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock, to be sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 for an aggregate offering price of $1,110.9 million. At the closing, we received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to CD&R in connection with the termination of the Consulting Agreement with CD&R which was recorded to selling, general and administrative expenses in the statements of operations.

Net proceeds from the initial public offering were used to (i) redeem in full the Company’s PIK Notes for a total of $479.6 million, which included a call premium pursuant to the indenture governing the PIK Notes and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement with CD&R, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million in principal amount of the 2019 Notes of which $5.2 million was held by our captive insurance subsidiary for a total of $356.5 million, which included a call premium pursuant to the indenture governing the 2019 Notes and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

Cash Flow

The table below summarizes cash flow information derived from our consolidated statements of cash flows for the periods indicated, amounts in thousands.

	Nine months ended September 30,
	2014			2013
Net cash provided by (used in):
Operating activities	$	194,004		$	25,625
Investing activities	(264,603		)	(70,031		)
Financing activities	113,057			562,335

Operating activities. Net cash provided by operating activities was $194.0 million for the nine months ended September 30, 2014 compared to net cash provided operating activities of $25.6 million for the nine months ended September 30, 2013. Operating cash flows for the nine months ended September 30, 2014 includes a payment of $9.7 million in settlement of prior period insurance claims. Cash flow from operating activities for nine months ended September 30, 2014 excluding this item was $203.7 million. Operating cash flows for the nine months ended September 30, 2013 includes a payment of $13.7 million to a prior shareholder in settlement of its appraisal action over its holdings in Corporation prior to the Merger, a payment of $20.0 million to terminate the Consulting Agreement with CD&R, and $24.5 million of payments related to AMR contract terminations and FEMA external providers. Cash flow from operating activities for the nine months ended September 30, 2013 excluding these payments was $83.8 million. Further, the increase of $168.4 million in net cash provided by operating activities relates primarily to improvements in accounts receivable collections and an increase in accounts payable and accrued liabilities from the timing of payments.

48

Accounts receivable increased $92.5 million and $126.5 million during nine months ended September 30, 2014 and 2013, respectively. Days sales outstanding (“DSO”) decreased 2 days during nine months ended September 30, 2014. While EmCare’s DSO decreased five (5) days, AMR’s DSO increased three (3) days.

We regularly analyze DSO which is calculated by dividing our net revenue for the quarter by the number of days in the quarter. The result is divided into net accounts receivable at the end of the period. DSO provides us with a gauge to measure receivables, revenue and collection activities.

The following table outlines our DSO by segment and in total excluding the impact of acquisitions completed within the specific quarter and the impact of the FEMA deployment at AMR in 2012:

	Q3 2014	Q2 2014	Q1 2014	Q4 2013	Q3 2013	Q2 2013	Q1 2013	Q4 2012
EmCare	77	79	82	82	77	71	68	65
AMR	66	62	62	63	64	64	66	68
Company	73	73	74	75	73	68	67	66

Investing activities. Net cash used in investing activities was $264.6 million for the nine months ended September 30, 2014 compared to $70.0 million for nine months ended September 30, 2013. The increase was primarily related to the increase in cash outflow for acquisitions of $171.9 million.

Financing activities. Net cash provided by financing activities was $113.1 million for the nine months ended September 30, 2014 compared to $562.3 million for the nine months ended September 30, 2013. For the nine months ended September 30, 2014, we received proceeds of $740.6 million from the issuance of the 2022 Notes, offset by our payment of $645.3 million, which includes a $37.6 million premium, to redeem $617.5 million in aggregate principal amount of our 2019 Notes of which $9.8 million was held by our captive insurance subsidiary. Additionally, we paid $14.4 million of employee related taxes related to the exercise of stock options in connection with the secondary offering in February of 2014, offset by the excess tax benefit from these stock option exercises of $38.5 million.

For the nine months ended September 30, 2013, we received proceeds from our initial public offering of $1,112.0 million, offset by related issuance costs paid of $63.4 million.  We paid $462.4 million, which included a $12.4 million premium, during the nine months ended September 30, 2013 to redeem our Senior PIK Toggle Notes due 2017.  We also increased our borrowings under our Term Loan Facility by $150.0 million, the proceeds of which were used to pay down our ABL Facility. Additionally, we paid approximately $5.0 million in costs incurred to refinance the Term Loan Facility and ABL Facility. Financing cash flows for the nine months ended September 30, 2013 also included a payment of $38.3 million to a prior shareholder in settlement of its appraisal action over its holdings in Corporation prior to the Merger.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary exposure to market risk consists of changes in fuel prices, changes in interest rates on certain of our borrowings, and changes in stock prices. While we have from time to time entered into transactions to mitigate our exposure to both changes in fuel prices and interest rates, we do not use these instruments for speculative or trading purposes.

We manage our exposure to changes in fuel prices and, as appropriate, use highly effective derivative instruments to manage well-defined risk exposures. As of September 30, 2014, we were party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.63 to $3.76 per gallon. We purchase the diesel fuel at the market rate and periodically settle with our counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 0.6 million gallons during the periods hedged through December 2014.

49

On October 17, 2011, we entered into interest rate swap agreements which mature on August 31, 2015. The swap agreements are with major financial institutions and effectively convert a notional amount of $400 million in variable rate debt to fixed rate debt with an effective rate of 4.49%. We will continue to make interest payments based on the variable rate associated with the debt (based on LIBOR, but not less than 1.0%) and will periodically settle with our counterparties for the difference between the rate paid and the fixed rate.

As of September 30, 2014, we had $2,040.1 million of debt, excluding capital leases, of which $1,289.4 million was variable rate debt under our senior secured credit facility and the balance was fixed rate debt. An increase or decrease in interest rates of 1.0%, above our LIBOR floor of 1.0%, will impact our interest costs by $12.9 million annually.

We are exposed to changes in stock prices primarily as a result of our holdings in publicly traded securities. We believe that changes in stock prices can be expected to vary as a result of general market conditions, specific industry changes, and other factors. As of September 30, 2014, the fair value of our available-for-sale securities was $25.0 million. Had the market price of such securities been 10% lower as of September 30, 2014, the aggregate fair value of such securities would have been $2.5 million lower.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintain systems of disclosure controls and procedures (as defined in Rule 13a-15(e)  under the Securities Exchange Act of 1934 (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the reports that they file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or furnishes under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, the Company’s management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of the Company’s management of the Company’s disclosure controls and procedures conducted as of the end of the period covered by this Report on Form 10-Q, the Company’s principal executive officer and principal financial officer have concluded that, as of the date of their evaluation, the Company’s disclosure controls and procedures (as defined in Rules 13e-15(e) promulgated under the Exchange Act) were effective as of September 30, 2014.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our fiscal quarter ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For information regarding legal proceedings, please refer to Note 12 to the accompanying consolidated financial statements included herein and the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

ITEM 1A. RISK FACTORS

A restated description of the risk factors associated with our business is set forth below. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously provided in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also materially and adversely affect our business operations. Any of the following risks could materially adversely affect our business, financial condition or results of operations.

50

Risks Related to Our Business

We are subject to decreases in our revenue and profit margin under our fee-for-service contracts, where we bear the risk of changes in volume, payor mix and third party reimbursement rates.

In our fee-for-service arrangements, which generated approximately 84% of our net revenue for the year ended December 31, 2013, we, or our affiliated physicians, collect the fees for transports and physician services provided. Under these arrangements, we assume financial risks related to changes in the mix of insured and uninsured patients and patients covered by government-sponsored healthcare programs, third party reimbursement rates, and transports and patient volume. In some cases, our revenue decreases if our volume or reimbursement decreases, but our expenses may not decrease proportionately. See “— Risks Related to Healthcare Regulation — Changes in the rates or methods of third party reimbursements, including due to political discord in the budgeting process outside our control, may adversely affect our revenue and operations”.

We collect a smaller portion of our fees for services rendered to uninsured patients than for services rendered to insured patients. Our credit risk related to services provided to uninsured individuals is exacerbated because the law requires communities to provide “911” emergency response services and hospital EDs to treat all patients presenting to the ED seeking care for an emergency medical condition regardless of their ability to pay. We also believe uninsured patients are more likely to seek care at hospital EDs because they frequently do not have a primary care physician with whom to consult.

Our revenue would be adversely affected if we lose existing contracts.

A significant portion of our growth historically has resulted from increases in the number of patient encounters and fees for services we provide under existing contracts, the addition of new contracts and the increase in the number of emergency and non-emergency transports. Substantially all of our net revenue in the year ended December 31, 2013 was generated under contracts, including exclusive contracts that accounted for approximately 89% of our 2013 net revenue. Our contracts with hospitals generally have terms of three years and the term of our contracts with communities to provide “911” services generally ranges from three to five years. Most of our contracts are terminable by either of the parties upon notice of as little as 30 days. Any of our contracts may not be renewed or, if renewed, may contain terms that are not as favorable to us as our current contracts. We cannot assure you that we will be successful in retaining our existing contracts or that any loss of contracts would not have a material adverse effect on our business, financial condition and results of operations. Furthermore, certain of our contracts will expire during each fiscal period, and we may be required to seek renewal of these contracts through a formal bidding process that often requires written responses to a request for proposal. We cannot assure you that we will be successful in retaining such contracts or that we will retain them on terms that are as favorable as present terms.

We may not accurately assess the costs we will incur under new contracts.

Our new contracts increasingly involve a competitive bidding process. When we obtain new contracts, we must accurately assess the costs we will incur in providing services in order to realize adequate profit margins and otherwise meet our financial and strategic objectives. Increasing pressures from healthcare payors to restrict or reduce reimbursement rates at a time when the costs of providing medical services continue to increase make assessing the costs associated with the pricing of new contracts, as well as maintenance of existing contracts, more difficult. Starting new contracts in a number of our service lines may also negatively impact cash flow as we absorb various expenses before we are able to bill and collect revenue associated with the new contracts. In addition, integrating new contracts, particularly those in new geographic locations, could prove more costly, and could require more management time, than we anticipate. Our failure to accurately predict costs or to negotiate an adequate profit margin could have a material adverse effect on our business, financial condition and results of operations.

We may not be able to successfully recruit and retain physicians and other healthcare professionals with the qualifications and attributes desired by us and our customers.

Our ability to recruit and retain affiliated physicians and other healthcare professionals significantly affects our performance under our contracts. Our customer hospitals have increasingly demanded a greater degree of specialized skills, training and experience in the healthcare professionals providing services under their contracts with us. This decreases the number of healthcare professionals who may be permitted to staff our contracts. Moreover, because of the scope of the geographic and demographic diversity of the hospitals and other facilities with which we contract, we must recruit healthcare professionals, and particularly physicians, to staff a broad spectrum of contracts. We have had difficulty in the past recruiting physicians to staff contracts in some regions of the country and at some less economically advantaged hospitals. Moreover, we compete with other entities to recruit and retain qualified physicians and other healthcare professionals to deliver clinical services. Our future success in retaining and winning new hospital contracts depends in part on our ability to recruit and retain physicians and other healthcare professionals to maintain and expand our operations.

51

Our non-compete agreements and other restrictive covenants involving physicians may not be enforceable.

We have contracts with physicians and professional corporations in many states. Some of these contracts, as well as our contracts with hospitals, include provisions preventing these physicians and professional corporations from competing with us both during and after the term of our relationship with them. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Some states are reluctant to strictly enforce non-compete agreements and restrictive covenants applicable to physicians. There can be no assurance that our non-compete agreements related to affiliated physicians and professional corporations will not be successfully challenged as unenforceable in certain states. In such event, we would be unable to prevent former affiliated physicians and professional corporations from competing with us, potentially resulting in the loss of some of our hospital contracts.

If we fail to implement our business strategy, our financial performance and our growth could be materially and adversely affected.

Our future financial performance and success are dependent in large part upon our ability to implement our business strategy successfully. Our business strategy includes several initiatives, including capitalizing on organic growth opportunities, growing complementary and integrated services lines, pursuing selective acquisitions, enhancing operational efficiencies and productivity, and expanding our Evolution Health business. We may not be able to implement our business strategy successfully or achieve the anticipated benefits of our business plan. If we are unable to do so, our long-term growth, profitability, and ability to service our debt will be adversely affected. Even if we are able to implement some or all of the initiatives of our business plan successfully, our operating results may not improve to the extent we anticipate, or at all.

Implementation of our business strategy could also be affected by a number of factors beyond our control, such as increased competition, legal developments, government regulation, general economic conditions or increased operating costs or expenses. In addition, to the extent we have misjudged the nature and extent of industry trends or our competition, we may have difficulty in achieving our strategic objectives.

Our margins may be negatively impacted by cross-selling to existing customers or selling bundled services to new customers.

One of our growth strategies involves the continuation and expansion of our efforts to sell complementary services across our businesses. There can be no assurance that we will be successful in our cross-selling efforts. As part of our cross-selling efforts, we may need to offer a bundled package of services that are at a lower price point to existing or new customers as compared to the price of individual services or otherwise offer services which may put downward price pressure on our services. Such price pressure may have a negative impact on our operating margins. In addition, if a complementary service offered as part of a bundled package underperforms as compared to the other services included in such package, we could face reputational harm which could negatively impact our relationships with our customers and ultimately our results of operations.

We may not succeed in our efforts to develop our Evolution Health business, which is subject to additional rules, prohibitions, regulations and reimbursement requirements that differ from our facility-based physician and healthcare transportation services.

We have only recently expanded our EmCare physician-led services outside the hospital through the formation of Evolution Health. Currently, Evolution Health accounts for less than 5% of our consolidated net revenue and provides services in only four states. A key component of our growth strategy is to continue to expand our Evolution Health business by adding new customers and entering new geographic markets. As part of this strategy, we intend to expand the non-hospital care services we provide through Evolution Health to hospital systems, transitional care programs, accountable care organizations and health plans. This anticipated expansion will expose us to additional risks, in part because our Evolution Health business requires compliance with additional federal and state laws and regulations, including those that govern licensure, enrollment, documentation, prescribing, coding, and scope of practice, which may differ from the laws and regulations that govern our other businesses. For example, we utilize nurses and other allied health personnel in providing care to patients outside the acute-care setting. It is necessary for us to make sure that these personnel only provide services within the scope of their license. Compliance with applicable laws and regulations may result in unanticipated expenses. In addition, if we are unable to comply with the additional legal requirements, we could incur liability which could materially and adversely affect our business, financial condition or results of operations.

The implementation of the PPACA is not complete, and is subject to various uncertainties that could affect our Evolution Health business, including (i) the degree to which the United States moves away from its traditional fee-for-service delivery model to an outcome-based delivery model, (ii) the number of additional healthcare consumers currently without means of payment that will ultimately gain access to insurance and (iii) the scope of reimbursement changes to the U.S. healthcare system. As such, there can be no assurance that our expansion efforts in this business will ultimately be successful. In addition, realizing growth opportunities in physician-led care management solutions outside the hospital setting will require significant attention from our management team, and if management is unable to provide such attention, implementation of this strategy could be delayed or hindered and thereby negatively impact our business.

52

We may enter into partnerships with payors and other healthcare providers, including risk-based partnerships under the PPACA. If this strategy is not successful, our financial performance could be adversely affected.

In recent years, we have entered into strategic business partnerships with hospital systems and other large payors to take advantage of commercial opportunities in our facility-based physician services business. For example, EmCare has entered into joint venture agreements with large hospital systems to provide physician services to various healthcare facilities. However, there can be no assurance that our efforts in these areas will continue to be successful. Moreover, joint venture and strategic partnership models expose us to commercial risks that may be different from our other business models, including that the success of the joint venture or partnership is only partially under our operational and legal control and the opportunity cost of not pursuing the specific venture independently or with other partners. In addition, under certain joint venture or strategic partnership arrangements, the hospital system partner has the option to acquire our stake in the venture on a predetermined financial formula, which, if exercised, would lead to the loss of our associated revenue and profits which may not be offset fully by the immediate proceeds of the sale of our stake. Furthermore, joint ventures may raise fraud and abuse issues. For example, the OIG has taken the position that certain contractual joint ventures between a party which makes referrals and a party which receives referrals for a specific type of service may violate the federal Anti-Kickback Statute if one purpose of the arrangement is to encourage referrals.

In addition, we plan to take advantage of various opportunities afforded by the PPACA to enter into risk-based partnerships designed to encourage healthcare providers to assume financial accountability for outcomes and work together to better coordinate care for patients, both when they are in the hospital and after they are discharged. Examples of such initiatives include the CMS Bundled Payments for Care Improvement initiative, the Medicare Shared Savings Program and the Independence at Home Demonstration. We view taking advantage of targeted initiatives in the new regulatory environment as an important part of our business strategy in order to develop our integrated service offerings across the patient continuum, further develop our relationships with hospitals, hospital systems and other payors and prepare for the possibility that Medicare may require us to participate in a capitated or value-based payment system for certain of our businesses in the future.

Advancing such initiatives can be time consuming and expensive, and there can be no assurance that our efforts in these areas would ultimately be successful. In addition, if we succeed in our efforts to enter into these risk-based partnerships but fail to deliver quality care at a cost consistent with our expectations, we may be subject to significant financial penalties depending on the program, and an unsuccessful implementation of such initiatives could materially and adversely affect our business, financial condition or results of operations.

We could be subject to lawsuits for which we are not fully reserved.

Physicians, hospitals and other participants in the healthcare industry have become subject to an increasing number of lawsuits alleging medical malpractice and related legal theories such as negligent hiring, supervision and credentialing. Similarly, ambulance transport services may result in lawsuits concerning vehicle collisions and personal injuries, patient care incidents or mistreatment and employee job-related injuries. Some of these lawsuits may involve large claim amounts and substantial defense costs.

EmCare generally procures professional liability insurance coverage for its affiliated medical professionals and professional and corporate entities. Beginning January 1, 2002, insurance coverage has been provided by affiliates of Columbia Casualty Company and Continental Casualty Company, which then reinsure the entire program, procured primarily by EmCare’s wholly owned insurance subsidiary, EMCA Insurance Company, Ltd. (“EMCA”). AMR currently has an insurance program which includes a combination of insurance purchased from third parties and large self-insured retentions and/or deductibles for all of its insurance programs subsequent to September 1, 2001. AMR reinsures a portion of these self-insured retentions and/or deductibles through an arrangement with EMCA. Under these insurance programs, we establish reserves, using actuarial estimates, for all losses covered under the policies. Moreover, in the normal course of our business, we are involved in lawsuits, claims, audits and investigations, including those arising out of our billing and marketing practices, employment disputes, contractual claims and other business disputes for which we may have no insurance coverage, and which are not subject to actuarial estimates. The outcome of these matters could have a material effect on our results of operations in the period when we identify the matter, and the ultimate outcome could have a material adverse effect on our financial position, results of operations, or cash flows.

53

Our liability to pay for EmCare’s and certain of AMR’s insurance program losses is partially collateralized by funds held through EMCA and letters of credit issued by EVHC and, to the extent these losses exceed the collateral and assets of EMCA or the limits of our insurance policies, will have to be funded by us. If our AMR losses with respect to such claims exceed the collateral held by AMR’s insurance providers or the collateral held through EMCA, and the letters of credit issued by EVHC in connection with our self-insurance program or the limits of our insurance policies, we will have to fund such amounts.

We are subject to a variety of federal, state and local laws and regulatory regimes, including a variety of labor laws and regulations. Failure to comply with laws and regulations could subject us to, among other things, penalties and legal expenses which could have a materially adverse effect on our business.

We are subject to various federal, state, and local laws and regulations including, but not limited to the Employee Retirement Income Security Act of 1974 (“ERISA”) and regulations promulgated by the Internal Revenue Service (“IRS”), the U.S. Department of Labor and the Occupational Safety and Health Administration. We are also subject to a variety of federal and state employment and labor laws and regulations, including the Americans with Disabilities Act, the Federal Fair Labor Standards Act, the Worker Adjustment and Retraining Notification Act, and other regulations related to working conditions, wage-hour pay, overtime pay, family leave, employee benefits, antidiscrimination, termination of employment, safety standards and other workplace regulations.

Failure to properly adhere to these and other applicable laws and regulations could result in investigations, the imposition of penalties or adverse legal judgments by public or private plaintiffs, and our business, financial condition and results of operations could be materially adversely affected. Similarly, our business, financial condition and results of operations could be materially adversely affected by the cost of complying with newly-implemented laws and regulations.

In addition, from time to time we have received, and expect to continue to receive, correspondence from former employees terminated by us who threaten to bring claims against us alleging that we have violated one or more labor and employment regulations. In certain instances former employees have brought claims against us and we expect that we will encounter similar actions against us in the future. An adverse outcome in any such litigation could require us to pay contractual damages, compensatory damages, punitive damages, attorneys’ fees and costs.

See “— Risks Related to Healthcare Regulation”.

The reserves we establish with respect to our losses covered under our insurance programs are subject to inherent uncertainties.

In connection with our insurance programs, we establish reserves for losses and related expenses, which represent estimates involving actuarial and statistical projections, at a given point in time, of our expectations of the ultimate resolution and administration costs of losses we have incurred in respect of our liability risks. Insurance reserves inherently are subject to uncertainty. Our reserves are based on historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions calculated by an independent actuary firm. The independent actuary firm performs studies of projected ultimate losses on an annual basis and provides quarterly updates to those projections. We use these actuarial estimates to determine appropriate reserves. Our reserves could be significantly affected if current and future occurrences differ from historical claim trends and expectations. While we monitor claims closely when we estimate reserves, the complexity of the claims and the wide range of potential outcomes may hamper timely adjustments to the assumptions we use in these estimates. Actual losses and related expenses may deviate, individually and in the aggregate, from the reserve estimates reflected in our consolidated financial statements. The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively. If we determine that our estimated reserves are inadequate, we will be required to increase reserves at the time of the determination, which would result in a reduction in our net income in the period in which the deficiency is determined.

Insurance coverage for some of our losses may be inadequate and may be subject to the credit risk of commercial insurance companies.

Some of our insurance coverage is through various third party insurers. To the extent we hold policies to cover certain groups of claims or rely on insurance coverage obtained by third parties to cover such claims, but either we or such third parties did not obtain sufficient insurance limits, did not buy an extended reporting period policy, where applicable, or the issuing insurance company is unable or unwilling to pay such claims, we may be responsible for those losses. Furthermore, for our losses that are insured or reinsured through commercial insurance companies, we are subject to the “credit risk” of those insurance companies. While we believe our commercial insurance company providers currently are creditworthy, there can be no assurance that such insurance companies will remain so in the future.

54

Volatility in market conditions could negatively impact insurance collateral balances and result in additional funding requirements.

Our insurance collateral is comprised principally of government and investment grade securities and cash deposits with third parties. The volatility experienced in the market has not had a material impact on our financial position or performance. Future volatility could, however, negatively impact the insurance collateral balances and result in additional funding requirements.

We may make acquisitions which could divert the attention of management and which may not be integrated successfully into our existing business.

We may pursue acquisitions to increase our market penetration, enter new geographic markets and expand the scope of services we provide. We have evaluated and expect to continue to evaluate possible acquisitions on an ongoing basis. We cannot assure you that we will identify suitable acquisition candidates, acquisitions will be completed on acceptable terms, our due diligence process will uncover all potential liabilities or issues affecting our integration process, we will not incur break-up, termination or similar fees and expenses, or we will be able to integrate successfully the operations of any acquired business into our existing business. Furthermore, acquisitions into new geographic markets and services may require us to comply with new and unfamiliar legal and regulatory requirements, which could impose substantial obligations on us and our management, cause us to expend additional time and resources, and increase our exposure to penalties or fines for non-compliance with such requirements. The acquisitions could be of significant size and involve operations in multiple jurisdictions. The acquisition and integration of another business would divert management attention from other business activities. This diversion, together with other difficulties we may incur in integrating an acquired business, could have a material adverse effect on our business, financial condition and results of operations. In addition, we may borrow money to finance acquisitions. Such borrowings might not be available on terms as favorable to us as our current borrowing terms and may increase our leverage.

The high level of competition in our segments of the market for medical services could adversely affect our contract and revenue base.

EmCare. The market for providing outsourced physician staffing and related management services to hospitals and clinics is highly competitive. Such competition could adversely affect our ability to obtain new contracts, retain existing contracts and increase or maintain profit margins. We compete with both national and regional enterprises such as Team Health, Hospital Physician Partners, The Schumacher Group, Sheridan Healthcare, California Emergency Physicians, National Emergency Services Healthcare Group, and IPC, some of which may have greater financial and other resources available to them, greater access to physicians or greater access to potential customers. We also compete against local physician groups and self-operated facility-based physician services departments for satisfying staffing and scheduling needs.

AMR. The market for providing ambulance transport services to municipalities, counties, other healthcare providers and third party payors is highly competitive. In providing ambulance transport services, we compete with governmental entities, including cities and fire districts, hospitals, local and volunteer private providers, and with several large national and regional providers such as Rural/Metro Corporation, Falck, Southwest Ambulance, Paramedics Plus and Acadian Ambulance. In many communities, our most important competitors are the local fire departments, which in many cases have acted traditionally as the first response providers during emergencies, and have been able to expand their scope of services to include emergency ambulance transport and do not wish to give up their franchises to a private competitor. In 2011, the California state legislature passed legislation which makes some public agencies eligible for additional federal funding for Medi-Cal ambulance transports if certain conditions are met. These additional funds may provide an opportunity for certain public agencies, including local fire departments, to enter into the ambulance transportation market or provide additional ambulance transports, which could increase competition in the California market.

We are required to make capital expenditures, particularly for our healthcare transportation business, in order to remain compliant and competitive.

Our capital expenditure requirements primarily relate to maintaining and upgrading our vehicle fleet and medical equipment to serve our customers and remain competitive. The aging of our vehicle fleet requires us to make regular capital expenditures to maintain our current level of service. Our net capital expenditures from purchases and sales of assets totaled $65.0 million, $53.0 million, and $64.6 million in the years ended December 31, 2013, 2012 and 2011, respectively. In addition, changing competitive conditions or the emergence of any significant advances in medical technology could require us to invest significant capital in additional equipment or capacity in order to remain competitive. If we are unable to fund any such investment or otherwise fail to invest in new vehicles or medical equipment, our business, financial condition or results of operations could be materially and adversely affected.

55

We depend on our senior management and may not be able to retain those employees or recruit additional qualified personnel.

We depend on our senior management. The loss of services of any of the members of our senior management could adversely affect our business until a suitable replacement can be found. There may be a limited number of persons with the requisite skills to serve in these positions, and we cannot assure you that we would be able to identify or employ such qualified personnel on acceptable terms.

Our business depends on numerous complex information systems, and any failure to successfully maintain these systems or implement new systems could materially harm our operations.

We depend on complex, integrated information systems and standardized procedures for operational and financial information and our billing operations. We may not have the necessary resources to enhance existing information systems or implement new systems where necessary to handle our volume and changing needs. Furthermore, we may experience unanticipated delays, complications and expenses in implementing, integrating and operating our systems. Any interruptions in operations during periods of implementation would adversely affect our ability to properly allocate resources and process billing information in a timely manner, which could result in customer dissatisfaction and delayed cash flow. We also use the development and implementation of sophisticated and specialized technology to differentiate our services from our competitors and improve our profitability. The failure to successfully implement and maintain operational, financial and billing information systems could have an adverse effect on our ability to obtain new business, retain existing business and maintain or increase our profit margins.

Disruptions in our disaster recovery systems or management continuity planning could limit our ability to operate our business effectively.

Our information technology systems facilitate our ability to conduct our business. While we have disaster recovery systems and business continuity plans in place, any disruptions in our disaster recovery systems or the failure of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations. Despite our implementation of a variety of security measures, our technology systems could be subject to physical or electronic break-ins, and similar disruptions from unauthorized tampering. In addition, in the event that a significant number of our management personnel were unavailable in the event of a disaster, our ability to effectively conduct business could be adversely affected.

We may not be able to adequately protect our intellectual property and other proprietary rights that are material to our business, or to defend successfully against intellectual property infringement claims by third parties.

Our ability to compete effectively depends in part upon our intellectual property rights, including but not limited to our trademarks and copyrights, and our proprietary technology. Our use of contractual provisions, confidentiality procedures and agreements, and trademark, copyright, unfair competition, trade secret and other laws to protect our intellectual property rights and proprietary technology may not be adequate. Litigation may be necessary to enforce our intellectual property rights and protect our proprietary technology, or to defend against claims by third parties that the conduct of our businesses or our use of intellectual property infringes upon such third party’s intellectual property rights. Any intellectual property litigation or claims brought against us, whether or not meritorious, could result in substantial costs and diversion of our resources, and there can be no assurances that favorable final outcomes will be obtained in all cases. The terms of any settlement or judgment may require us to pay substantial amounts to the other party or cease exercising our rights in such intellectual property, including ceasing the use of certain trademarks used by us to distinguish our services from those of others or ceasing the exercise of our rights in copyrightable works. In addition, we may have to seek a license to continue practices found to be in violation of a third party’s rights, which may not be available on reasonable terms, or at all. Our business, financial condition or results of operations could be adversely affected as a result.

A successful challenge by tax authorities to our treatment of certain physicians as independent contractors or the elimination of an existing safe harbor could materially increase our costs relating to these physicians.

We contract with approximately 4,200 physicians and clinical personnel as independent contractors to fulfill our contractual obligations to customers. Because we treat these physicians as independent contractors rather than as employees, we do not (i) withhold federal or state income or other employment related taxes from the compensation that we pay to them, (ii) make federal or state unemployment tax or Federal Insurance Contributions Act payments with respect to them, (iii) provide workers compensation insurance with respect to them (except in states that require us to do so for independent contractors), or (iv) allow them to participate in benefits and retirement programs available to employed physicians. Our contracts with these physicians obligate them to pay these taxes and other costs. Whether these physicians are properly classified as independent contractors generally depends upon the facts and circumstances of our relationship with them. It is possible that the nature of our relationship with these physicians would support a challenge to our treatment of them as independent contractors. Under current federal tax law, however, if our treatment of these physicians is consistent with a long-standing practice of a significant segment of our industry and we meet certain other requirements, it is possible, but not certain, that our treatment would qualify under a “safe harbor” and, consequently, we would be protected from the imposition of taxes. However, if a challenge to our treatment of these physicians as independent contractors by federal or state taxing authorities were successful and these physicians were treated as employees instead of independent contractors, we could be liable for taxes, penalties and interest to the extent that these physicians did not fulfill their contractual obligations to pay those taxes. In addition, there are currently, and have been in the past, proposals made to eliminate the safe harbor, and similar proposals could be made in the future. If such a challenge were successful or if the safe harbor were eliminated, there could be a material increase in our costs relating to these physicians and, therefore, there could be a material adverse effect on our business, financial condition and results of operations.

56

Many of our AMR employees are represented by labor unions and any work stoppage could adversely affect our business.

Approximately 46% of AMR employees are represented by 39 active collective bargaining agreements. There are 19 operational locations representing approximately 4,000 employees that are currently in the process of negotiations or will begin negotiations in 2014. There are also two additional operational locations that have completed negotiations and are awaiting ratification that represent approximately 900 employees. In addition, six collective bargaining agreements, representing 600 employees, will be subject to negotiations in 2015. We cannot assure you that we will be able to negotiate a satisfactory renewal of these collective bargaining agreements or that our employee relations will remain stable.

Our consolidated revenue and earnings could vary significantly from period to period due to our national contract with the Federal Emergency Management Agency.

Our revenue and earnings under our national contract with FEMA are likely to vary significantly from period to period. In the past five years of the FEMA contract, our annual revenues from services rendered under this contract have varied by approximately $44 million. In its present form, the contract generates significant revenue for us only in the event of a national emergency and then only if FEMA exercises its broad discretion to order a deployment. Our FEMA revenue therefore depends largely on circumstances outside of our control. We therefore cannot predict the revenue and earnings, if any, we may generate in any given period from our FEMA contract. This may lead to increased volatility in our actual revenue and earnings period to period.

We may be required to enter into large scale deployment of resources in response to a national emergency under our contract with FEMA, which may divert management attention and resources.

We do not believe that a FEMA deployment adversely affects our ability to service our local “911” contracts. However, any significant FEMA deployment requires significant management attention and could reduce our ability to pursue other local transport opportunities, such as inter-facility transports, and to pursue new business opportunities, which could have an adverse effect on our business and results of operations.

Risks Related to Healthcare Regulation

We conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations.

The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we provide and bill for services, our contractual relationships with our physicians, vendors and customers, our marketing activities and other aspects of our operations. Failure to comply with these laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status and exclusion from the Medicare and Medicaid programs. The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

Our practitioners and our customers are also subject to ethical guidelines and operating standards of professional and trade associations and private accreditation agencies. Compliance with these guidelines and standards is often required by our contracts with our customers or to maintain our reputation.

The laws, regulations and standards governing the provision of healthcare services may change significantly in the future. We cannot assure you that any new or changed healthcare laws, regulations or standards will not materially adversely affect our business. We cannot assure you that a review of our business by judicial, law enforcement, regulatory or accreditation authorities will not result in a determination that could adversely affect our operations.

57

We are subject to comprehensive and complex laws and rules that govern the manner in which we bill and are paid for our services by third party payors, and the failure to comply with these rules, or allegations that we have failed to do so, can result in civil or criminal sanctions, including exclusion from federal and state healthcare programs.

Like most healthcare providers, the majority of our services are paid for by private and governmental third party payors, such as Medicare and Medicaid. These third party payors typically have differing and complex billing and documentation requirements that we must meet in order to receive payment for our services. Reimbursement to us is typically conditioned on our providing the correct procedure and diagnostic codes and properly documenting the services themselves, including the level of service provided, the medical necessity for the services, the site of service and the identity of the practitioner who provided the service.

We must also comply with numerous other laws applicable to our documentation and the claims we submit for payment, including but not limited to (i) “coordination of benefits” rules that dictate which payor we must bill first when a patient has potential coverage from multiple payors, (ii) requirements that we obtain the signature of the patient or patient representative, or, in certain cases, alternative documentation, prior to submitting a claim, (iii) requirements that we make repayment within a specified period of time to any payor which pays us more than the amount to which we are entitled, (iv) requirements that we bill a hospital or nursing home, rather than Medicare, for certain ambulance transports provided to Medicare patients of such facilities, (v) “reassignment” rules governing our ability to bill and collect professional fees on behalf of our physicians, (vi) requirements that our electronic claims for payment be submitted using certain standardized transaction codes and formats and (vii) laws requiring us to handle all health and financial information of our patients in a manner that complies with specified security and privacy standards.

Governmental and private third party payors and other enforcement agencies carefully audit and monitor our compliance with these and other applicable rules, and in some cases in the past have found that we were not in compliance. We have received in the past, and expect to receive in the future, repayment demands from third party payors based on allegations that our services were not medically necessary, were billed at an improper level, or otherwise violated applicable billing requirements. Our failure to comply with the billing and other rules applicable to us could result in non-payment for services rendered or refunds of amounts previously paid for such services. In addition, non-compliance with these rules may cause us to incur civil and criminal penalties, including fines, imprisonment and exclusion from government healthcare programs such as Medicare and Medicaid, under a number of state and federal laws. These laws include the federal False Claims Act, the Civil Monetary Penalties Law, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the federal Anti-Kickback Statute and other provisions of federal, state and local law. The federal False Claims Act and the Anti-Kickback Statute were both recently amended in a manner which makes it easier for the government to demonstrate that a violation has occurred.

A number of states have enacted false claims acts that are similar to the federal False Claims Act. Additional states are expected to enact such legislation in the future because Section 6031 of the Deficit Reduction Act of 2005 (“DRA”) amended the federal law to encourage these types of changes, along with a corresponding increase in state initiated false claims enforcement efforts.

Under the DRA, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets certain other requirements, such state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under such state’s false claims act. The OIG, in consultation with the Attorney General of the United States, is responsible for determining if a state’s false claims act complies with the statutory requirements. Currently, at least 29 states and the District of Columbia have some form of false claims act. The OIG has reviewed 28 of these and determined that 15 of these satisfy the DRA standards. We anticipate this figure will continue to increase.

In addition, from time to time we self-identify practices that may have resulted in Medicare or Medicaid overpayments or other regulatory issues. For example, we have previously identified situations in which we may have inadvertently utilized incorrect billing codes for some of the services we have billed to government programs such as Medicare or Medicaid. In such cases, if appropriate, it is our practice to disclose the issue to the affected government programs and to refund any resulting overpayments. Although the government usually accepts such disclosures and repayments without taking further enforcement action, it is possible that such disclosures or repayments will result in allegations by the government that we have violated the False Claims Act or other laws, leading to investigations and possibly civil or criminal enforcement actions.

On January 16, 2009, the HHS released the final rule mandating that everyone covered by the Administrative Simplification Provisions of HIPAA, which includes EmCare and AMR, must implement ICD-10 (International Classification of Diseases, 10th Edition) for medical coding on October 1, 2013. ICD-10 codes contain significantly more information than the ICD-9 codes currently used for medical coding and will require covered entities to code with much greater detail and specificity than ICD-9 codes. HHS subsequently postponed the deadline for implementation of ICD-10 codes until October 1, 2014. The Protecting Access to Medicare Act of 2014 was signed into law on April 1, 2014, and further extended the deadline to October 1, 2015. We may incur additional costs for computer system updates, training, and other resources required to implement these changes.

58

Other changes to the Medicare program intended to implement Medicare’s new “pay for performance” philosophy may require us to make investments to receive maximum Medicare reimbursement for our services. These program revisions may include (but are not necessarily limited to) the Medicare Physician Quality Reporting System, formerly known as the Medicare Physician Quality Reporting Initiative, which provides additional Medicare compensation to physicians who implement and report certain quality measures.

If our operations are found to be in violation of these or any of the other laws which govern our activities, any resulting penalties, damages, fines or other sanctions could adversely affect our ability to operate our business and our financial results.

Under recently enacted amendments to federal privacy law, we are subject to more stringent penalties in the event we improperly use or disclose protected health information regarding our patients.

HIPAA required HHS to adopt standards to protect the privacy and security of certain health-related information. The HIPAA privacy regulations contain detailed requirements concerning the use and disclosure of individually identifiable health information by covered entities, which include EmCare and AMR.

In addition to the privacy requirements, HIPAA covered entities must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality and availability of certain electronic health information received, maintained, or transmitted by covered entities or their business associates. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.

The Health Information Technology for Economic and Clinical Health Act (“HITECH”), as implemented by an omnibus final rule published in the Federal Register on January 25, 2013, significantly expands the scope of the privacy and security requirements under HIPAA and increases penalties for violations. Prior to HITECH, the focus of HIPAA enforcement was on resolution of alleged non-compliance through voluntary corrective action without fines or penalties in most cases. That focus changed under HITECH, which now imposes mandatory penalties for certain violations of HIPAA that are due to “willful neglect”. Penalties start at $100 per violation and are not to exceed $50,000, subject to a cap of $1.5 million for violations of the same standard in a single calendar year. HITECH also authorized state attorneys general to file suit on behalf of their residents. Courts will be able to award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. In addition, HITECH mandates that the Secretary of HHS conduct periodic compliance audits of a cross-section of HIPAA covered entities or business associates. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured protected health information (“PHI”) may receive a percentage of the Civil Monetary Penalty fine paid by the violator.

HITECH and implementing regulations enacted by HHS further require that patients be notified of any unauthorized acquisition, access, use, or disclosure of their unsecured PHI that compromises the privacy or security of such information, with some exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals within the “same facility”. HITECH and implementing regulations specify that such notifications must be made “without unreasonable delay and in no case later than 60 calendar days after discovery of the breach”. If a breach affects 500 patients or more, it must be reported immediately to HHS, which will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually. These security breach notification requirements apply not only to unauthorized disclosures of unsecured PHI to outside third parties, but also to unauthorized internal access to such PHI. This means that unauthorized employee “snooping” into medical records could trigger the notification requirements.

Many states in which we operate also have state laws that protect the privacy and security of confidential, personal information. These laws may be similar to or even more protective than the federal provisions. Not only may some of these state laws impose fines and penalties upon violators, but some may afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages.

The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, but may adversely affect our business model, financial condition or results of operations.

Our revenue is either from the healthcare industry or could be affected by changes in healthcare spending and policy. The healthcare industry is subject to changing political, regulatory and other influences. In March 2010, the President signed into law the PPACA, commonly referred to as “the healthcare reform legislation”, which made major changes in how healthcare is delivered and reimbursed, and increased access to health insurance benefits to the uninsured and underinsured population of the United States. The PPACA, among other things, increases the number of individuals with Medicaid and private insurance coverage, implements reimbursement policies that tie payment to quality, facilitates the creation of accountable care organizations that may use capitation and other alternative payment methodologies, strengthens enforcement of fraud and abuse laws, and encourages the use of information technology. Many of these changes did not go into effect until 2014, and many require implementing regulations which have not yet been drafted or have been released only as proposed rules. For example, on May 12, 2014, the OIG issued a proposed rule that would establish new civil monetary penalties for certain fraud and abuse violations, including penalties of $10,000 per day for failing to repay overpayments within 60 days of discovery.

59

The impact of many of these provisions is unknown at this time. For example, the PPACA provides for establishment of an Independent Payment Advisory Board that could recommend changes in payment for physicians under certain circumstances not earlier than January 15, 2014, which HHS generally would be required to implement unless Congress enacts superseding legislation. The PPACA also requires HHS to develop a budget neutral value-based payment modifier that provides for differential payment under the Physician Fee Schedule for physicians or groups of physicians that is linked to quality of care furnished compared to cost. HHS has begun implementing the modifier through the Physician Fee Schedule rulemaking for 2013, by, among other things, specifying the initial performance period and how it will apply the upward and downward modifier for certain physicians and physician groups beginning January 1, 2015, and all physicians and physician groups starting not later than January 1, 2017. During this rulemaking process, HHS considered whether it should develop a value-based payment modifier option for hospital-based physicians, but ultimately, HHS decided to deal with this issue in future rulemaking. The impact of this payment modifier cannot be determined at this time.

In addition, certain provisions of the PPACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services, and post-acute services for episodes of hospital care. The Medicare Acute Care Episode Demonstration is currently underway at several healthcare system demonstration sites. The impact of these projects on us cannot be determined at this time.

Furthermore, the PPACA may adversely affect payors by increasing their medical cost trends, which could have an effect on the industry and potentially impact our business and revenues as payors seek to offset these increases by reducing costs in other areas, although the extent of this impact is currently unknown.

Following challenges to the constitutionality of certain provisions of the PPACA by a number of states, on June 28, 2012, the U.S. Supreme Court upheld the constitutionality of the individual mandate provisions of the PPACA, but struck down the provisions that would have allowed HHS to penalize states that do not implement Medicaid expansion provisions through the loss of existing federal Medicaid funding. At least 26 states and the District of Columbia have implemented or are planning to implement the Medicaid expansion. It is uncertain whether the remaining states will implement the expansion at a later date, or whether any participating states will discontinue the expansion. While the PPACA will increase the likelihood that more people in the United States will have access to health insurance benefits, we cannot quantify or predict with any certainty the likely impact of the PPACA on our business model, financial condition or results of operations.

Another key part of the PPACA has also been challenged in the courts and, depending on the outcome, could have an impact on the number of uninsured persons we treat. The PPACA provides for subsidies to individuals who cannot afford health insurance and who purchase it through healthcare “exchanges”, which are electronic marketplaces where individuals can shop for and purchase health insurance.  The PPACA authorizes two types of exchanges:  exchanges established by the states (“state exchanges”), and, in states which do not establish state exchanges, federally-facilitated exchanges or “federal exchanges”.  In several cases challenging the PPACA, opponents of the law have alleged that subsidies should only be payable to purchasers who buy insurance through state exchanges and that subsidies paid under the federal exchanges are illegal.  Trial courts in two of these cases ruled in favor of the Obama Administration and the plaintiffs in both cases appealed. One of the cases, Halbig v. Burwell, No. 14-5018, 2014 U.S. App. LEXIS 13880 (D.C. Cir. Jul. 22, 2014) was heard by the District of Columbia Circuit Court of Appeals, and the other case, King v. Burwell, No. 14-1158, 2014 U.S. App. LEXIS 13902 (4th Cir. Jul. 22, 2014), was heard by the Fourth Circuit Court of Appeals.  Although the two appeals court decisions were handed down the same day, July 22, 2014, they reached opposite conclusions, with the King court upholding the payment of subsidies under federal exchanges and the Halbig decision finding them illegal.  A petition for writ of certiorari has been filed with the U.S. Supreme Court in the King case. A petition for rehearing en banc has been filed with the District of Columbia Circuit Court of Appeals in the Halbig case.

In the event that federal exchange subsidies are ultimately deemed unlawful, some states that currently have a federal exchange may establish their own state exchanges in order for their residents to remain eligible for the subsidies.  However, to the extent that does not occur, the payor mix of the patients we treat may be adversely affected, such that we incur additional bad debt from increased numbers of uninsured and underinsured patients.  Further, in the absence of federal exchange subsidies, the individual and employer mandates imposed by the PPACA could be adversely affected and may not be fully enforceable. Since the outcome of these contradictory court decisions is unknown, and any conclusions regarding the reaction of consumers and insurers would be speculative, we cannot predict the impact of these cases on our business or profitability.

60

If we are unable to timely enroll our providers in the Medicare program, our collections and revenue will be harmed.

The 2009 Physician Fee Schedule rule substantially reduced the time within which providers can retrospectively bill Medicare for services provided by such providers from 27 months prior to the effective date of the enrollment to 30 days prior to the effective date of the enrollment. In addition, the new enrollment rules also provide that the effective date of the enrollment will be the later of the date on which the enrollment application was filed and approved by the Medicare contractor, or the date on which the provider began providing services. If we are unable to properly enroll physicians and midlevel providers within the 30 days after the provider begins providing services, we will be precluded from billing Medicare for any services which were provided to a Medicare beneficiary more than 30 days prior to the effective date of the enrollment. Such failure to timely enroll providers could have a material adverse effect on our business, financial condition or results of operations.

In addition, the PPACA added additional enrollment requirements for Medicare and Medicaid enrollment. Those statutory requirements have been further enhanced through implementing regulations and increased enforcement scrutiny. Every enrolled provider must revalidate its enrollment at regular intervals, and must update the Medicare contractors and many state Medicaid programs with significant changes on a timely (and typically very short) basis. If we fail to provide sufficient documentation as required to maintain our enrollment, Medicare could deny continued future enrollment or revoke our enrollment and billing privileges.

If current or future laws or regulations force us to restructure our arrangements with physicians, professional corporations and hospitals, we may incur additional costs, lose contracts and suffer a reduction in net revenue under existing contracts, and we may need to refinance our debt or obtain debt holder consent.

A number of laws bear on our relationships with our physicians. There is a risk that state authorities in some jurisdictions may find that our contractual relationships with our physicians violate laws prohibiting the corporate practice of medicine and fee-splitting. These laws generally prohibit the practice of medicine by lay entities or persons and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing the physician’s professional judgment. They may also prevent the sharing of professional services income with non-professional or business interests. From time to time, including recently, we have been involved in litigation in which private litigants have raised these issues.

Our physician contracts include contracts with individual physicians and with physicians organized as separate legal professional entities (e.g., professional medical corporations). Antitrust laws may deem each such physician/entity to be separate, both from EmCare and from each other and, accordingly, each such physician/practice is subject to a wide range of laws that prohibit anti-competitive conduct between or among separate legal entities or individuals. A review or action by regulatory authorities or the courts could force us to terminate or modify our contractual relationships with physicians and affiliated medical groups or revise them in a manner that could be materially adverse to our business.

Various licensing and certification laws, regulations and standards apply to us, our affiliated physicians and our relationships with our affiliated physicians. Failure to comply with these laws and regulations could result in our services being found to be non-reimbursable or prior payments being subject to recoupment, and can give rise to civil or criminal penalties. We routinely take the steps we believe are necessary to retain or obtain all requisite licensure and operating authorities. While we have made reasonable efforts to substantially comply with federal, state and local licensing and certification laws and regulations and standards as we interpret them, we cannot assure you that agencies that administer these programs will not find that we have failed to comply in some material respects.

EmCare’s professional liability insurance program, under which insurance is provided for most of our affiliated medical professionals and professional and corporate entities, is reinsured through our wholly owned subsidiary, EMCA. The activities associated with the business of insurance, and the companies involved in such activities, are closely regulated. Failure to comply with the laws and regulations can result in civil and criminal fines and penalties and loss of licensure. While we have made reasonable efforts to substantially comply with these laws and regulations, and utilize licensed insurance professionals where necessary or appropriate, we cannot assure you that we will not be found to have violated these laws and regulations in some material respects.

Adverse judicial or administrative interpretations could result in a finding that we are not in compliance with one or more of these laws and rules that affect our relationships with our physicians.

These laws and rules, and their interpretations, may also change in the future. Any adverse interpretations or changes could force us to restructure our relationships with physicians, professional corporations or our hospital customers, or to restructure our operations. This could cause our operating costs to increase significantly. A restructuring could also result in a loss of contracts or a reduction in revenue under existing contracts. Moreover, if we are required to modify our structure and organization to comply with these laws and rules, our financing agreements may prohibit such modifications and require us to obtain the consent of the holders of such debt or require the refinancing of such debt.

61

Our relationships with healthcare providers and facilities and our marketing practices are subject to the federal Anti-Kickback Statute and similar state laws, and we entered into a settlement in 2006 for alleged violations of the Anti-Kickback Statute.

We are subject to the federal Anti-Kickback Statute, which prohibits the knowing and willful offer, payment, solicitation or receipt of any form of “remuneration” in return for, or to induce, the referral of business or ordering of services paid for by Medicare or other federal programs. “Remuneration” has been broadly interpreted to mean anything of value, including, for example, gifts, discounts, credit arrangements, and in-kind goods or services, as well as cash. Certain federal courts have held that the Anti-Kickback Statute can be violated if “one purpose” of a payment is to induce referrals. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Violations of the Anti-Kickback Statute can result in imprisonment, civil or criminal fines or exclusion from Medicare and other governmental programs. Recognizing that the federal Anti-Kickback Statute is broad, Congress authorized the OIG to issue a series of regulations, known as “safe harbors”. These safe harbors set forth requirements that, if met in their entirety, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal, or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG.

In 1999, the OIG issued an Advisory Opinion indicating that discounts provided to health facilities on the transports for which they are financially responsible potentially violate the Anti-Kickback Statute when the ambulance company also receives referrals of Medicare and other government-funded transports from the facility. The OIG has clarified that not all discounts violate the Anti-Kickback Statute, but that the statute may be violated if part of the purpose of the discount is to induce the referral of the transports paid for by Medicare or other federal programs, and the discount does not meet certain “safe harbor” conditions. In the Advisory Opinion and subsequent pronouncements, the OIG has provided guidance to ambulance companies to help them avoid unlawful discounts.

Like other ambulance companies, we have provided discounts to our healthcare facility customers (nursing homes and hospitals) in certain circumstances. We have attempted to comply with applicable law when such discounts are provided. However, the government alleged that certain of our hospital and nursing home contracts in effect in Texas prior to 2002 contained discounts in violation of the federal Anti-Kickback Statute, and in 2006 we entered into a settlement with the government regarding these allegations. The settlement included a CIA. The term of that CIA has expired, we have filed a final report with the OIG and this CIA was released in February 2012.

There can be no assurance that other investigations or legal action related to our contracting practices will not be pursued against AMR in other jurisdictions or for different time frames. Many states have adopted laws similar to the federal Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any payor, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. Additionally, we could be subject to private actions brought pursuant to the False Claims Act’s “whistleblower” or “qui tam” provisions which, among other things, allege that our practices or relationships violate the Anti-Kickback Statute. The False Claims Act imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claim laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third party payor and not merely a federal healthcare program. There are many potential bases for liability under these false claim statutes. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement. Pursuant to changes in the PPACA, a claim resulting from a violation of the Anti-Kickback Statute can constitute a false or fraudulent claim for purposes of the federal False Claims Act. Further, the PPACA amended the Anti-Kickback Statute in a manner which makes it easier for the government to demonstrate intent to violate the statute which is an element of a violation.

In addition to AMR’s contracts with healthcare facilities and public agencies, other marketing practices or transactions entered into by EmCare and AMR may implicate the Anti-Kickback Statute. Although we have attempted to structure our past and current marketing initiatives and business relationships to comply with the Anti-Kickback Statute, we cannot assure you that we will not have to defend against alleged violations from private or public entities or that the OIG or other authorities will not find that our marketing practices and relationships violate the statute.

If we are found to have violated the Anti-Kickback Statute or a similar state statute, we may be subject to civil and criminal penalties, including exclusion from the Medicare or Medicaid programs, or may be required to enter into settlement agreements with the government to avoid such sanctions. Typically, such settlement agreements require substantial payments to the government in exchange for the government to release its claims, and may also require us to enter into a CIA.

62

Changes in our ownership structure and operations require us to comply with numerous notification and reapplication requirements in order to maintain our licensure, certification or other authority to operate, and failure to do so, or an allegation that we have failed to do so, can result in payment delays, forfeiture of payment or civil and criminal penalties.

We and our affiliated physicians are subject to various federal, state and local licensing and certification laws with which we must comply in order to maintain authorization to provide, or receive payment for, our services. For example, Medicare and Medicaid require that we complete and periodically update enrollment forms in order to obtain and maintain certification to participate in programs. Compliance with these requirements is complicated by the fact that they differ from jurisdiction to jurisdiction, and in some cases are not uniformly applied or interpreted even within the same jurisdiction. Failure to comply with these requirements can lead not only to delays in payment and refund requests, but in extreme cases can give rise to civil or criminal penalties.

In certain jurisdictions, changes in our ownership structure require pre- or post-notification to governmental licensing and certification agencies, or agencies with which we have contracts. Relevant laws in some jurisdictions may also require re-application or re-enrollment and approval to maintain or renew our licensure, certification, contracts or other operating authority. Our changes in corporate structure and ownership involving changes in our beneficial ownership required us in some instances to give notice, re-enroll or make other applications for authority to continue operating in various jurisdictions or to continue receiving payment from their Medicaid or other payment programs. The extent of such notices and filings may vary in each jurisdiction in which we operate, although those regulatory entities requiring notification generally request factual information regarding the new corporate structure and new ownership composition of the operating entities that hold the applicable licensing and certification.

While we have made reasonable efforts to substantially comply with these requirements, we cannot assure you that the agencies that administer these programs or have awarded us contracts will not find that we have failed to comply in some material respects. A finding of non-compliance and any resulting payment delays, refund demands or other sanctions could have a material adverse effect on our business, financial condition or results of operations.

If we fail to comply with the terms of our settlement agreements with the government, we could be subject to additional litigation or other governmental actions which could be harmful to our business.

In the last seven years, we have entered into two settlement agreements with the U.S. Government. In September 2006, AMR entered into a settlement agreement to resolve allegations that AMR subsidiaries provided discounts to healthcare facilities in Texas in periods prior to 2002 in violation of the federal Anti-Kickback Statute. In May 2011, AMR entered into a settlement agreement with the DOJ and a CIA with the OIG to resolve allegations that AMR subsidiaries submitted claims for reimbursement in periods dating back to 2000. The government believed such claims lacked support for the level billed in violation of the False Claims Act.

In connection with the September 2006 settlement for AMR, we entered into a CIA which required us to maintain a compliance program which included the training of employees and safeguards involving our contracting process nationwide (including tracking of contractual arrangements in Texas). The term of that CIA has expired, we have filed a final report with the OIG and this CIA was released in February 2012.

In December 2006, AMR received a subpoena from the DOJ. The subpoena requested copies of documents for the period from January 2000 through the present. The subpoena required us to produce a broad range of documents relating to the operations of certain AMR affiliates in New York. We produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited us to respond to the identified areas of concern. We reviewed the information provided by the government and provided our response. On May 20, 2011, AMR entered into a settlement agreement with the DOJ and a CIA with the OIG in connection with this matter. Under the terms of the settlement, AMR paid $2.7 million to the federal government. We entered into the settlement in order to avoid the uncertainties of litigation, and have not admitted any wrongdoing.

In connection with the May 2011 settlement for AMR, we entered into a CIA with the OIG which requires us to maintain a compliance program. This program includes, among other elements, the appointment of a compliance officer and committee, training of employees nationwide, safeguards for our billing operations as they relate to services provided in New York, including specific training for operations and billing personnel providing services in New York, review by an independent review organization and reporting of certain reportable events. On July 1, 2013, we divested substantially all of the assets underlying AMR’s service in New York, although the obligations of our compliance program remain in effect for ongoing AMR operations.

In July 2011, AMR received a subpoena from the USAO seeking certain documents concerning AMR’s provision of ambulance services within the City of Riverside, California. The USAO indicated that it, together with the OIG, was investigating whether AMR violated the federal False Claims Act and/or the federal Anti-Kickback Statute in connection with AMR’s provision of ambulance transport services within the City of Riverside. The California Attorney General’s Office conducted a parallel state investigation for possible violations of the California False Claims Act. In December 2012, we were notified that both investigations were concluded and that the agencies had closed the matter. There were no findings made against AMR, and the closure of the matter did not require any payments from AMR.

63

On August 7, 2012, EmCare received a subpoena from the OIG requesting copies of documents for the period from January 1, 2007 through the present that appears to primarily be focused on EmCare’s contracts for services at hospitals that are affiliated with HMA. The Company has been cooperating with the government during its investigation and, as such, continues to gather responsive documents. During the months of December 2013 and January 2014, several lawsuits filed by whistleblowers on behalf of the federal and certain state governments against HMA have been unsealed; the Company is a named defendant in two of these lawsuits. Although the federal government intervened in these lawsuits in connection with certain of the allegations against HMA, the federal government has not, at this time, disclosed whether it will intervene in these matters as they relate to the Company. The Company continues to engage in meaningful dialogue with the relevant government representatives and, at this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

On February 14, 2013, EmCare received a subpoena from the OIG requesting documents and other information relating to EmCare’s relationship with Community Health Services, Inc. The Company is cooperating with the government during its investigation, has provided responsive documents and is engaged in a meaningful dialogue with the relevant government representatives regarding additional requests. At this time, we are unable to determine the potential impact, if any, that will result from these investigations.

In November 2013, AMR received a subpoena from the New Hampshire Department of Insurance directed to American Medical Response of Massachusetts, Inc. The subpoena requested documents relating to ambulance services provided to approximately 150 patients residing in the state of New Hampshire who had been involved in motor vehicle accidents and who were ultimately transported by AMR. In addition, the subpoena requested information relating to any agreements for reimbursement between AMR and Progressive Insurance. The Company is cooperating with the Department during its investigation and, as such, is in the process of gathering responsive documents, formulating a response to the subpoena, and is seeking to engage in a meaningful dialogue with the relevant New Hampshire Department of Insurance and Attorney General’s Office representatives. At this time, we are unable to determine the potential impact, if any, that will result from this investigation.

We cannot assure you that the CIAs or the compliance program we have initiated have prevented, or will prevent, any repetition of the conduct or allegations that were the subject of these settlement agreements, or that the government will not raise similar allegations in other jurisdictions or for other periods of time. If such allegations are raised, or if we fail to comply with the terms of the CIAs, we may be subject to fines and other contractual and regulatory remedies specified in the CIAs or by applicable laws, including exclusion from the Medicare program and other federal and state healthcare programs. Such actions could have a material adverse effect on the conduct of our business, our financial condition or our results of operations.

If we are unable to effectively adapt to changes in the healthcare industry, our business may be harmed.

Political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental change. The PPACA was signed into law in 2010 and is currently in the implementation stages. See “— Risks Related to Healthcare Regulation — The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, but may adversely affect our business model, financial condition or results of operations”. The PPACA and other changes in the healthcare industry and in healthcare spending may adversely affect our revenue. We anticipate that Congress and state legislatures may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation effecting additional fundamental changes in the healthcare delivery system.

We cannot assure you as to the ultimate content, timing or effect of changes, nor is it possible at this time to estimate the impact of potential legislation. Further, it is possible that future legislation enacted by Congress or state legislatures could adversely affect our business or could change the operating environment of our customers. It is possible that changes to the Medicare or other government reimbursement programs may serve as precedent to similar changes in other payors’ reimbursement policies in a manner adverse to us. Similarly, changes in private payor reimbursement programs could lead to adverse changes in Medicare and other government payor programs which could have a material adverse effect on our business, financial condition or results of operations.

64

Changes in the rates or methods of third party reimbursements, including due to political discord in the budgeting process outside our control, may adversely affect our revenue and operations.

We derive a majority of our revenue from direct billings to patients and third party payors such as Medicare, Medicaid and private health insurance companies. As a result, any changes in the rates or methods of reimbursement for the services we provide could have a significant adverse impact on our revenue and financial results. The PPACA could ultimately result in substantial changes in Medicare and Medicaid coverage and reimbursement, as well as changes in coverage or amounts paid by private payors, which could have an adverse impact on our revenues from those sources.

In addition to changes from the PPACA, government funding for healthcare programs is subject to statutory and regulatory changes, administrative rulings, interpretations of policy and determinations by intermediaries and governmental funding restrictions, all of which could materially impact program coverage and reimbursements for both ambulance and physician services. In recent years, Congress has consistently attempted to curb spending on Medicare, Medicaid and other programs funded in whole or part by the federal government. For example, Congress has mandated that the Medicare Payment Advisory Commission, commonly known as “MedPAC”, provide it with a report making recommendations regarding certain aspects of the Medicare ambulance fee schedule. MedPAC issued a Report to the Congress on Medicare and the Health Care Delivery System in June 2013. In that report, MedPAC recommended reductions in payment for some types of ambulance services and increases in others. If Congress implements these recommendations it is possible that the resultant changes in the ambulance fee schedule will decrease payments by Medicare for our ambulance services. State and local governments have also attempted to curb spending on those programs for which they are wholly or partly responsible. This has resulted in cost containment measures such as the imposition of new fee schedules that have lowered reimbursement for some of our services and restricted the rate of increase for others, and new utilization controls that limit coverage of our services. For example, we estimate that the impact of the ambulance service rate decreases under the national fee schedule mandated under the Balanced Budget Act of 1997, as modified by the phase-in provisions of the Medicare Modernization Act, resulted in a decrease in AMR’s net revenue of approximately $18 million in 2010, an increase of less than $1 million in 2011, and an increase of $6 million in 2012. In 2013, we expected an increase of approximately $3 million from the provisions outlined above, but the sequestration cuts implemented on April 1, 2013 offset the increase resulting in a reduction of approximately $2 million for the full year 2013. In addition, state and local government regulations or administrative policies regulate ambulance rate structures in some jurisdictions in which we conduct transport services. We may be unable to receive ambulance service rate increases on a timely basis where rates are regulated, or to establish or maintain satisfactory rate structures where rates are not regulated.

Legislative provisions at the national level impact payments received by EmCare physicians under the Medicare program. Physician payments under the Physician Fee Schedule are updated on an annual basis according to a statutory formula (the “SGR”). Because application of the statutory formula for the update factor would result in a decrease in total physician payments for the past several years, Congress has intervened with interim legislation to prevent the reductions. The Medicare and Medicaid Extenders Act of 2010, which was signed into law on December 15, 2010, froze the 2010 updates through 2011. For 2012, CMS projected a rate reduction of 27.4% from 2011 levels (earlier estimates had projected a 29.5% reduction). The Temporary Payroll Tax Cut Continuation Act of 2011, signed into law on December 23, 2011, froze the 2011 updates through February 29, 2012 and the American Taxpayer Relief Act, enacted January 2, 2013, extended this through December 31, 2013.

On December 26, 2013, the President signed into law the Continuing Appropriations Resolution 2014 (Public Law 113-67), which included a 3-month delay in the SGR 20% cuts, and a small update of 0.5% in the conversion factor (the dollar amount paid per Relative Value Unit, or “RVU”). Further, the bill also extended the national floor of 1.0 for the Geographic Practice Cost Index (“GPCI”). This factor geographically adjusts the “work” portion of each RVU before it is paid, based on the locality labor costs. This “work floor” set at the national average labor rate of 1.0 was set to expire after December 31, 2013. Like the SGR delays, the work floor expired starting April 1, 2014. On April 1, 2014, the Protecting Access to Medicare Act of 2014 (Public Law 113-93) was signed into law, which further delayed the SGR cuts through March 31, 2015 and extended the GPCI work floor through April 1, 2015. However, despite the benefits of the delays in both SGR cuts and the RVU’s work floor, the Congressional actions do not avert the scheduled 2% sequestration cuts for Medicare discussed below.

The modest update factor of 0.5% does not translate to 2014 payment rates increased uniformly from the 2013 level for all physician procedures. Rather, from year-to-year, some physician specialties, including EmCare’s physicians (who are emergency medicine physicians, anesthesiologists, hospitalists and radiologists), may see higher or lower payments due to a variety of regulatory factors. Each physician service bill codes given weights (RVUs) that measure its costliness relative to other physician services. CMS is required to make periodic assessments regarding the weighting of procedures, impacting the payment amounts. For 2014, CMS published estimates of changes by specialty based on a number of factors. The full impact of these changes on any given practice went into effect at the beginning of 2014. CMS estimated that the impact for 2014 is a 2% increase for emergency medicine, 1% increase in anesthesiology, a 1% increase for internal medicine, and a 2% reduction in radiology. CMS estimates in a proposed rule published July 11, 2014 (CMS-1612-P) that the impact for 2015 is flat for emergency medicine, anesthesiology, and radiology, and estimates a 1% increase for internal medicine. At this time, we cannot predict the impact, if any, these changes will have on EmCare’s future revenues.

65

We believe that regulatory trends in cost containment will continue. We cannot assure you that we will be able to offset reduced operating margins through cost reductions, increased volume, the introduction of additional procedures or otherwise. In addition, we cannot assure you that federal, state and local governments will not impose reductions in the fee schedules or rate regulations applicable to our services in the future. Any such reductions could have a material adverse effect on our business, financial condition or results of operations.

On August 2, 2011, the Budget Control Act was enacted. Under the Budget Control Act, the Joint Committee was established to develop recommendations to reduce the deficit, over 10 years, by $1.2 to $1.5 trillion, and was required to report its recommendations to Congress by November 23, 2011. Under the Budget Control Act, Congress was then required to consider the Joint Committee’s recommendations by December 23, 2011. If the Joint Committee failed to refer agreed upon legislation to Congress or did not meet the required savings threshold set out in the Budget Control Act, a sequestration process would be put into effect, government-wide, to reduce federal outlays by the proposed amount. Because the Joint Committee failed to report the requisite recommendations for deficit reduction, the sequestration process was set to automatically start, impacting Medicare and certain other government programs beginning in January 2013. Congress passed the American Taxpayer Relief Act, signed into law on January 2, 2013, delaying the start of sequestration until March 1, 2013. In order to provide its contractors and providers sufficient lead time to implement the cuts in Medicare, CMS delayed implementation of the cuts until April 1, 2013. As there has been no further Congressional action with respect to the sequestration, reimbursements were cut by 2% for Medicare providers, including physicians and ambulance providers, starting April 1, 2013, and cuts are scheduled annually through 2021. A subsequent round of budget sequestration cuts took effect in January 2014, further reducing Medicare provider reimbursements by another 2% for 2014. The Continuing Appropriations Resolution 2014 (Public Law 113-67), enacted December 26, 2013, extends the annual budget sequestration cuts to Medicare provider payments for an additional two years through 2023.

Risks Related to Our Substantial Indebtedness

Our substantial indebtedness may adversely affect our financial health and prevent us from making payments on our indebtedness.

We have substantial indebtedness. As of September 30, 2014, we had total indebtedness, including capital leases, of approximately $2,041.3 million, including $750.0 million of the 2022 Notes, $1,289.3 million of borrowings under the Term Loan Facility and approximately $2.0 million of other long-term indebtedness. In addition, as of September 30, 2014, after giving effect to approximately $130.2 million of letters of credit issued under the ABL Facility, we are able to borrow approximately $319.8 million under the ABL Facility. As of September 30, 2014, we also had approximately $142.0 million in operating lease commitments.

The degree to which we are leveraged may have important consequences for holders of our common stock. For example, it may:

·make it more difficult for us to make payments on our indebtedness;

·increase our vulnerability to general economic and industry conditions, including recessions and periods of significant inflation and financial market volatility;

·expose us to the risk of increased interest rates because any borrowings we make under the ABL Facility, and our borrowings under the Term Loan Facility under certain circumstances, will bear interest at variable rates;

·require us to use a substantial portion of our cash flow from operations to service our indebtedness, thereby reducing our ability to fund working capital, capital expenditures and other expenses;

·limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;

·place us at a competitive disadvantage compared to competitors that have less indebtedness; and

·limit our ability to borrow additional funds that may be needed to operate and expand our business.

66

Despite our indebtedness levels, we, our subsidiaries and our affiliated professional corporations may be able to incur substantially more indebtedness which may increase the risks created by our substantial indebtedness.

We, our subsidiaries and our affiliated professional corporations may be able to incur substantial additional indebtedness in the future. The Company is not subject to any restriction on its ability to incur indebtedness. The terms of the indenture governing the 2022 Notes and the credit agreements governing the Senior Secured Credit Facilities do not fully prohibit our subsidiaries and our affiliated professional corporations from incurring indebtedness. If the Company’s subsidiaries are in compliance with certain incurrence ratios set forth in the credit agreements governing the Senior Secured Credit Facilities and the indenture governing the 2022 Notes, the Company’s subsidiaries may be able to incur substantial additional indebtedness, which may increase the risks created by our current substantial indebtedness. Our affiliated professional corporations are not subject to the covenants governing any of our indebtedness. After giving effect to $130.2 million of letters of credit issued under the ABL Facility, as of September 30, 2014, we are able to borrow an additional $319.8 million under the ABL Facility.

We will require a significant amount of cash to service our indebtedness. The ability to generate cash or refinance our indebtedness as it becomes due depends on many factors, some of which are beyond our control.

The Company and EVHC are each holding companies, and as such they have no independent operations or material assets other than their ownership of equity interests in their respective subsidiaries and our subsidiaries’ contractual arrangements with physicians and professional corporations. The Company and EVHC each depend on their respective subsidiaries to distribute funds to them so that they may pay their obligations and expenses, including satisfying their indebtedness. Our ability to make scheduled payments on, or to refinance our obligations under, our indebtedness and to fund planned capital expenditures and other corporate expenses will depend on the ability of our subsidiaries to make distributions, dividends or advances, which in turn will depend on their future operating performance and on economic, financial, competitive, legislative, regulatory and other factors and any legal and regulatory restrictions on the payment of distributions and dividends to which they may be subject. Many of these factors are beyond our control. We cannot assure you that our business will generate sufficient cash flow from operations, that currently anticipated cost savings and operating improvements will be realized or that future borrowings will be available to us in an amount sufficient to enable it to satisfy our obligations under our indebtedness or to fund our other needs. In order for us to satisfy our obligations under our respective indebtedness and fund our planned capital expenditures, we must continue to execute our business strategy. If we are unable to do so, we may need to reduce or delay our planned capital expenditures or refinance all or a portion of our indebtedness on or before maturity. Significant delays in our planned capital expenditures may materially and adversely affect our future revenue prospects. In addition, we cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all.

The indenture governing the 2022 Notes and the credit agreements governing the Senior Secured Credit Facilities restrict the ability of most of our subsidiaries to engage in some business and financial transactions.

Indenture. The indenture governing the 2022 Notes contains restrictive covenants that, among other things, limit our ability and the ability of our subsidiaries to:

·incur additional indebtedness or issue certain preferred shares;

·pay dividends on, redeem or repurchase stock or make other distributions in respect of our capital stock;

·repurchase, prepay or redeem subordinated indebtedness;

·create liens;

·transfer or sell assets;

·create restrictions on the ability of our restricted subsidiaries to pay dividends to us or make other intercompany transfers;

·make investments;

·consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;

·enter into certain transactions with our affiliates; and

67

·designate any of our subsidiaries as unrestricted subsidiaries.

Senior Secured Credit Facilities. The credit agreements governing the Senior Secured Credit Facilities contain a number of covenants that limit our ability and the ability of our restricted subsidiaries to:

·incur additional indebtedness or issue certain preferred shares;

·pay dividends on, redeem or repurchase stock or make other distributions in respect of our capital stock;

·make investments;

·repurchase, prepay or redeem junior indebtedness;

·agree to payment restrictions affecting the ability of our restricted subsidiaries to pay dividends to us or make other intercompany transfers;

·incur additional liens;

·transfer or sell assets;

·consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;

·enter into certain transactions with affiliates;

·agree to payment restrictions affecting our restricted subsidiaries;

·make negative pledges; and

·designate any of our subsidiaries as unrestricted subsidiaries.

The credit agreement governing the ABL Facility also contains other covenants customary for asset-based facilities of this nature. Our ability to borrow additional amounts under the credit agreement governing the ABL Facility depends upon satisfaction of these covenants. Events beyond our control can affect our ability to meet these covenants.

Our failure to comply with obligations under the indenture governing the 2022 Notes and the credit agreements governing the Senior Secured Credit Facilities may result in an event of default under that indenture or those credit agreements. A default, if not cured or waived, may permit acceleration of our indebtedness. We cannot be certain that we will have funds available to remedy these defaults. If our indebtedness is accelerated, we cannot be certain that we will have sufficient funds available to pay the accelerated indebtedness or that we will have the ability to refinance the accelerated indebtedness on terms favorable to us or at all.

An increase in interest rates would increase the cost of servicing our debt and could reduce our profitability.

Our indebtedness under the ABL Facility bears interest at variable rates, and, to the extent LIBOR exceeds 1.00%, our indebtedness under the Term Loan Facility bears interest at variable rates. As a result, increases in interest rates could increase the cost of servicing such debt and materially reduce our profitability and cash flows. As of September 30, 2014, assuming all ABL Facility revolving loans were fully drawn and LIBOR exceeded 1.00%, each one percentage point increase in interest rates would result in approximately a $17.4 million increase in annual interest expense on the Senior Secured Credit Facilities. The impact of such an increase would be more significant for us than it would be for some other companies because of our substantial debt.

We may be unable to raise funds necessary to finance the change of control repurchase offers required by the indenture governing the 2022 Notes.

Under the indenture governing the 2022 Notes, upon the occurrence of specific kinds of change of control, EVHC must offer to repurchase the 2022 Notes at a price equal to 101% of the principal amount of the 2022 Notes plus accrued and unpaid interest to the date of purchase. The occurrence of specified events that would constitute a change of control under the indenture governing the 2022 Notes would also constitute a default under the credit agreements governing the Senior Secured Credit Facilities that permits the lenders to accelerate the maturity of borrowings thereunder and would require EVHC to offer to repurchase the 2022 Notes under the indenture governing the 2022 Notes. In addition, the Senior Secured Credit Facilities may limit or prohibit the purchase of the 2022 Notes by us in the event of a change of control, unless and until the indebtedness under the ABL Facility and the Term Loan Facility is repaid in full. As a result, following a change of control event, EVHC may not be able to repurchase the 2022 Notes unless all indebtedness outstanding under the Senior Secured Credit Facilities is first repaid and any other indebtedness that contains similar provisions is repaid, or EVHC may obtain a waiver from the holders of such indebtedness to provide it with sufficient cash to repurchase the 2022 Notes. Any future debt agreements that we enter into may contain similar provisions. We may not be able to obtain such a waiver, in which case EVHC may be unable to repay all indebtedness under the 2022 Notes. We may also require additional financing from third parties to fund any such repurchases, and we may be unable to obtain financing on satisfactory terms or at all. Further, our ability to repurchase the 2022 Notes may be limited by law. In order to avoid the obligations to repurchase the 2022 Notes and events of default and potential breaches of the credit agreements governing the Senior Secured Credit Facilities, we may have to avoid certain change of control transactions that would otherwise be beneficial to us.

68

Risks Related to Our Common Stock

The Company is a holding company with no operations of its own, and it depends on its subsidiaries for cash to fund all of its operations and expenses, including to make future dividend payments, if any.

Our operations are conducted entirely through our subsidiaries and our ability to generate cash to fund all of our operations and expenses, to pay dividends or to meet any debt service obligations is highly dependent on the earnings and the receipt of funds from our subsidiaries via dividends or intercompany loans. We do not currently expect to declare or pay dividends on our common stock for the foreseeable future; however, to the extent that we determine in the future to pay dividends on our common stock, none of our subsidiaries will be obligated to make funds available to us for the payment of dividends. Further, the indenture governing the 2022 Notes and the agreements governing the Senior Secured Credit Facilities significantly restrict the ability of our subsidiaries to pay dividends, make loans or otherwise transfer assets to us. In addition, Delaware law may impose requirements that may restrict our ability to pay dividends to holders of our common stock.

The market price of our common stock may fluctuate significantly.

The market price of our common stock may fluctuate significantly. Among the factors that could affect our stock price are:

·industry or general market conditions;

·domestic and international economic factors unrelated to our performance;

·changes in our customers’ preferences;

·new regulatory pronouncements and changes in regulatory guidelines;

·lawsuits, enforcement actions and other claims by third parties or governmental authorities;

·actual or anticipated fluctuations in our quarterly operating results;

·changes in securities analysts’ estimates of our financial performance or lack of research and reports by industry analysts;

·action by institutional stockholders or other large stockholders (including the CD&R Affiliates), including future sales;

·speculation in the press or investment community;

·investor perception of us and our industry;

·changes in market valuations or earnings of similar companies;

·announcements by us or our competitors of significant contracts, acquisitions or strategic partnerships;

·any future sales of our common stock or other securities; and

·additions or departures of key personnel.

69

The stock markets have experienced extreme volatility in recent years that has been unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the market price of our common stock. In the past, following periods of volatility in the market price of a company’s securities, class action litigation has often been instituted against such company. Any litigation of this type brought against us could result in substantial costs and a diversion of our management’s attention and resources, which would harm our business, operating results and financial condition.

Future sales of shares by existing stockholders could cause our stock price to decline.

Sales of substantial amounts of our common stock in the public market, or the perception that these sales could occur, could cause the market price of our common stock to decline. As of September 30, 2014, we had 183,381,792 shares of common stock outstanding. Of these shares, all of the 129,050,000 shares of common stock sold in our initial public offering in August of 2013, and in the secondary offerings in February, July, and September of 2014, are freely transferable without restriction or further registration under the Securities Act, unless purchased by our “affiliates” as that term is defined in Rule 144 under the Securities Act. The remaining shares of our common stock outstanding will be restricted securities within the meaning of Rule 144 under the Securities Act, but will be eligible for resale subject to applicable volume, means of sale, holding period and other limitations of Rule 144 under the Securities Act.

In August 2013, we filed a registration statement under the Securities Act to register the shares of common stock to be issued under our equity compensation plans and, as a result, all shares of common stock acquired upon exercise of stock options granted under our plans will also be freely tradable under the Securities Act, unless purchased by our affiliates. As of September 30, 2014, there were stock options outstanding to purchase a total of 12,686,968 shares of our common stock and there were 124,182 shares of our common stock subject to restricted stock units. In addition, 16,539,527 shares of our common stock are reserved for future issuances under our Omnibus Incentive Plan.

In the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement or employee arrangement or otherwise. Any of these issuances could result in substantial dilution to our existing stockholders and could cause the trading price of our common stock to decline.

If securities or industry analysts do not publish research or publish misleading or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more analysts downgrade our stock or publishes misleading or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price or trading volume to decline.

The CD&R Affiliates will have significant influence over us and may not always exercise their influence in a way that benefits our public stockholders.

The CD&R Affiliates own approximately 27.7% of the outstanding shares of our common stock. As a result, the CD&R Affiliates will continue to exercise significant influence over all matters requiring stockholder approval for the foreseeable future, including approval of significant corporate transactions, which may reduce the market price of our common stock.

Although the CD&R Affiliates have reduced their beneficial ownership below 30% of our outstanding common stock, they will still be able to assert significant influence over our Board of Directors and certain corporate actions. The CD&R Affiliates have the right to designate a number of nominees for election to our Board of Directors (the “CD&R Designees”) equal to: (i) at least 20% of the total number of directors comprising our Board of Directors as long as the CD&R Affiliates own at least 20% but less than 30% of the outstanding shares of our common stock; and (ii) at least 5% of the total number of directors comprising our Board of Directors as long as the CD&R Affiliates own at least 5% but less than 20% of the outstanding shares of our common stock.

Because the CD&R Affiliates’ interests may differ from your interests, actions the CD&R Affiliates take as a significant stockholder may not be favorable to you. For example, the concentration of ownership held by the CD&R Affiliates could delay, defer or prevent a change of control of us or impede a merger, takeover or other business combination which another stockholder may otherwise view favorably. Other potential conflicts could arise, for example, over matters such as employee retention or recruiting, or our dividend policy.

70

Under our amended and restated certificate of incorporation, the CD&R Affiliates and their respective affiliates and, in some circumstances, any of our directors and officers who is also a director, officer, employee, member or partner of the CD&R Affiliates and their respective affiliates, have no obligation to offer us corporate opportunities.

The policies relating to corporate opportunities and transactions with the CD&R Affiliates set forth in our second amended and restated certificate of incorporation (“amended and restated certificate of incorporation”) address potential conflicts of interest between the Company, on the one hand, and the CD&R Affiliates and their respective officers and directors who are directors or officers of our company, on the other hand. By becoming a stockholder in the Company, you will be deemed to have notice of and have consented to these provisions of our amended and restated certificate of incorporation. Although these provisions are designed to resolve conflicts between us and the CD&R Affiliates and their respective affiliates fairly, conflicts may not be so resolved.

Future offerings of debt or equity securities, which would rank senior to our common stock, may adversely affect the market price of our common stock.

If, in the future, we decide to issue debt or equity securities that rank senior to our common stock, it is likely that such securities will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution to owners of our common stock. We and, indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, holders of our common stock will bear the risk of our future offerings reducing the market price of our common stock and diluting the value of their stock holdings in us.

Fulfilling our obligations incident to being a public company, including with respect to the requirements of and related rules under the Sarbanes-Oxley Act of 2002, is expensive and time-consuming, and any delays or difficulties in satisfying these obligations could have a material adverse effect on our future results of operations and our stock price.

Our initial public offering was completed on August 19, 2013. As a new public company, we are subject to the reporting and corporate governance requirements, under the listing standards of the New York Stock Exchange (“NYSE”) and the Sarbanes-Oxley Act of 2002, that apply to issuers of listed equity, which impose certain significant compliance costs and obligations upon us. The changes necessitated by being a publicly listed company require a significant commitment of additional resources and management oversight which will increase our operating costs. These changes will also place additional demands on our finance and accounting staff and on our financial accounting and information systems. Other expenses associated with being a public company include increases in auditing, accounting and legal fees and expenses, investor relations expenses, increased directors’ fees and director and officer liability insurance costs, registrar and transfer agent fees and listing fees, as well as other expenses. As a public company, we are required, among other things, to define and expand the roles and the duties of our Board of Directors and its committees and institute more comprehensive compliance and investor relations functions.

In particular, beginning with the year ending December 31, 2014 our independent registered public accounting firm will be required to provide an attestation report on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. If our independent registered public accounting firm is unable to provide us with an unmodified report regarding the effectiveness of our internal control over financial reporting (at such time as it is required to do so), investors could lose confidence in the reliability of our consolidated financial statements. This could result in a decrease in the value of our common stock. Failure to comply with the Sarbanes-Oxley Act of 2002 could potentially subject us to sanctions or investigations by the SEC, the NYSE, or other regulatory authorities.

We could be the subject of securities class action litigation due to future stock price volatility, which could divert management’s attention and adversely affect our results of operations.

The stock market in general, and market prices for the securities of companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. A certain degree of stock price volatility can be attributed to being a newly public company. These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our operating performance. In certain situations in which the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a similar lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results.

71

Anti-takeover provisions in our amended and restated certificate of incorporation and amended and restated by-laws could discourage, delay or prevent a change of control of our company and may affect the trading price of our common stock.

Our amended and restated certificate of incorporation and amended and restated by-laws include a number of provisions that may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. For example, our amended and restated certificate of incorporation and amended and restated by-laws collectively:

·authorize the issuance of “blank check” preferred stock that could be issued by our Board of Directors to thwart a takeover attempt;

·provide for our classified Board of Directors, which divides our Board of Directors into three classes, with members of each class serving staggered three-year terms, which prevents stockholders from electing an entirely new Board of Directors at an annual meeting;

·limit the ability of stockholders to remove directors;

·provide that vacancies on our Board of Directors, including vacancies resulting from an enlargement of our Board of Directors, may be filled only by a majority vote of directors then in office;

·prohibit stockholders from calling special meetings of stockholders;

·prohibit stockholder action by written consent, thereby requiring all actions to be taken at a meeting of the stockholders;

·establish advance notice requirements for nominations of candidates for election as directors or to bring other business before an annual meeting of our stockholders; and

·require the approval of holders of at least 66 2/3% of the outstanding shares of our common stock to amend our amended and restated by-laws and certain provisions of our amended and restated certificate of incorporation.

These provisions may prevent our stockholders from receiving the benefit from any premium to the market price of our common stock offered by a bidder in a takeover context. Even in the absence of a takeover attempt, the existence of these provisions may adversely affect the prevailing market price of our common stock if the provisions are viewed as discouraging takeover attempts in the future.

Our amended and restated certificate of incorporation and amended and restated by-laws may also make it difficult for stockholders to replace or remove our management. These provisions may facilitate management entrenchment that may delay, deter, render more difficult or prevent a change in our control, which may not be in the best interests of our stockholders.

We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We do not intend to declare and pay dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth, to develop our business, for working capital needs and for general corporate purposes. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future and the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares. In addition, our operations are conducted almost entirely through our subsidiaries. As such, to the extent that we determine in the future to pay dividends on our common stock, none of our subsidiaries will be obligated to make funds available to us for the payment of dividends. Further, the indenture governing the 2022 Notes and the agreements governing the ABL Facility and the Term Loan Facility significantly restrict the ability of our subsidiaries to pay dividends or otherwise transfer assets to us. In addition, Delaware law may impose requirements that may restrict our ability to pay dividends to holders of our common stock.

We are no longer a “controlled company” within the meaning of the NYSE rules and the rules of the SEC. However, we may continue to rely on exemptions from certain corporate governance requirements during a one year transition period.

As of July 16, 2014, the CD&R Affiliates no longer control a majority of the voting power of our outstanding common stock. As a result, we are no longer a “controlled company” within the meaning of the corporate governance rules of the NYSE. Consequently, under the NYSE corporate governance rules, we are required to (i) appoint a majority of independent directors to our Board of Directors within one year of the date we no longer qualified as a “controlled company”, (ii) appoint a majority of independent directors to each of the compensation and nominating and corporate governance committees within 90 days of the date we no longer qualified as a “controlled company” and such committees must be composed entirely of independent directors within one year of such date, and (iii) have an annual performance evaluation of the nominating and corporate governance and compensation committees. During these transition periods, we may continue to utilize the available exemptions from certain corporate governance requirements as permitted by the NYSE rules. Accordingly, during the transition periods, you will not have the same protections afforded to stockholders of companies that are subject to all of the NYSE corporate governance standards.

72

Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed to us or our stockholders by any of our directors, officers, employees or agents, (iii) any action asserting a claim against us arising under the General Corporation Law of the State of Delaware (“DGCL”) or (iv) any action asserting a claim against us that is governed by the internal affairs doctrine. By becoming a stockholder in our company, you will be deemed to have notice of and have consented to the provisions of our amended and restated certificate of incorporation related to choice of forum. The choice of forum provision in our amended and restated certificate of incorporation may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

ITEM 5. OTHER INFORMATION

On November 12, 2014, our Board of Directors appointed William A. Sanger, the Company’s Chief Executive Officer, to serve as Chairman of the Board of Directors, succeeding Ronald A. Williams in that role.  Mr. Williams, who has served as non-executive Chairman of the Board of Directors since May 2011, has been appointed by the independent directors of the Board of Directors to serve as the Board’s lead director.

ITEM 6. EXHIBITS

See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.

73

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ENVISION HEALTHCARE HOLDINGS, INC.
	(registrant)
November 12, 2014	By:	/s/ William A. Sanger
Date		William A. Sanger
		Chief Executive Officer
	By:	/s/ Randel G. Owen
		Randel G. Owen
		Chief Financial Officer and Executive Vice President

74

EXHIBIT INDEX

4.1	Second Supplemental Indenture, dated as of September 10, 2014, among Envision Healthcare Corporation, the Subsidiary Guarantors named therein and Wilmington Trust, National Association. *
10.1	Form of Employee Stock Option Agreement.*
10.2	Form of Employee Restricted Stock Unit Agreement.*
10.3	Form of Director Restricted Stock Unit Agreement.*
31.1	Certification of the Chief Executive Officer of Envision Healthcare Holdings, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2	Certification of the Chief Financial Officer of Envision Healthcare Holdings, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1	Certification of the Chief Executive Officer and the Chief Financial Officer of Envision Healthcare Holdings, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 formatted in XBRL (eXtensible Business Reporting Language): (1) the Consolidated Statements of Operations and Comprehensive Income, (2) the Consolidated Balance Sheets, (3) the Consolidated Statements of Cash Flows and (4) Notes to the Unaudited Consolidated Financial Statements.*

*Filed with this Report

75

EX-4.1

Exhibit 4.1

Execution Version

Supplemental Indenture in Respect of Subsidiary Guarantees

SECOND SUPPLEMENTAL INDENTURE, dated as of September 10, 2014 (this “Supplemental Indenture”), among the Guarantors listed on Schedule A hereto (the “New Subsidiary Guarantors” and each, a “New Subsidiary Guarantor”), Envision Healthcare Corporation, the “Company”), and Wilmington Trust, National Association, as Trustee under the Indenture referred to below.

W I T N E S S E T H:

WHEREAS, the Company and each other then existing Subsidiary Guarantor under the Indenture (as defined below) (the “Existing Guarantors”) and the Trustee have heretofore become parties to an Indenture, dated as of June 18, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing for the issuance of Notes in series;

WHEREAS, Section 1308 of the Indenture provides that the Company is required to cause the New Subsidiary Guarantors to execute and deliver to the Trustee a supplemental indenture pursuant to which the New Subsidiary Guarantors shall guarantee the Company’s Subsidiary Guaranteed Obligations under the Notes pursuant to a Subsidiary Guarantee on the terms and conditions set forth herein and in Article XIII of the Indenture;

WHEREAS, each New Subsidiary Guarantor desires to enter into such supplemental indenture for good and valuable consideration, including substantial economic benefit in that the financial performance and condition of such New Subsidiary Guarantor is dependent on the financial performance and condition of the Company, the obligations hereunder of which such New Subsidiary Guarantor has guaranteed, and on such New Subsidiary Guarantor’s access to working capital through the Company’s access to revolving credit borrowings under the Senior ABL Facility; and

WHEREAS, pursuant to Section 901 of the Indenture, the parties hereto are authorized to execute and deliver this Supplemental Indenture to amend the Indenture, without the consent of any Holder;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New Subsidiary Guarantors, the Company and the Trustee mutually covenant and agree for the benefit of the Holders of the Notes as follows:

1.             Defined Terms.  As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recital hereto are used herein as therein defined.  The words “herein,” “hereof” and “hereby” and other words of similar import

used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

2.             Agreement to Guarantee.  Each New Subsidiary Guarantor hereby agrees, jointly and severally with all other New Subsidiary Guarantors and fully and unconditionally, to guarantee the Subsidiary Guaranteed Obligations under the Indenture and the Notes on the terms and subject to the conditions set forth in Article XIII of the Indenture and to be bound by (and shall be entitled to the benefits of) all other applicable provisions of the Indenture as a Subsidiary Guarantor (as defined in the Indenture).

3.             Termination, Release and Discharge.  Each New Subsidiary Guarantor’s Subsidiary Guarantee shall terminate and be of no further force or effect, and each New Subsidiary Guarantor shall be released and discharged from all obligations in respect of such Subsidiary Guarantee, as and when provided in Section 1303 of the Indenture.

4.             Parties.  Nothing in this Supplemental Indenture is intended or shall be construed to give any Person, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of each New Subsidiary Guarantor’s Subsidiary Guarantee or any provision contained herein or in Article XIII of the Indenture.

5.             Governing Law.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.  THE TRUSTEE, THE COMPANY, ANY OTHER OBLIGOR IN RESPECT OF THE NOTES AND (BY THEIR ACCEPTANCE OF THE NOTES) THE HOLDERS AGREE TO SUBMIT TO THE JURISDICTION OF ANY UNITED STATES FEDERAL OR STATE COURT LOCATED IN THE BOROUGH OF MANHATTAN, IN THE CITY OF NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE.

6.             Ratification of Indenture; Supplemental Indentures Part of Indenture.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture or as to the accuracy of the recitals to this Supplemental Indenture.

7.             Counterparts.  The parties hereto may sign one or more copies of this Supplemental Indenture in counterparts, all of which together shall constitute one and the same agreement.

8.             Headings.  The section headings herein are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

ENVISION HEALTHCARE CORPORATION
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary
PHOENIX PHYSICIANS, LLC
STREAMLINED MEDICAL SOLUTIONS LLC
By:	Emcare, Inc., as sole member
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary
EVERGREEN EMERGENCY SERVICES OF ALLENTOWN, INC.
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary
ARKANSAS RIVER EMERGENCY SERVICES, LLC
By:	Phoenix Emergency Physicians of the Northeast, LLC, as sole member
By:	Phoenix Physicians, LLC, as sole member
By:	Emcare, Inc., as sole member
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary

[Signature Page to Second Supplemental Indenture]

DAN RIVER EMERGENCY SERVICES, LLC
EMERGENCY SERVICES OF CENTRAL OHIO, LLC
PHOENIX EMERGENCY MEDICINE OF BROWARD, LLC
PHOENIX EMERGENCY PHYSICIANS OF THE MIDWEST, LLC
PHOENIX EMERGENCY PHYSICIANS OF THE NORTHEAST, LLC
PHOENIX EMERGENCY PHYSICIANS OF THE SOUTHEAST, LLC
PHOENIX EMERGENCY SERVICES OF INVERNESS, LLC
PHOENIX EMERGENCY SERVICES OF LEESBURG, LLC
PHOENIX OBSTETRICS/GYNECOLOGY, LLC
PHOENIX PEDIATRICS OF BROWARD, LLC
By: Phoenix Physicians, LLC, as sole member
By: Emcare, Inc., as sole member
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary
AMERICAN MEDICAL RESPONSE HPPP, LLC
By: American Medical Response, Inc., as sole member
By:	/s/ Craig A. Wilson
Name:	Craig A. Wilson
Title:	Secretary

WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee
By:	/s/ Joseph P. O’Donnell
Authorized Officer

Schedule A

	Additional Granting Parties	Jurisdiction of Organization
1.	Streamlined Medical Solutions LLC	Texas
2.	Phoenix Physicians, LLC	Florida
3.	Dan River Emergency Services, LLC	Virginia
4.	Emergency Services of Central Ohio, LLC	Ohio
5.	Phoenix Emergency Medicine of Broward, LLC	Florida
6.	Phoenix Emergency Physicians of the Midwest, LLC	Florida
7.	Phoenix Emergency Physicians of the Northeast, LLC	Florida
8.	Phoenix Emergency Physicians of the Southeast, LLC	Florida
9.	Phoenix Emergency Services of Inverness, LLC	Florida
10.	Phoenix Emergency Services of Leesburg, LLC	Florida
11.	Phoenix Obstetrics/Gynecology, LLC	Florida
12.	Phoenix Pediatrics of Broward, LLC	Florida
13.	Evergreen Emergency Services of Allentown, Inc.	Pennsylvania
14.	Arkansas River Emergency Services, LLC	Arkansas
15.	American Medical Response HPPP, LLC	Delaware

EX-10.1

Exhibit 10.1

Employee Stock Option Agreement

This Employee Stock Option Agreement (the “Agreement”), by and between Envision Healthcare Holdings, Inc., a Delaware corporation (the “Company”), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (the “Plan”) and is dated as of the date it is accepted and agreed to by the Employee in accordance with Section 7(m).  Capitalized terms that are used but not defined herein shall have the respective meanings given to them in the Plan.

Section 1.Grant of Options.

(a)Confirmation of Grant.  The Company hereby evidences and confirms, effective as of the date set forth on Exhibit A hereto (the “Grant Date”), its grant to the Employee of the number of options to purchase Shares as set forth on Exhibit A hereto (the “Options”).  The Options are not intended to be incentive stock options under the Code.  This Agreement is entered into pursuant to, and the terms of the Options are subject to, the terms of the Plan.  If there is any inconsistency between this Agreement and the terms of the Plan, the terms of the Plan shall govern.

(b)Option Price.  The Option Price for each Share covered by the Options is the price set forth on Exhibit A hereto.

Section 2.Vesting and Exercisability.

(a)Vesting.  Except as otherwise provided in Section 2(b) or Section 5 of this Agreement, the Options shall become vested, if at all, in the percentage(s), and on the vesting date(s) set forth on Exhibit A hereto (each, a “Vesting Date”); provided that if the Employee’s employment with the Company is terminated by reason of the Employee’s death or Disability (either a “Special Termination”), any Options held by the Employee shall immediately vest as of the effective date of such Special Termination.

(b)Discretionary Acceleration.  The Administrator, in its sole discretion, may accelerate the vesting or exercisability of all or a portion of the Options, at any time and from time to time.

(c)Exercise.  Once vested in accordance with the provisions of this Agreement, the Options may be exercised at any time and from time to time prior to the date such Options terminate pursuant to Section 3.  Options may only be exercised with respect to whole shares of Company Common Stock and must be exercised in accordance with Section 4.

(d)No Other Accelerated Vesting.  The vesting and exercisability provisions set forth in this Section 2 or in Section 5, or expressly set forth in the Plan, shall be the exclusive vesting and exercisability provisions applicable to the Options and shall supersede any other provisions relating to vesting and exercisability, unless such other such provision expressly refers to the Plan by name and this Agreement by name and date.

Section 3.Termination of Options.

(a)Normal Termination Date.  Unless earlier terminated pursuant to Section 3(b) or Section 5, the Options shall terminate on the tenth anniversary of the Grant Date (the “Normal Termination Date”), if not exercised prior to such date.

(b)Early Termination.  If the Employee’s employment with the Company terminates for any reason, any Options held by the Employee that have not vested before the effective date of such termination of employment (determined without regard to any statutory or deemed or express contractual notice period) or that do not become vested on such date in accordance with Section 2 shall terminate immediately upon such termination of employment and, if the Employee’s employment is terminated for Cause, all Options (whether or not then vested or exercisable) shall automatically terminate immediately upon such termination.  All vested Options held by the Employee following the effective date of a termination of employment shall remain exercisable until the first to occur of (i) the 90th day following the effective date of the Employee’s termination of employment (or the 180th day in the case of a Special Termination or a retirement at normal retirement age) (in each case, determined without regard to any statutory or deemed or express contractual notice period), (ii) the Normal Termination Date or (iii) the cancellation of the Options pursuant to Section 5, and if not exercised within such period the Options shall automatically terminate upon the expiration of such period.  If, on the first date of the periods set forth in Section 3(b)(i), the Option is not exercisable solely due to any of the restrictions set forth in Section 4(b)(i), (ii) or (iii), the Option will not expire until the earlier of the Normal Termination Date or 90 days following the first date on which exercise of the Option ceases to be barred by any such restriction.

Section 4.Manner of Exercise.

(a)General.  Subject to such reasonable administrative regulations as the Administrator may adopt from time to time, the exercise of vested Options by the Employee shall be pursuant to procedures contained in the Plan and such other procedures established by the Administrator from time to time and shall include the Employee specifying in writing the proposed date on which the Employee desires to exercise a vested Option (the “Exercise Date”), the number of whole shares with respect to which the Options are being exercised (the “Exercise Shares”) and the aggregate Option Price for such Exercise Shares (the “Exercise Price”), or such other or different requirements as may be specified by the Administrator.  On or before any Exercise Date, at the Company’s request, the Company and the Employee shall enter into a Subscription Agreement that establishes the rights and obligations of the Company and the Employee relating to the Exercise Shares, in the form then customarily used by the Company under the Plan for such purpose.  Unless otherwise determined by the Administrator, (i) on or before the Exercise Date the Employee shall deliver to the Company full payment for the Exercise Shares in United States dollars in cash, or cash equivalents satisfactory to the Company, in an amount equal to the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees, or, pursuant to a broker-assisted exercise program established by the Company, the Employee may exercise vested Options by an exercise and sell procedure (cashless exercise) in which the Exercise Price (together with any required withholding taxes or other similar taxes, charges or fees) is deducted from the proceeds of the exercise of an Option and (ii) the Company shall register the issuance of the Exercise Shares on its records (or direct

2

such issuance to be registered by the Company’s transfer agent).  The Administrator may require the Employee to furnish or execute such other documents as the Administrator shall reasonably deem necessary (i) to evidence such exercise or (ii) to comply with or satisfy the requirements of the Securities Act, applicable state or non-U.S. securities laws or any other law.

(b)Restrictions on Exercise.  Notwithstanding any other provision of this Agreement, the Options may not be exercised in whole or in part, (i) unless all requisite approvals and consents of any governmental authority of any kind shall have been secured, (ii) unless the purchase of the Exercise Shares shall be exempt from registration under applicable U.S. federal and state securities laws, and applicable non-U.S. securities laws, or the Exercise Shares shall have been registered under such laws, (iii) at any time that exercise of the Option would violate the Company’s insider trading policy and unless, if applicable, the Employee has obtained pre-trading clearance for the exercise and (iv) unless all applicable U.S. federal, state and local and non-U.S. tax withholding requirements shall have been satisfied.  The Company shall use its commercially reasonable efforts to obtain any consents or approvals referred to in clause (i) of the preceding sentence, but shall otherwise have no obligations to take any steps to prevent or remove any impediment to exercise described in such sentence.

Section 5.Change in Control.  In the event of a Change in Control, the treatment of any outstanding Options shall be governed by Article XIV of the Plan.

Section 6.Certain Definitions.  As used in this Agreement, capitalized terms that are not defined herein have the respective meaning given in the Plan, and the following additional terms shall have the following meanings:

“Agreement” means this Employee Stock Option Agreement, as amended from time to time in accordance with the terms hereof.

“Code” means the United States Internal Revenue Code of 1986, as amended, and any successor thereto.

“Company” means Envision Healthcare Holdings, Inc., provided that for purposes of determining the status of Employee’s employment with the “Company,” such term shall include the Company and/or any of its Subsidiaries that employ the Employee.

“Employee” means the grantee of the Options, whose name is set forth on Exhibit A hereto; provided that for purposes of Section 4 and Section 7, following such person’s death, “Employee” shall be deemed to include such person’s beneficiary or estate and following such Person’s Disability, “Employee” shall be deemed to include such person’s legal representative.

“Exercise Date” has the meaning given in Section 4(a).

“Exercise Price” has the meaning given in Section 4(a).

“Exercise Shares” has the meaning given in Section 4(a).

“Grant Date” has the meaning given in Section 1(a), which is the date on which the Options are granted to the Employee.

3

“Normal retirement age” has the meaning provided in the Company’s customary policies.

“Normal Termination Date” has the meaning given in Section 3(a).

“Option” means the right granted to the Employee hereunder to purchase one share of Company Common Stock for a purchase price equal to the Option Price subject to the terms of this Agreement and the Plan.

“Option Price” means, with respect to each share of Company Common Stock covered by an Option, the purchase price specified in Section 1(b) for which the Employee may purchase such share of Company Common Stock upon exercise of an Option.

“Plan” means the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan.

“Special Termination” has the meaning given in Section 2(a).

Section 7.Miscellaneous.

(a)Tax Withholding.  The Company or one of its Subsidiaries shall require the Employee to satisfy any applicable U.S. federal, state and local and non-U.S. tax withholding or other similar charges or fees that may arise in connection with the grant, vesting, exercise or purchase of the Options.

(b)No Rights as Stockholder; No Voting Rights.  The Employee shall have no rights as a stockholder of the Company with respect to any shares of Common Stock covered by the Options until the exercise of the Options and delivery of the shares of Common Stock.  No adjustment shall be made for dividends or other rights for which the record date is prior to the delivery of the shares of Common Stock.  Any shares of Common Stock delivered in respect of the Options shall be subject to any Subscription Agreement, which the Company may require the Employee to accept and agree to as a condition of the issuance and delivery of such shares of Common Stock.

(c)No Right to Continued Employment.  Nothing in this Agreement shall be deemed to confer on the Employee any right to continue in the employ of the Company or any Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to terminate such employment at any time.

(d)Non-Transferability of Options.  The Options may be exercised only by the Employee, or, following the Employee’s death, by his designated beneficiary or by his estate in the absence of a designated beneficiary.  The Options are not assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered, transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered (including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of descent and distribution to the estate of the Employee upon the Employee’s death or with the Company’s consent.

(e)Forfeiture of Awards.  The Options granted hereunder (and gains earned or accrued in connection therewith) shall be subject to such generally applicable policies as to

4

forfeiture and recoupment (including, without limitation, upon the occurrence of material financial or accounting errors, financial or other misconduct or Competitive Activity) as may be adopted by the Administrator or the Board from time to time and communicated to the Employee, and are otherwise subject to forfeiture or disgorgement of profits as provided by the Plan.

(f)Consent to Electronic Delivery.  By entering into this Agreement and accepting the Options evidenced hereby, the Employee hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Employee pursuant to applicable securities laws) regarding the Company and its Subsidiaries, the Plan, this Agreement and the Options via Company website or other electronic delivery.

(g)Binding Effect; Benefits.  This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors and assigns.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

(h)Waiver; Amendment.

(i)Waiver.  Any party hereto or beneficiary hereof may by written notice to the other parties (A) extend the time for the performance of any of the obligations or other actions of the other parties under this Agreement, (B) waive compliance with any of the conditions or covenants of the other parties contained in this Agreement and (C) waive or modify performance of any of the obligations of the other parties under this Agreement.  Except as provided in the preceding sentence, no action taken pursuant to this Agreement, including, without limitation, any investigation by or on behalf of any party or beneficiary, shall be deemed to constitute a waiver by the party or beneficiary taking such action of compliance with any representations, warranties, covenants or agreements contained herein.  The waiver by any party hereto or beneficiary hereof of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach and no failure by a party or beneficiary to exercise any right or privilege hereunder shall be deemed a waiver of such party’s or beneficiary’s rights or privileges hereunder or shall be deemed a waiver of such party’s or beneficiary’s rights to exercise the same at any subsequent time or times hereunder.

(ii)Amendment.  This Agreement may not be amended, modified or supplemented orally, but only by a written instrument executed by the Employee and the Company.

(i)Assignability.  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or the Employee without the prior written consent of the other party.

(j)Applicable Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.

5

(k)Waiver of Jury Trial.  Each party hereby waives, to the fullest extent permitted by applicable law, any right they may have to a trial by jury in respect of any suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby.  Each party (i) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (ii) acknowledges that they and the other parties have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 7(k).

(l)Section and Other Headings, etc.  The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

(m)Acceptance of Options and Agreement.  The Employee has indicated his or her consent and acknowledgement of the terms of this Agreement pursuant to the instructions provided to the Employee by or on behalf of the Company.  The Employee acknowledges receipt of the Plan, represents to the Company that he or she has read and understood this Agreement and the Plan, and, as an express condition to the grant of the Options under this Agreement, agrees to be bound by the terms of both this Agreement and the Plan.  The Employee and the Company each agrees and acknowledges that the use of electronic media (including, without limitation, a clickthrough button or checkbox on a website of the Company or a third-party administrator) to indicate the Employee’s confirmation, consent, signature, agreement and delivery of this Agreement and the Options is legally valid and has the same legal force and effect as if the Employee and the Company signed and executed this Agreement in paper form.  The same use of electronic media may be used for any amendment or waiver of this Agreement.

6

Exhibit A to
Employee Stock Option Agreement

Employee:
Grant Date:	, 201
Options granted hereby:
Option Price:

Vesting Date Percentage
Vesting
on such Vesting
Date

7

EX-10.2

Exhibit 10.2

Employee Restricted Stock Unit Agreement

This Employee Restricted Stock Unit Agreement (the “Agreement”), by and between Envision Healthcare Holdings, Inc., a Delaware corporation (the “Company”), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (the “Plan”) and is dated as of the date it is accepted and agreed to by the Employee in accordance with Section 7(q).  Capitalized terms that are used but not defined herein shall have the respective meanings given to them in the Plan.

Section 1.Grant of Restricted Stock Units.  The Company hereby evidences and confirms its grant to the Employee, effective as of the date set forth on Exhibit A hereto (the “Grant Date”), of the number of Restricted Stock Units set forth on Exhibit A hereto.  This Agreement is entered into pursuant to, and the Restricted Stock Units granted hereunder are subject to, the terms and conditions of the Plan, which are incorporated by reference herein.  If there is any inconsistency between this Agreement and the terms of the Plan, the terms of the Plan shall govern.

Section 2.Vesting of Restricted Stock Units.

(a)Vesting.  Except as otherwise provided in this Section 2, the Restricted Stock Units shall become vested, if at all, in the percentage(s), and on the vesting date(s) set forth on Exhibit A hereto (each, a “Vesting Date”), subject to the continued employment of the Employee by the Company or any Subsidiary thereof through such date.  Vested Restricted Stock Units shall be settled as provided in Section 3 of this Agreement.

(b)Effect of Termination of Employment.

(i)If the Employee’s employment is terminated by reason of the Employee’s death or Disability (such termination, a “Special Termination”), all outstanding Restricted Stock Units shall immediately vest as of the date of such Special Termination.  Vested Restricted Stock Units shall be settled as provided in Section 3 of this Agreement.

(ii)Any Other Reason.  Upon termination of the Employee’s employment for any reason other than a Special Termination (whether initiated by the Company or by the Employee), any unvested Restricted Stock Units shall be forfeited and canceled effective as of the date of such termination.

(c)Effect of a Change in Control.  In the event of a Change in Control, the treatment of any unvested Restricted Stock Units shall be governed by Article XIV of the Plan.

(d)Discretionary Acceleration.  Notwithstanding anything contained in this Agreement to the contrary, the Administrator, in its sole discretion, may accelerate the vesting with respect to any Restricted Stock Units under this Agreement, at such times and upon such terms and conditions as the Administrator shall determine.

Section 3.Settlement of Restricted Stock Units.

(a)Timing of Settlement.  Subject to Section 6(a), any outstanding Restricted Stock Units that became vested on a Vesting Date shall be settled into an equal number of shares of Common Stock on a date selected by the Company that is within 30 days following such Vesting Date (each such date, a “Settlement Date”).

(b)Mechanics of Settlement.  On each Settlement Date, the Company shall electronically issue to the Employee one whole share of Common Stock for each Restricted Stock Unit that then became vested, and, upon such issuance, the Employee’s rights in respect of such Restricted Stock Unit shall be extinguished.  On or before any Settlement Date, at the Company’s request, the Company and the Employee shall enter into a Subscription Agreement that establishes the rights and obligations of the Company and the Employee relating to the shares of Common Stock issued in respect of the Restricted Stock Units, in the form then customarily used by the Company under the Plan for such purpose.  In the event that there are any fractional Restricted Stock Units that became vested on such date, such fractional Restricted Stock Units shall be settled through a cash payment equal to the portion of Restricted Stock Unit multiplied by the Fair Market Value of the Common Stock on such Settlement Date.  No fractional shares of Common Stock shall be issued.

Section 4.Securities Law Compliance.  Notwithstanding any other provision of this Agreement, the Employee may not sell the shares of Common Stock acquired upon settlement of the Restricted Stock Units unless such shares are registered under the Securities Act of 1933, as amended (the “Securities Act”), or, if such shares are not then so registered, such sale would be exempt from the registration requirements of the Securities Act.  The sale of such shares must also comply with other applicable laws and regulations governing the Common Stock, and the Employee may not sell the shares of Common Stock if the Company determines that such sale would not be in material compliance with such laws and regulations.

Section 5.Restriction on Transfer; Non-Transferability of Restricted Stock Units.  The Restricted Stock Units are not assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered, transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered (including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of descent and distribution to the estate of the Employee upon the Employee’s death.  Any purported transfer in violation of this Section 5 shall be void ab initio.

Section 6.Miscellaneous.

(a)Tax Withholding.  The Company or one of the Subsidiaries shall require the Employee to remit to the Company an amount in cash sufficient to satisfy any applicable U.S. federal, state and local and non-U.S. tax withholding obligations that may arise in connection with the vesting of the Restricted Stock Units and the related issuance of shares of Common stock.  Notwithstanding the preceding sentence, if the Employee elects not to remit cash in respect of such obligations, the Company shall retain a number of shares issued in respect of the Restricted Stock Units then vesting that have an aggregate Fair Market Value as of the Settlement Date equal to the amount of such taxes required to be withheld (and the Employee

2

shall thereupon be deemed to have satisfied his or her obligations under this Section 6(a)); provided that the number of such shares retained shall not be in excess of the minimum amount required to satisfy the statutory withholding tax obligations (it being understood that the value of any fractional share of Common Stock shall be paid in cash).  The number of shares of Common Stock to be issued in respect of Restricted Stock Units shall thereupon be reduced by the number of shares of Common Stock so retained.  The method of withholding set forth in the immediately preceding sentence shall not be available if withholding in this manner would violate any financing instrument of the Company or any of the Subsidiaries.

(b)Dividend Equivalents.  In the event that the Company pays any ordinary dividend in cash on a share of Common Stock following the Grant Date and prior to an applicable Settlement Date, there shall be credited to the account of the Employee in respect of each outstanding Restricted Stock Unit an amount equal to the amount of such dividend.  The amount so credited shall be deferred (without interest, unless the Administrator determines otherwise) until the settlement of such related Restricted Stock Unit and then paid in cash, but shall be forfeited upon the forfeiture of such related Restricted Stock Unit.

(c)Authorization to Share Personal Data.  The Employee authorizes the Company or any Affiliate of the Company that has or lawfully obtains personal data relating to the Employee to divulge or transfer such personal data to the Company or to a third party, in each case in any jurisdiction, if and to the extent reasonably appropriate in connection with this Agreement or the administration of the Plan.

(d)No Rights as Stockholder; No Voting Rights.  The Employee shall have no rights as a stockholder of the Company with respect to any shares of Common Stock covered by the Restricted Stock Units prior to the issuance of such shares of Common Stock.

(e)No Right to Awards.  The Employee acknowledges and agrees that the grant of any Restricted Stock Units (i) is being made on an exceptional basis and is not intended to be renewed or repeated, (ii) is entirely voluntary on the part of the Company and the Subsidiaries and (iii) should not be construed as creating any obligation on the part of the Company or any of the Subsidiaries to offer any Restricted Stock Units in the future.

(f)No Right to Continued Employment. Nothing in this Agreement shall be deemed to confer on the Employee any right to continue in the employ of the Company or any Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to terminate such employment at any time.

(g)Interpretation.  The Administrator shall have full power and discretion to construe and interpret the Plan (and any rules and regulations issued thereunder) and this Award.  Any determination or interpretation by the Administrator under or pursuant to the Plan or this Award shall be final and binding and conclusive on all persons affected hereby.

(h)Forfeiture of Awards.  The Restricted Stock Units granted hereunder (and gains earned or accrued in connection therewith) shall be subject to such generally applicable policies as to forfeiture and recoupment (including, without limitation, upon the occurrence of material financial or accounting errors, financial or other misconduct or Competitive Activity) as may be

3

adopted by the Administrator or the Board from time to time and communicated to the Employee, and is otherwise subject to forfeiture or disgorgement of profits as provided by the Plan.

(i)Consent to Electronic Delivery.  By entering into this Agreement and accepting the Restricted Stock Units evidenced hereby, the Employee hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Employee pursuant to applicable securities laws) regarding the Company and the Subsidiaries, the Plan, this Agreement and the Restricted Stock Units via Company website or other electronic delivery.

(j)Binding Effect; Benefits.  This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors and assigns.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

(k)Amendment.  This Agreement may not be amended, modified or supplemented orally, but only by a written instrument executed by the Employee and the Company.

(l)Assignability.  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or the Employee without the prior written consent of the other party.

(m)Applicable Law.  This Agreement shall be governed by and construed in accordance with laws of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.

(n)Waiver of Jury Trial.  Each party hereby waives, to the fullest extent permitted by applicable law, any right they may have to a trial by jury in respect of any suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby.  Each party (i) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (ii) acknowledges that they and the other party hereto have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 6(n).

(o)Limitations of Actions. No lawsuit relating to this Agreement may be filed before a written claim is filed with the Administrator and is denied or deemed denied as provided in the Plan and any lawsuit must be filed within one year of such denial or deemed denial or be forever barred.

(p)Section and Other Headings, etc.  The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

(q)Acceptance of Restricted Stock Units and Agreement.  The Employee has indicated his or her consent and acknowledgement of the terms of this Agreement pursuant to the instructions provided to the Employee by or on behalf of the Company.  The Employee

4

acknowledges receipt of the Plan, represents to the Company that he or she has read and understood this Agreement and the Plan, and, as an express condition to the grant of the Restricted Stock Units under this Agreement, agrees to be bound by the terms of both this Agreement and the Plan.  The Employee and the Company each agrees and acknowledges that the use of electronic media (including, without limitation, a clickthrough button or checkbox on a website of the Company or a third-party administrator) to indicate the Employee’s confirmation, consent, signature, agreement and delivery of this Agreement and the Restricted Stock Units is legally valid and has the same legal force and effect as if the Employee and the Company signed and executed this Agreement in paper form.  The same use of electronic media may be used for any amendment or waiver of this Agreement.

5

Exhibit A to
Employee Restricted Stock Unit Agreement

Employee:
Grant Date:	, 201
Restricted Stock Units granted hereby:

Vesting Date Percentage
Vesting
on such Vesting
Date

6

EX-10.3

Exhibit 10.3

Form of
Director Restricted Stock Unit Agreement
(Annual Grant)

This Director Restricted Stock Unit Agreement (the “Agreement”), by and between Envision Healthcare Holdings, Inc., a Delaware corporation (the “Company”), and the Director whose name is set forth on Exhibit A hereto, is being entered into pursuant to the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (the “Plan”).  Capitalized terms that are used but not defined herein shall have the respective meanings given to them in the Plan.

Section 1.Grant of Restricted Stock Units.  The Company hereby evidences and confirms its grant to the Director, effective as of the date set forth on Exhibit A hereto (the “Grant Date”), of the number of Restricted Stock Units set forth on Exhibit A hereto, as satisfaction of the equity portion of the Director’s annual fee for the current year ($          divided by the Fair Market Value of the Common Stock on the Grant Date).  This Agreement is entered into pursuant to, and the Restricted Stock Units granted hereunder are subject to, the terms and conditions of the Plan, which are incorporated by reference herein.  If there is any inconsistency between any express provision of this Agreement and any express term of the Plan, the express term of the Plan shall govern.

Section 2.Vesting of Restricted Stock Units.

(a)Vesting.  Except as otherwise provided in this Section 2, the Restricted Stock Units shall become vested, if at all, on the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the Company’s next annual shareholders meeting after the Grant Date, in each case subject to the Director’s continued service on the Board of Directors of the Company (the “Board”) from the Grant Date until the applicable vesting date.  Vested Restricted Stock Units shall be settled as provided in Section 3 of this Agreement.

(b)Effect of Termination of Services.

(i)Death or Disability.  If the Director’s service on the Board is terminated due to death or Disability (each, a “Special Termination”), all outstanding Restricted Stock Units shall immediately vest as of the date of such Special Termination.  Vested Restricted Stock Units shall be settled as provided in Section 3 of this Agreement.

(ii)Any Other Reason.  Upon termination of the Director’s services on the Board for any reason other than a Special Termination (whether initiated by the Company or by the Director), any unvested Restricted Stock Units shall be forfeited and canceled effective as of the date of such termination.

(c)Effect of a Change in Control.  In the event of a Change in Control, the treatment of any unvested Restricted Stock Units shall be governed by Article XIV of the Plan.

(d)Discretionary Acceleration.  Notwithstanding anything contained in this Agreement to the contrary, the Administrator, in its sole discretion, may accelerate the vesting with respect to any Restricted Stock Units under this Agreement, at such times and upon such terms and conditions as the Administrator shall determine.

Section 3.Settlement of Restricted Stock Units.

(a)Timing of Settlement.  Any outstanding vested Restricted Stock Units shall be settled into an equal number of shares of Common Stock on a date selected by the Company that is within 30 days following the applicable vesting date (such date, the “Settlement Date”).

(b)Mechanics of Settlement.  On the Settlement Date, the Company shall electronically issue to the Director one whole share of Common Stock for each vested Restricted Stock Unit, and, upon such issuance, the Director’s rights in respect of such Restricted Stock Unit shall be extinguished.  On or before the Settlement Date, at the Company’s request, the Company and the Director shall enter into a Subscription Agreement that establishes the rights and obligations of the Company and the Director relating to the shares of Common Stock issued in respect of the Restricted Stock Units, in the form then customarily used by the Company under the Plan for such purpose.  In the event that there are any fractional Restricted Stock Units, such fractional Restricted Stock Units shall be settled through a cash payment equal to the portion of Restricted Stock Unit multiplied by the Fair Market Value of the Common Stock on the Settlement Date.  No fractional shares of Common Stock shall be issued.

Section 4.Securities Law Compliance.  Notwithstanding any other provision of this Agreement, the Director may not sell the shares of Common Stock acquired upon settlement of the Restricted Stock Units unless such shares are registered under the Securities Act of 1933, as amended (the “Securities Act”), or, if such shares are not then so registered, such sale would be exempt from the registration requirements of the Securities Act.  The sale of such shares must also comply with other applicable laws and regulations governing the Common Stock, and the Director may not sell the shares of Common Stock if the Company determines that such sale would not be in material compliance with such laws and regulations.

Section 5.Restriction on Transfer; Non-Transferability of Restricted Stock Units.  The Restricted Stock Units are not assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered, transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered (including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of descent and distribution to the estate of the Director upon the Director’s death.  Any purported transfer in violation of this Section 5 shall be void ab initio.

2

Section 6.Miscellaneous.

(a)Tax Withholding.  Upon the settlement of vested Restricted Stock Units and (if applicable) delivery of cash in respect of any fractional Restricted Stock Units, the Director shall be obligated to satisfy any applicable U.S. federal, state and local and non-U.S. tax withholding or other similar charges or fees that may arise in connection therewith.

(b)Dividend Equivalents.  In the event that the Company pays any ordinary dividend in cash on a share of Common Stock following the Grant Date and prior to an applicable Settlement Date, there shall be credited to the account of the Director in respect of each outstanding Restricted Stock Unit an amount equal to the amount of such dividend.  The amount so credited shall be deferred (without interest, unless the Administrator determines otherwise) until the settlement of such related Restricted Stock Unit and then paid in cash but shall be forfeited upon the forfeiture of such related Restricted Stock Unit.

(c)Authorization to Share Personal Data.  The Director authorizes the Company or any Affiliate of the Company that has or lawfully obtains personal data relating to the Director to divulge or transfer such personal data to the Company or to a third party, in each case in any jurisdiction, if and to the extent reasonably appropriate in connection with this Agreement or the administration of the Plan.

(d)No Rights as Stockholder; No Voting Rights.  The Director shall have no rights as a stockholder of the Company with respect to any shares of Common Stock covered by the Restricted Stock Units prior to the issuance of such shares of Common Stock.

(e)No Right to Continued Service on Board. Nothing in this Agreement shall be deemed to confer on the Director any right to continue in the service of the Company or any Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to terminate such service at any time.

(f)Interpretation.  The Administrator shall have full power and discretion to construe and interpret the Plan (and any rules and regulations issued thereunder) and this Award.  Any determination or interpretation by the Administrator under or pursuant to the Plan or this Award shall be final and binding and conclusive on all persons affected hereby.

(g)Forfeiture of Awards  The Restricted Stock Units granted hereunder (and gains earned or accrued in connection therewith) shall be subject to such generally applicable policies as to forfeiture and recoupment (including, without limitation, upon the occurrence of material financial or accounting errors, financial or other misconduct) as may be adopted by the Administrator or the Board from time to time and communicated to the Director, and is otherwise subject to forfeiture or disgorgement of profits as provided by the Plan.

(h)Consent to Electronic Delivery.  By entering into this Agreement and accepting the Restricted Stock Units evidenced hereby, the Director hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Director pursuant to applicable securities laws) regarding the Company and the Subsidiaries, the Plan, this Agreement and the Restricted Stock Units via Company website or other electronic delivery.

3

(i)Binding Effect; Benefits.  This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors and assigns.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

(j)Amendment.  This Agreement may not be amended, modified or supplemented orally, but only by a written instrument executed by the Director and the Company.

(k)Assignability.  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or the Director without the prior written consent of the other party.

(l)Applicable Law.  This Agreement shall be governed in all respects, including, but not limited to, as to validity, interpretation and effect, by the internal laws of the State of Delaware, without reference to principles of conflict of law that would require application of the law of another jurisdiction.

(m)Waiver of Jury Trial.  Each party hereby waives, to the fullest extent permitted by applicable law, any right they may have to a trial by jury in respect of any suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby.  Each party (i) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (ii) acknowledges that they and the other party hereto have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 6(m).

(n)Limitations of Actions. No lawsuit relating to this Agreement may be filed before a written claim is filed with the Administrator and is denied or deemed denied as provided in the Plan and any lawsuit must be filed within one year of such denial or deemed denial or be forever barred.

(o)Section and Other Headings, etc.  The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

(p)Acceptance of Restricted Stock Units and Agreement.  The Director has indicated his or her consent and acknowledgement of the terms of this Agreement pursuant to the instructions provided to the Director by or on behalf of the Company.  The Director acknowledges receipt of the Plan, represents to the Company that he or she has read and understood this Agreement and the Plan, and, as an express condition to the grant of the Restricted Stock Units under this Agreement, agrees to be bound by the terms of both this Agreement and the Plan.  The Director and the Company each agrees and acknowledges that the use of electronic media (including, without limitation, a clickthrough button or checkbox on a website of the Company or a third-party administrator) to indicate the Director’s confirmation, consent, signature, agreement and delivery of this Agreement and the Restricted Stock Units is legally valid and has the same legal force and effect as if the Director and the Company signed and executed this Agreement in paper form.  The same use of electronic media may be used for any amendment or waiver of this Agreement.

4

Exhibit A to
Director Restricted Stock Unit Agreement
(Annual Grant)

Director:
Grant Date:	, 201
Restricted Stock Units granted hereby:

5

EX-31.1

Exhibit 31.1

CERTIFICATION

I, William A. Sanger, certify that:

1.           I have reviewed this Form 10-Q of Envision Healthcare Holdings, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2014

/s/ WILLIAM A. SANGER

Name: William A. Sanger

Title: Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Randel G. Owen, certify that:

1.           I have reviewed this Form 10-Q of Envision Healthcare Holdings, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2014

/s/ RANDEL G. OWEN

Name: Randel G. Owen

Title: Chief Financial Officer

EX-32.1

Exhibit 32.1

Written Statement of the Chief Executive Officer and Chief Financial Officer

Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

The undersigned, the Chief Executive Officer and the Chief Financial Officer of Envision Healthcare Holdings, Inc., a Delaware corporation (the “Company”), each hereby certifies that, to his knowledge on the date hereof:

(a)     the Form 10-Q of the Company for the quarter ended September 30, 2014, filed on the date hereof with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)     the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ WILLIAM A. SANGER

William A. Sanger

Chief Executive Officer

November 12, 2014

/s/ RANDEL G. OWEN

Randel G. Owen

Chief Financial Officer

November 12, 2014

XML

Summary of Significant Accounting Policies (Details 5) (Senior subordinated unsecured notes purchased by EVHC subsidiary, USD $) In Millions, unless otherwise specified	Sep. 30, 2014
Senior subordinated unsecured notes purchased by EVHC subsidiary
Financial Instruments
Estimated fair value of the senior subordinate notes	$ 738.8
Carrying value of the senior subordinate notes	$ 750.0

XML

Equity Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Omnibus Incentive Plan item	Aug. 19, 2013 Omnibus Incentive Plan	Sep. 30, 2014 Omnibus Incentive Plan Minimum	Sep. 30, 2014 Omnibus Incentive Plan Maximum	Sep. 30, 2014 Omnibus Incentive Plan Performance based awards	Sep. 30, 2014 Omnibus Incentive Plan Performance based awards Minimum	Sep. 30, 2014 Omnibus Incentive Plan Stock options Maximum
Equity based compensation
Shares of Common Stock available for grant					16,539,527	16,708,289
Number of shares granted							2,500,000		0	1,500,000
Number of participants, to whom awards granted in calendar year					0
Fair market value of awards granted								$ 5,000,000
Term of awards											10 years
Compensation charges	$ 1,100,000	$ 1,100,000	$ 3,612,000	$ 3,186,000

XML

Debt and Capital Lease Obligations (Details 2) (USD $)	3 Months Ended	9 Months Ended		0 Months Ended	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Aug. 30, 2013 PIK Notes	Sep. 30, 2013 PIK Notes	Oct. 01, 2012 PIK Notes
Debt
Face amount of debt						$ 450,000,000
Redemption price of debt instrument as a percentage of principal amount				102.75%
Repayments of debt and capital lease obligations				17,200,000
Loss on early debt extinguishment	$ 29,519,000	$ 66,397,000	$ 29,641,000		$ 29,500,000

XML

Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Accrued liabilities
Accrued wages and benefits	$ 186,983	$ 161,398
Accrued paid time-off	30,115	25,713
Current portion of self-insurance reserve	73,719	73,738
Accrued restructuring	6,200	5,682	12,318
Current portion of compliance and legal	3,928	2,000
Accrued billing and collection fees	3,057	2,954
Accrued incentive compensation	33,297	19,570
Accrued income taxes	8,015
Accrued interest	12,812	6,898
Other	55,559	52,983
Total accrued liabilities	$ 413,685	$ 350,936

XML

Consolidating Financial Information (Tables)

9 Months Ended

Sep. 30, 2014

Consolidating Financial Information

Schedule of Consolidating Balance Sheet

Consolidating Balance Sheet

As of September 30, 2014

(in thousands, unaudited)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	5		$	247,165		$	—		$	247,170
Insurance collateral	—			27,899			—			27,899
Trade and other accounts receivable, net	—			913,413			—			913,413
Parts and supplies inventory	—			23,983			—			23,983
Prepaids and other current assets	27,273			54,245			(29,568		)	51,950
Total current assets	27,278			1,266,705			(29,568		)	1,264,415
Property, plant, and equipment, net	—			203,405			—			203,405
Intangible assets, net	—			543,226			—			543,226
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			8,663			—			8,663
Goodwill	—			2,536,156			—			2,536,156
Other long-term assets	—			38,629			—			38,629
Investment in wholly owned subsidiary	1,677,128			—			(1,677,128		)	—
Total assets	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494
Liabilities and Equity
Current liabilities:
Accounts payable	$	1,117		$	50,955		$	—		52,072
Accrued liabilities	—			422,941			(9,256		)	413,685
Current deferred tax liabilities	—			56,695			(20,312		)	36,383
Current portion of long-term debt and capital lease obligations	—			12,235			—			12,235
Total current liabilities	1,117			542,826			(29,568		)	514,375
Long-term debt and capital lease obligations	—			2,029,095			—			2,029,095
Long-term deferred tax liabilities	—			151,353			(128		)	151,225
Insurance reserves	—			167,628			—			167,628
Other long-term liabilities	—			16,707			—			16,707
Total liabilities	1,117			2,907,609			(29,696		)	2,879,030
Equity:
Common stock	1,834			—			—			1,834
Preferred stock	—			—			—			—
Additional paid-in capital	1,609,244			1,516,383			(1,516,383		)	1,609,244
Retained earnings	93,950			162,356			(162,356		)	93,950
Accumulated other comprehensive loss	(1,611		)	(1,611		)	1,611			(1,611		)
Total Envision Healthcare Holdings, Inc. equity	1,703,417			1,677,128			(1,677,128		)	1,703,417
Noncontrolling interest	—			12,047			—			12,047
Total equity	1,703,417			1,689,175			(1,677,128		)	1,715,464
Total liabilities and equity	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494

Consolidating Balance Sheet

As of December 31, 2013

(in thousands)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	81,722		$	122,990		—			$	204,712
Insurance collateral	—			29,619			—			29,619
Trade and other accounts receivable, net	—			801,146			—			801,146
Parts and supplies inventory	—			23,376			—			23,376
Prepaids and other current assets	26,860			23,925			(27,355		)	23,430
Total current assets	108,582			1,001,056			(27,355		)	1,082,283
Property, plant, and equipment, net	—			194,715			—			194,715
Intangible assets, net	—			513,698			—			513,698
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			12,716			—			12,716
Goodwill	—			2,435,670			—			2,435,670
Other long-term assets	—			60,935			—			60,935
Investment in wholly owned subsidiary	1,486,129			—			(1,486,129		)	—
Total assets	$	1,594,839		$	4,218,790		(1,513,612		)	$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable	$	116		$	52,472		—			$	52,588
Accrued liabilities	—			357,979			(7,043		)	350,936
Current deferred tax liabilities	—			55,799			(20,312		)	35,487
Current portion of long-term debt and capital lease obligations	—			12,318			—			12,318
Total current liabilities	116			478,568			(27,355		)	451,329
Long-term debt and capital lease obligations	—			1,895,381			—			1,895,381
Long-term deferred tax liabilities	—			151,258			(128		)	151,130
Insurance reserves	—			175,427			—			175,427
Other long-term liabilities	—			16,997			—			16,997
Total liabilities	116			2,717,631			(27,483		)	2,690,264
Equity:
Common stock	1,804			—			—			1,804
Preferred stock	—			—			—			—
Additional paid-in capital	1,575,417			1,402,861			(1,402,861		)	1,575,417
Retained earnings	18,341			84,107			(84,107		)	18,341
Accumulated other comprehensive loss	(839		)	(839		)	839			(839		)
Total Envision Healthcare Holdings, Inc. equity	1,594,723			1,486,129			(1,486,129		)	1,594,723
Noncontrolling interest	—			15,030			—			15,030
Total equity	1,594,723			1,501,159			(1,486,129		)	1,609,753
Total liabilities and equity	$	1,594,839		$	4,218,790		$	(1,513,612	)	$	4,300,017

Schedule of Consolidating Statements of Operations

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2014
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	1,150,329		$	—		$	1,150,329
Compensation and benefits	—			819,353			—			819,353
Operating expenses	—			129,535			—			129,535
Insurance expense	—			27,527			—			27,527
Selling, general and administrative expenses	—			22,851			—			22,851
Depreciation and amortization expense	—			36,796			—			36,796
Restructuring charges	—			366			—			366
Income (loss) from operations	—			113,901			—			113,901
Interest income from restricted assets	—			175			—			175
Interest expense, net	—			(25,742		)	—			(25,742		)
Realized gains (losses) on investments	—			(466		)	—			(466		)
Other income (expense), net	(1,433		)	773			—			(660		)
Loss on early debt extinguishment	—			—			—			—
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(1,433		)	88,641			—			87,208
Income tax benefit (expense)	697			(35,134		)	—			(34,437		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(736		)	53,507			—			52,771
Equity in net income (loss) of subsidiary	53,512			—			(53,512		)	—
Equity in earnings of unconsolidated subsidiary	—			72			—			72
Net income (loss)	52,776			53,579			(53,512		)	52,843
Less: Net (income) loss attributable to noncontrolling interest	—			(67		)	—			(67		)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776		$	53,512		$	(53,512	)	$	52,776

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2013
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	955,888		$	—		$	955,888
Compensation and benefits	—			677,797			—			677,797
Operating expenses	(17		)	110,404			—			110,387
Insurance expense	—			26,974			—			26,974
Selling, general and administrative expenses	2			40,731			—			40,733
Depreciation and amortization expense	—			35,175			—			35,175
Restructuring charges	—			1,319			—			1,319
Income from operations	15			63,488			—			63,503
Interest income from restricted assets	—			2			—			2
Interest expense, net	(7,641		)	(39,131		)	—			(46,772		)
Realized gains (losses) on investments	—			158			—			158
Other income (expense), net	—			(52		)	—			(52		)
Loss on early debt extinguishment	(29,519		)	—			—			(29,519		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(37,145		)	24,465			—			(12,680		)
Income tax benefit (expense)	14,765			(9,816		)	—			4,949
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(22,380		)	14,649			—			(7,731		)
Equity in net income (loss) of subsidiary	14,717			—			(14,717		)	—
Equity in earnings of unconsolidated subsidiary	—			68			—			68
Net income (loss)	(7,663		)	14,717			(14,717		)	(7,663		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(7,663	)	$	14,717		$	(14,717	)	$	(7,663	)

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	3,239,867		$	—		$	3,239,867
Compensation and benefits	—			2,330,021			—			2,330,021
Operating expenses	—			364,885			—			364,885
Insurance expense	—			90,091			—			90,091
Selling, general and administrative expenses	—			65,820			—			65,820
Depreciation and amortization expense	—			108,786			—			108,786
Restructuring charges	—			4,906			—			4,906
Income from operations	—			275,358			—			275,358
Interest income from restricted assets	—			507			—			507
Interest expense, net	—			(84,793		)	—			(84,793		)
Realized gains (losses) on investments	—			648			—			648
Other income (expense), net	(4,232		)	800			—			(3,432		)
Loss on early debt extinguishment	—			(66,397		)	—			(66,397		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(4,232		)	126,123			—			121,891
Income tax benefit (expense)	1,592			(51,292		)	—			(49,700		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(2,640		)	74,831			—			72,191
Equity in net income (loss) of subsidiary	78,249			—			(78,249		)	—
Equity in earnings of unconsolidated subsidiary	—			185			—			185
Net income (loss)	75,609			75,016			(78,249		)	72,376
Less: Net (income) loss attributable to noncontrolling interest	—			3,233			—			3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	75,609		$	78,249		$	(78,249	)	$	75,609

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	2,743,467		$	—		$	2,743,467
Compensation and benefits	—			1,963,546			—			1,963,546
Operating expenses	70			313,075			—			313,145
Insurance expense	—			78,647			—			78,647
Selling, general and administrative expenses	3			86,518			—			86,521
Depreciation and amortization expense	—			104,552			—			104,552
Restructuring charges	—			4,988			—			4,988
Income from operations	(73		)	192,141			—			192,068
Interest income from restricted assets	—			634			—			634
Interest expense, net	(30,567		)	(117,959		)	—			(148,526		)
Realized gains (losses) on investments	—			276			—			276
Other income (expense), net	—			(13,022		)	—			(13,022		)
Loss on early debt extinguishment	(29,519		)	(122		)	—			(29,641		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(60,159		)	61,948			—			1,789
Income tax benefit (expense)	23,850			(27,782		)	—			(3,932		)
Income before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(36,309		)	34,166			—			(2,143		)
Equity in net income (loss) of subsidiary	34,396			—			(34,396		)	—
Equity in earnings of unconsolidated subsidiary	—			230			—			230
Net income (loss)	(1,913		)	34,396			(34,396		)	(1,913		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(1,913	)	$	34,396		$	(34,396	)	$	(1,913	)

Schedule of Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(859	)	$	194,863		$	194,004
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(52,654		)	(52,654		)
Sales and maturities of available-for-sale securities	—			40,425			40,425
Purchase of property, plant and equipment	—			(55,659		)	(55,659		)
Proceeds from sale of property, plant and equipment	—			2,299			2,299
Acquisition of businesses, net of cash received	—			(199,261		)	(199,261		)
Net change in insurance collateral	—			2,021			2,021
Other investing activities	—			(1,774		)	(1,774		)
Net cash provided by (used in) investing activities	—			(264,603		)	(264,603		)
Cash Flows from Financing Activities
Borrowings under the ABL Facility	—			50,000			50,000
Proceeds from issuance of senior notes	—			740,625			740,625
Repayments of the Term Loan	—			(6,686		)	(6,686		)
Repayments of the ABL Facility	—			(50,000		)	(50,000		)
Repayments of PIK Notes and senior notes	—			(607,750		)	(607,750		)
Payment for debt extinguishment premiums	—			(37,630		)	(37,630		)
Debt issuance costs	—			(2,221		)	(2,221		)
Proceeds from stock options exercised	—			7,405			7,405
Excess tax benefits from equity-based compensation	—			38,520			38,520
Shares repurchased for tax withholdings	—			(14,430		)	(14,430		)
Proceeds from noncontrolling interest	—			250			250
Other financing activities	859			(5,885		)	(5,026		)
Net intercompany borrowings (payments)	(81,717		)	81,717			—
Net cash provided by (used in) financing activities	(80,858		)	193,915			113,057
Change in cash and cash equivalents	(81,717		)	124,175			42,458
Cash and cash equivalents, beginning of period	81,722			122,990			204,712
Cash and cash equivalents, end of period	$	5		$	247,165		$	247,170

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(38,375	)	$	64,000		$	25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(2,615		)	(2,615		)
Sales and maturities of available-for-sale securities	—			7,616			7,616
Purchase of property, plant and equipment	—			(45,493		)	(45,493		)
Proceeds from sale of property, plant and equipment	—			396			396
Acquisition of businesses, net of cash received	—			(27,358		)	(27,358		)
Net change in insurance collateral	—			(2,121		)	(2,121		)
Other investing activities	—			(456		)	(456		)
Net cash provided by (used in) investing activities	—			(70,031		)	(70,031		)
Cash Flows from Financing Activities
Issuance of common stock	1,110,900			1,117			1,112,017
Borrowings under the Term Loan	—			150,000			150,000
Borrowings under the ABL Facility	—			345,440			345,440
Repayments of the Term Loan	—			(10,028		)	(10,028		)
Repayments of the ABL Facility	—			(470,440		)	(470,440		)
Repayments of PIK Notes and senior notes	(450,000		)	—			(450,000		)
Payment for debt extinguishment premiums	(12,386		)	—			(12,386		)
Dividend paid	20,813			(20,813		)	—
Debt issuance costs	(4		)	(5,007		)	(5,011		)
Equity issuance costs	(63,420		)	—			(63,420		)
Excess tax benefits from equity-based compensation	—			3,168			3,168
Payment of dissenting shareholder settlement	—			(38,336		)	(38,336		)
Net change in bank overdrafts	—			1,686			1,686
Other financing activities	—			(355		)	(355		)
Net intercompany borrowings (payments)	(86,087		)	86,087			—
Net cash provided by (used in) financing activities	519,816			42,519			562,335
Change in cash and cash equivalents	481,441			36,488			517,929
Cash and cash equivalents, beginning of period	281			57,551			57,832
Cash and cash equivalents, end of period	$	481,722		$	94,039		$	575,761

XML

Variable Interest Entities (Details) (USD $) In Thousands, unless otherwise specified				9 Months Ended			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 UHS-EmCare JV	Sep. 30, 2014 UHS-EmCare JV EmCare	Sep. 30, 2014 HCA-EmCare JV	Dec. 31, 2013 HCA-EmCare JV	Sep. 30, 2014 HCA-EmCare JV EmCare
Variable Interest Entities
Voting control (as a percent)				50.00%			50.00%
Summary of the assets and liabilities which are included in the Company's consolidated financial statements
Current assets	$ 1,264,415	$ 1,082,283	$ 18,021		$ 137,992	$ 88,479
Current liabilities	$ 514,375	$ 451,329	$ 8,773		$ 31,294	$ 22,005

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2014

Acquisitions

Schedule of allocation of the purchase price, which is subject to adjustment based upon the completion of purchase price allocations

The allocation of the purchase price is in the table below, which is subject to adjustment based upon the completion of purchase price allocations (in thousands):

Cash	$	7,052
Accounts receivable	16,748
Prepaid and other current assets	17,268
Property, plant, and equipment	92
Acquired intangible assets	56,000
Goodwill	98,402
Accounts payable	(1,073		)
Accrued liabilities	(11,039		)
Insurance reserves	(14,000		)
Total purchase price	$	169,450

Schedule of unaudited pro forma operating results

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
	(in thousands)
Net revenue	$	34,076	$	28,647	$	98,346	$	84,576
Net income	1,833		733		3,943		1,714

XML

Derivative Instruments and Hedging Activities (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014 gal	Sep. 30, 2013	Sep. 30, 2014 agreement gal	Sep. 30, 2013	Dec. 31, 2013
Fuel hedge
Derivative Instruments and Hedging Activities
Number of master agreements			1
Total gallons of diesel fuel	600,000		600,000
Gallons of diesel fuel as a percentage of total estimated annual usage	25.20%		25.20%
Fair value of derivative asset	$ 0.7		$ 0.7		$ 0.7
Period over which deferred gain (loss) is expected to be reclassified from accumulated comprehensive income			12 months
Net receipts from the counterparty	0.1	0.1	0.4	0.4
Fuel hedge | Minimum
Derivative Instruments and Hedging Activities
Diesel fuel price (in dollars per gallon)			3.63
Fuel hedge | Maximum
Derivative Instruments and Hedging Activities
Diesel fuel price (in dollars per gallon)			3.76
Fair value of derivative liability	0.1		0.1		0.1
Amount of deferred gain (loss) expected to be reclassified from accumulated comprehensive income			(0.1)
Interest rate swap agreements
Derivative Instruments and Hedging Activities
Notional amount of debt obligations	400		400
Effective rate of interest of debt (as a percent)	4.49%		4.49%
Minimum variable interest rate of debt (as a percent)	1.00%		1.00%
Fair value of derivative liability	2.0		2.0		3.1
Period over which deferred gain (loss) is expected to be reclassified from accumulated comprehensive income			12 months
Amount of deferred gain (loss) expected to be reclassified from accumulated comprehensive income			(2.0)
Net payments to the counterparty	$ 0.5	$ 0.5	$ 1.5	$ 1.5

XML

Basic and Diluted Net Income (Loss) Per Share (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Basic and diluted net income (loss) per share
Net income (loss)	$ 52,776	$ (7,663)	$ 75,609	$ (1,913)
Weighted-average common shares outstanding - common stock:
Basic (in shares)	182,564,837	157,282,885	181,502,232	139,969,940
Dilutive impact of stock awards outstanding (in shares)	7,619,486		8,205,377
Diluted (in shares)	190,184,323	157,282,885	189,707,609	139,969,940
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic (in dollars per share)	$ 0.29	$ (0.05)	$ 0.42	$ (0.01)
Diluted (in dollars per share)	$ 0.28	$ (0.05)	$ 0.40	$ (0.01)
Stock awards of common stock outstanding excluded from the computations of diluted loss per share and weighted-average common shares outstanding		6,088,252	0	8,663,107	0

XML

Summary of Significant Accounting Policies (Details 3) (USD $)	0 Months Ended				9 Months Ended				0 Months Ended
	Sep. 23, 2014	Jul. 10, 2014	Feb. 05, 2014	Aug. 19, 2013	Sep. 30, 2013	Sep. 30, 2014 Senior PIK Toggle Notes due 2017	Sep. 30, 2014 Revolving credit facility	Sep. 30, 2014 Senior subordinated unsecured notes due 2019	Aug. 19, 2013 CD&R	Aug. 19, 2013 Initial public offering	Aug. 13, 2013 Initial public offering	Jul. 10, 2014 Underwriters overallotment option	Feb. 05, 2014 Underwriters overallotment option	Aug. 19, 2013 Underwriters overallotment option	Aug. 13, 2013 Underwriters overallotment option
Equity Structure and Public Offerings
Shares of common stock issued	17,500,000	31,625,000	31,625,000							48,300,000	42,000,000	4,125,000	4,125,000		6,300,000
Issue price (in dollars per share)	$ 34.97	$ 34.00	$ 30.50							$ 23.00					$ 23.00
Aggregate offering price					$ 1,112,017,000									$ 1,110,900,000
Net proceeds, initial public offering				1,025,900,000
Underwriters' discounts and commissions and offering expenses														85,000,000
Payment made in connection with the termination of a corporation consulting agreement									20,000,000
Amount used to redeem or repay the debt outstanding						$ 479,600,000	$ 16,500,000	$ 332,500,000

XML

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amounts Reclassified from Accumulated Other Comprehensive Income
Operating expenses	$ 129,535	$ 110,387	$ 364,885	$ 313,145
Interest expense, net	25,742	46,772	84,793	148,526
Realized gains (losses) on investments	(466)	158	648	276
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	(12,680)	121,891	1,789
Tax benefit (expense)	(34,437)	4,949	(49,700)	(3,932)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	(7,663)	75,609	(1,913)
Gains and losses on cash flow hedges | Amounts Reclassified from Accumulated Other Comprehensive Income
Amounts Reclassified from Accumulated Other Comprehensive Income
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	(410)	(396)	(1,127)	(1,163)
Tax benefit (expense)	153	149	424	437
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	(257)	(247)	(703)	(726)
Gains and losses on cash flow hedges | Fuel hedge | Amounts Reclassified from Accumulated Other Comprehensive Income
Amounts Reclassified from Accumulated Other Comprehensive Income
Operating expenses	86	106	362	326
Gains and losses on cash flow hedges | Interest rate swap | Amounts Reclassified from Accumulated Other Comprehensive Income
Amounts Reclassified from Accumulated Other Comprehensive Income
Interest expense, net	(496)	(502)	(1,489)	(1,489)
Unrealized holding gains on available-for-sale securities | Amounts Reclassified from Accumulated Other Comprehensive Income
Amounts Reclassified from Accumulated Other Comprehensive Income
Realized gains (losses) on investments	(466)	158	648	276
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	(466)	158	648	276
Tax benefit (expense)	176	(59)	(244)	(104)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$ (290)	$ 99	$ 404	$ 172

XML

Consolidating Financial Information (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Condensed Consolidating Statements of Operations
Net revenue	$ 1,150,329	$ 955,888	$ 3,239,867	$ 2,743,467
Compensation and benefits	819,353	677,797	2,330,021	1,963,546
Operating expenses	129,535	110,387	364,885	313,145
Insurance expense	27,527	26,974	90,091	78,647
Selling, general and administrative expenses	22,851	40,733	65,820	86,521
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988	5,699
Income from operations	113,901	63,503	275,358	192,068
Interest income from restricted assets	175	2	507	634
Interest expense, net	(25,742)	(46,772)	(84,793)	(148,526)
Realized gains (losses) on investments	(466)	158	648	276
Other income (expense), net	(660)	(52)	(3,432)	(13,022)
Loss on early debt extinguishment		(29,519)	(66,397)	(29,641)
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	(12,680)	121,891	1,789
Income tax benefit (expense)	(34,437)	4,949	(49,700)	(3,932)
Income (loss) before equity in earnings of unconsolidated subsidiary	52,771	(7,731)	72,191	(2,143)
Equity in earnings of unconsolidated subsidiary	72	68	185	230
Net income (loss)	52,843	(7,663)	72,376	(1,913)
Less: Net (income) loss attributable to noncontrolling interest	(67)		3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	(7,663)	75,609	(1,913)
Consolidating Adjustments
Condensed Consolidating Statements of Operations
Equity in earnings of unconsolidated subsidiary	(53,512)	(14,717)	(78,249)	(34,396)
Net income (loss)	(53,512)	(14,717)	(78,249)	(34,396)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	(53,512)	(14,717)	(78,249)	(34,396)
EVHC (excluding Corporation) | Reportable legal entity
Condensed Consolidating Statements of Operations
Operating expenses		(17)		70
Selling, general and administrative expenses		2		3
Income from operations		15		(73)
Interest expense, net		(7,641)		(30,567)
Other income (expense), net	(1,433)		(4,232)
Loss on early debt extinguishment		(29,519)		(29,519)
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	(1,433)	(37,145)	(4,232)	(60,159)
Income tax benefit (expense)	697	14,765	1,592	23,850
Income (loss) before equity in earnings of unconsolidated subsidiary	(736)	(22,380)	(2,640)	(36,309)
Equity in earnings of unconsolidated subsidiary	53,512	14,717	78,249	34,396
Net income (loss)	52,776	(7,663)	75,609	(1,913)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	(7,663)	75,609	(1,913)
Corporation and Subsidiaries | Reportable legal entity
Condensed Consolidating Statements of Operations
Net revenue	1,150,329	955,888	3,239,867	2,743,467
Compensation and benefits	819,353	677,797	2,330,021	1,963,546
Operating expenses	129,535	110,404	364,885	313,075
Insurance expense	27,527	26,974	90,091	78,647
Selling, general and administrative expenses	22,851	40,731	65,820	86,518
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988
Income from operations	113,901	63,488	275,358	192,141
Interest income from restricted assets	175	2	507	634
Interest expense, net	(25,742)	(39,131)	(84,793)	(117,959)
Realized gains (losses) on investments	(466)	158	648	276
Other income (expense), net	773	(52)	800	(13,022)
Loss on early debt extinguishment			(66,397)	(122)
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	88,641	24,465	126,123	61,948
Income tax benefit (expense)	(35,134)	(9,816)	(51,292)	(27,782)
Income (loss) before equity in earnings of unconsolidated subsidiary	53,507	14,649	74,831	34,166
Equity in earnings of unconsolidated subsidiary	72	68	185	230
Net income (loss)	53,579	14,717	75,016	34,396
Less: Net (income) loss attributable to noncontrolling interest	(67)		3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$ 53,512	$ 14,717	$ 78,249	$ 34,396

XML

Debt and Capital Lease Obligations (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended		3 Months Ended		0 Months Ended							0 Months Ended				1 Months Ended	0 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended	9 Months Ended		9 Months Ended			2 Months Ended		0 Months Ended								2 Months Ended			0 Months Ended									2 Months Ended	3 Months Ended	9 Months Ended						0 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jun. 18, 2014 Senior unsecured notes due 2019	Dec. 30, 2013 Senior unsecured notes due 2019	Jun. 30, 2014 Senior unsecured notes due 2019	Dec. 31, 2013 Senior unsecured notes due 2019	May 25, 2011 Senior unsecured notes due 2019 Corporation	Jun. 18, 2014 Senior unsecured notes due 2019 Captive insurance subsidiary	Dec. 30, 2013 Senior unsecured notes due 2019 Captive insurance subsidiary	Jun. 18, 2014 Senior unsecured notes purchased by captive insurance subsidiary	Dec. 30, 2013 Senior unsecured notes purchased by captive insurance subsidiary	Jun. 30, 2012 Senior unsecured notes purchased by captive insurance subsidiary	May 25, 2011 Credit Facilities Corporation	Feb. 07, 2013 Term Loan Facility	Sep. 30, 2014 Term Loan Facility	Dec. 31, 2013 Term Loan Facility	May 25, 2011 Term Loan Facility Corporation	Feb. 06, 2013 Term Loan Facility Option one	Feb. 07, 2013 Term Loan Facility Option one Corporation	Feb. 07, 2013 Term Loan Facility Option one Adjusted LIBOR rate Corporation	Feb. 06, 2013 Term Loan Facility Option two	Feb. 07, 2013 Term Loan Facility Option two Corporation	Feb. 06, 2013 Term Loan Facility Option two Overnight federal funds rate	Feb. 07, 2013 Term Loan Facility Option two Overnight federal funds rate Corporation	Feb. 07, 2013 Term Loan Facility Option two Adjusted LIBOR rate Corporation	Feb. 06, 2013 Term Loan Facility Option two LIBOR rate	Sep. 30, 2014 ABL Facility	Feb. 27, 2013 ABL Facility	Sep. 30, 2014 ABL Facility Minimum	Sep. 30, 2014 ABL Facility Maximum	May 25, 2011 ABL Facility Corporation	Feb. 26, 2013 ABL Facility Option one Adjusted LIBOR rate Minimum	Feb. 26, 2013 ABL Facility Option one Adjusted LIBOR rate Maximum	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Average daily excess availability less than or equal to 33% of availability Maximum	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Average daily excess availability greater than 33% but less than or equal to 66% of availability Minimum	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Average daily excess availability greater than 33% but less than or equal to 66% of availability Maximum	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Average daily excess availability greater than 66% of availability Minimum	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Corporation	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Corporation Average daily excess availability less than or equal to 33% of availability	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Corporation Average daily excess availability greater than 33% but less than or equal to 66% of availability	Feb. 27, 2013 ABL Facility Option one Adjusted LIBOR rate Corporation Average daily excess availability greater than 66% of availability	Feb. 26, 2013 ABL Facility Option two Minimum	Feb. 26, 2013 ABL Facility Option two Maximum	Feb. 26, 2013 ABL Facility Option two Overnight federal funds rate	Feb. 27, 2013 ABL Facility Option two Overnight federal funds rate Corporation	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Average daily excess availability less than or equal to 33% of availability Maximum	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Average daily excess availability greater than 33% but less than or equal to 66% of availability Minimum	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Average daily excess availability greater than 33% but less than or equal to 66% of availability Maximum	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Average daily excess availability greater than 66% of availability Minimum	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Corporation	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Corporation Average daily excess availability less than or equal to 33% of availability	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Corporation Average daily excess availability greater than 33% but less than or equal to 66% of availability	Feb. 27, 2013 ABL Facility Option two Adjusted LIBOR rate Corporation Average daily excess availability greater than 66% of availability	Feb. 26, 2013 ABL Facility Option two LIBOR rate	Jun. 30, 2014 Senior Unsecured Notes due 2022	Sep. 30, 2014 Senior Unsecured Notes due 2022	Sep. 30, 2014 Senior Unsecured Notes due 2022 Period prior to July 1, 2017	Sep. 30, 2014 Senior Unsecured Notes due 2022 Period on and after July 1, 2017 and prior to July 1, 2018	Sep. 30, 2014 Senior Unsecured Notes due 2022 Period on or after July 1, 2018 and prior to July 1, 2019	Sep. 30, 2014 Senior Unsecured Notes due 2022 Period on or after July 1, 2019 and prior to July 1, 2020	Sep. 30, 2014 Senior Unsecured Notes due 2022 Period on or after July 1, 2020	Jun. 18, 2014 Senior Unsecured Notes due 2022 Corporation	Sep. 30, 2014 Senior Unsecured Notes due 2022 Corporation
Long-Term Debt
Debt issued										$ 950,000,000							$ 150,000,000																																																$ 750,000,000
Amount of debt held			2,041,330,000		1,907,699,000						9,800,000	5,200,000	0	0	15,000,000			1,292,917,000	1,302,945,000																																								750,000,000
Principal amount of debt redeemed						617,500,000	332,500,000
Redemption price (as a percent)						106.094%	108.125%																																																					100.00%	103.844%	102.563%	101.281%	100.00%
Repayments of debt and capital lease obligations						2,400,000	2,200,000
Maximum borrowing capacity																1,800,000,000				1,440,000,000											450,000,000			350,000,000
Reference rate (as a percent)																					1.50%	1.00%		2.50%	2.00%
Variable interest rate basis																							LIBOR					one-month LIBOR rate	one-month Term Loan LIBOR rate												LIBOR												one-month LIBOR rate				one-month ABL LIBOR
Interest rate margin (as a percent)																					3.75%	3.00%		2.75%	2.00%	0.50%	0.50%	1.00%	1.00%						2.25%	2.75%						2.00%	1.75%	1.50%	1.25%	1.75%	0.50%	0.50%					1.00%	1.00%	0.75%	0.50%	1.00%
Interest rate in the event of meeting specified consolidated first lien net leverage ratio (as a percent)																						2.75%			1.75%
Consolidated first lien net leverage ratio																						2.50			2.50
Loss on early debt extinguishment	29,519,000		66,397,000	29,641,000				66,400,000	38,700,000								100,000																																									9,400,000
Average daily excess availability as a percentage of availability																																					33.00%	33.00%	66.00%	66.00%									33.00%	33.00%	66.00%	66.00%
Commitment fee (as a percent)																																0.375%	0.50%
Outstanding debt			130,200,000		129,900,000																									130,200,000
Available borrowing capacity																														319,800,000
Period of average excess availability exceeding agreed upon thresholds																														30 days
Fixed charge coverage ratio																														1.0
Debt issuance expense related to amendments		$ 5,000,000	$ 2,221,000	$ 5,011,000
Interest rate (as a percent)																		4.00%	4.00%																																															5.125%
Percentage of aggregate principal amount of debt instrument that may be redeemed																																																												40.00%
Redemption price of debt instrument as a percentage of principal amount with proceeds of certain equity offerings																																																												105.125%
Repurchase price of debt instrument as a percentage of principal amount in the event of a change of control																																																											101.00%
Repurchase price of debt instrument as a percentage of principal amount in the event of sale of assets																																																											100.00%

XML

Acquisitions

9 Months Ended

Sep. 30, 2014

Acquisitions

Acquisitions

4. Acquisitions

2014 Acquisitions

Phoenix Physicians, LLC (“Phoenix Physicians”). On June 17, 2014, the Company acquired the stock of Phoenix Physicians for a total purchase price of $169.5 million paid in cash (the “Phoenix Physicians Acquisition”).  Phoenix Physicians, in part through management services agreements with professional entities, is engaged in providing medical practices support and emergency department management and staffing services to hospitals, physicians and healthcare facilities in Florida. The Company has accounted for the acquisition of Phoenix Physicians using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. All of the goodwill is tax deductible and assigned to the EmCare segment.

The allocation of the purchase price is in the table below, which is subject to adjustment based upon the completion of purchase price allocations (in thousands):

Cash	$	7,052
Accounts receivable	16,748
Prepaid and other current assets	17,268
Property, plant, and equipment	92
Acquired intangible assets	56,000
Goodwill	98,402
Accounts payable	(1,073		)
Accrued liabilities	(11,039		)
Insurance reserves	(14,000		)
Total purchase price	$	169,450

During the three months ended September 30, 2014, the Company made a purchase price allocation adjustment that increased goodwill and other current assets by $1.6 million and $16.9 million, respectively, with a corresponding increase to accrued liabilities and insurance reserves of $4.5 million and $14.0 million, respectively, to record the transfer of risk of the malpractice claims liability.

The following unaudited pro forma operating results give effect to the Phoenix Physicians Acquisition, as if it had been completed as of January 1, 2013. These pro forma amounts are not necessarily indicative of the operating results that would have occurred if these transactions had occurred on such date. The pro forma adjustments are based on certain assumptions that the Company believes are reasonable.

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
	(in thousands)
Net revenue	$	34,076	$	28,647	$	98,346	$	84,576
Net income	1,833		733		3,943		1,714

The Company’s statements of operations for the three months and nine months ended September 30, 2014 include net revenue of $34.1 million and $37.6 million, respectively, and net income of $1.8 million and $2.1 million, respectively, attributable to Phoenix Physicians.

Other 2014 Acquisitions. The Company completed the acquisitions of Life Line Ambulance Service, Inc., an emergency medical transportation service provider with operations in Arizona, on February 6, 2014, MedStat EMS, Inc., an emergency and non-emergency medical ground transportation service provider with operations in Mississippi, on March 7, 2014, and Streamlined Medical Solutions, LLC, a healthcare technology company which has developed proprietary software to enhance patient direct admission and referral management processes, on May 21, 2014 for total aggregate purchase consideration of approximately $38.0 million paid in cash.

The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $12.1 million. The total purchase price for these acquisitions was allocated to goodwill of $7.1 million, $6.9 million of which is tax deductible goodwill, other acquired intangible assets of $27.1 million, and net current assets of $3.8 million, which are subject to adjustment based upon the completion of purchase price allocations.

2013 Acquisitions

During the year ended December 31, 2013, indirect, wholly-owned subsidiaries of the Company completed the acquisitions of CMORx, LLC and Loya Medical Services, PLLC, which provide clinical management software, each of T.M.S. Management Group, Inc. and Transportation Management Services of Brevard, Inc. (collectively, “TMS”), two related corporations that leverage the provision of non-emergency medical transportation services by third-party transportation service providers, Jackson Emergency Consultants, which provides facility based physician staffing in northern Florida, and other smaller acquisitions for a combined purchase price of $34.2 million paid in cash.

The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $5.4 million. The total purchase price for these acquisitions was allocated to goodwill of $20.8 million, all of which is tax deductible goodwill, other acquired intangible assets of $14.9 million, and net current liabilities of $1.5 million. The allocation of purchase price for the 2013 acquisitions is subject to adjustment based upon the completion of purchase price allocations, except for the allocation of the TMS purchase price which is complete as of September 30, 2014.

XML

Consolidating Financial Information (Details 3) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		$ 194,004	$ 25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities		(52,654)	(2,615)
Sales and maturities of available-for-sale securities		40,425	7,616
Purchase of property, plant and equipment		(55,659)	(45,493)
Proceeds from sale of property, plant and equipment		2,299	396
Acquisition of businesses, net of cash received		(199,261)	(27,358)
Net change in insurance collateral		2,021	(2,121)
Other investing activities		(1,774)	(456)
Net cash provided by (used in) investing activities		(264,603)	(70,031)
Cash Flows from Financing Activities
Issuance of common stock			1,112,017
Borrowings under the Term Loan			150,000
Borrowings under the ABL Facility		50,000	345,440
Proceeds from issuance of senior notes		740,625
Repayments of the Term Loan		(6,686)	(10,028)
Repayments of the ABL Facility		(50,000)	(470,440)
Repayments of PIK Notes and senior notes		(607,750)	(450,000)
Payment for debt extinguishment premiums		(37,630)	(12,386)
Debt issuance costs	(5,000)	(2,221)	(5,011)
Proceeds from stock options exercised		7,405
Equity issuance costs			(63,420)
Excess tax benefits from equity-based compensation		38,520	3,168
Shares repurchased for tax withholdings		(14,430)
Proceeds from noncontrolling interest		250
Payment of dissenting shareholder settlement			(38,336)
Net change in bank overdrafts			1,686
Other financing activities		(5,026)	(355)
Net cash provided by (used in) financing activities		113,057	562,335
Change in cash and cash equivalents		42,458	517,929
Cash and cash equivalents, beginning of period		204,712	57,832
Cash and cash equivalents, end of period		247,170	575,761
EVHC (excluding Corporation)
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		(859)	(38,375)
Cash Flows from Financing Activities
Issuance of common stock			1,110,900
Repayments of PIK Notes and senior notes			(450,000)
Payment for debt extinguishment premiums			(12,386)
Dividend paid			20,813
Debt issuance costs			(4)
Equity issuance costs			(63,420)
Other financing activities		859
Net intercompany borrowings (payments)		(81,717)	(86,087)
Net cash provided by (used in) financing activities		(80,858)	519,816
Change in cash and cash equivalents		(81,717)	481,441
Cash and cash equivalents, beginning of period		81,722	281
Cash and cash equivalents, end of period		5	481,722
Corporation and Subsidiaries
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		194,863	64,000
Cash Flows from Investing Activities
Purchases of available-for-sale securities		(52,654)	(2,615)
Sales and maturities of available-for-sale securities		40,425	7,616
Purchase of property, plant and equipment		(55,659)	(45,493)
Proceeds from sale of property, plant and equipment		2,299	396
Acquisition of businesses, net of cash received		(199,261)	(27,358)
Net change in insurance collateral		2,021	(2,121)
Other investing activities		(1,774)	(456)
Net cash provided by (used in) investing activities		(264,603)	(70,031)
Cash Flows from Financing Activities
Issuance of common stock			1,117
Borrowings under the Term Loan			150,000
Borrowings under the ABL Facility		50,000	345,440
Proceeds from issuance of senior notes		740,625
Repayments of the Term Loan		(6,686)	(10,028)
Repayments of the ABL Facility		(50,000)	(470,440)
Repayments of PIK Notes and senior notes		(607,750)
Payment for debt extinguishment premiums		(37,630)
Dividend paid			(20,813)
Debt issuance costs		(2,221)	(5,007)
Proceeds from stock options exercised		7,405
Excess tax benefits from equity-based compensation		38,520	3,168
Shares repurchased for tax withholdings		(14,430)
Proceeds from noncontrolling interest		250
Payment of dissenting shareholder settlement			(38,336)
Net change in bank overdrafts			1,686
Other financing activities		(5,885)	(355)
Net intercompany borrowings (payments)		81,717	86,087
Net cash provided by (used in) financing activities		193,915	42,519
Change in cash and cash equivalents		124,175	36,488
Cash and cash equivalents, beginning of period		122,990	57,551
Cash and cash equivalents, end of period		$ 247,165	$ 94,039

XML

Acquisitions (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	9 Months Ended		12 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jun. 17, 2014 Phoenix Physicians	Sep. 30, 2014 Phoenix Physicians	Mar. 07, 2014 Life Line Ambulance Service, Inc. and MedStat EMS, Inc.	Dec. 31, 2013 CMORx, LLC and Loya Medical Services, PLLC item	Sep. 30, 2014 CMORx, LLC and Loya Medical Services, PLLC	May 21, 2014 Other 2014 Acquisition	Sep. 30, 2014 Other 2014 Acquisition
Acquisitions
Number of related corporations which leverage the provision of non-emergency medical transportation services									2
Total consideration of acquisitions paid in cash						$ 169,500,000			$ 34,200,000		$ 38,000,000
Allocation of the purchase price, which is subject to adjustment based upon the completion of purchase price allocations
Cash						7,052,000
Accounts receivable						16,748,000
Prepaid and other current assets						17,268,000
Property, plant and equipment						92,000
Acquired intangible assets						56,000,000		27,100,000	14,900,000	5,400,000		12,100,000
Goodwill	2,536,156,000		2,536,156,000		2,435,670,000	98,402,000		7,100,000	20,800,000
Accounts payable						(1,073,000)
Accrued liabilities						(11,039,000)
Insurance reserves						(14,000,000)
Total purchase price						169,450,000
Increase in goodwill							1,600,000
Increase in other current assets							16,900,000
Increase in accrued liabilities							4,500,000
Increase in insurance reserves							14,000,000
Unaudited pro forma operating results
Net revenue	34,076,000	28,647,000	98,346,000	84,576,000
Net income	1,833,000	733,000	3,943,000	1,714,000
Net revenue	34,100,000		37,600,000
Net income	1,800,000		2,100,000
Tax deductible goodwill								6,900,000
Net current assets								3,800,000
Net current liabilities									$ 1,500,000

XML

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Tables)

9 Months Ended

Sep. 30, 2014

Changes in Accumulated Other Comprehensive Income (Loss) by Component

Summary of changes in the Company's accumulated other comprehensive income ("AOCI") by component, after tax

The following table summarizes the changes in the Company’s accumulated other comprehensive income (loss) (“AOCI”) by component as of September 30, 2014 and December 31, 2013 (in thousands). 

	Fuel hedge			Interest rate swap			Unrealized holding gains on available-for-sale securities			Total
Balance as of January 1, 2013	$	1,057		$	(2,861	)	$	1,591		(213		)
Other comprehensive income (loss) before reclassifications	(396		)	(336		)	(598		)	(1,330		)
Amounts reclassified from accumulated other comprehensive income (loss)	(241		)	1,239			(294		)	704
Net current-period other comprehensive income (loss)	(637		)	903			(892		)	(626		)
Balance as of December 31, 2013	$	420		$	(1,958	)	$	699		$	(839	)
Other comprehensive income (loss) before reclassifications	(501		)	38			(608		)	(1,071		)
Amounts reclassified from accumulated other comprehensive income (loss)	(226		)	929			(404		)	299
Net current-period other comprehensive income (loss)	(727		)	967			(1,012		)	(772		)
Balance as of September 30, 2014	$	(307	)	$	(991	)	$	(313	)	$	(1,611	)

Schedule of statements of operations affected by reclassifications out of AOCI

The following table shows the line item on the statements of operations affected by reclassifications out of AOCI (in thousands):

	Amount reclassified from AOCI
	Three months endedSeptember 30,						Nine months endedSeptember 30,
Details about AOCI components	2014			2013			2014			2013			Statements of Operations
Gains and losses on cash flow hedges:
Fuel Hedge	$	86		$	106		$	362		$	326		Operating expenses
Interest rate swap	(496		)	(502		)	(1,489		)	(1,489		)	Interest expense, net
	(410		)	(396		)	(1,127		)	(1,163		)	Total before tax
	153			149			424			437			Tax benefit (expense)
	$	(257	)	$	(247	)	$	(703	)	$	(726	)	Net of tax
Unrealized holding gains on available-for-sale securities	$	(466	)	$	158		$	648		$	276		Realized gains (losses) on investments
	(466		)	158			648			276			Total before tax
	176			(59		)	(244		)	(104		)	Tax benefit (expense)
	$	(290	)	$	99		$	404		$	172		Net of tax

XML

Debt and Capital Lease Obligations (Tables)

9 Months Ended

Sep. 30, 2014

Debt and Capital Lease Obligations

Schedule of long-term debt and capital lease obligations

Debt and capital lease obligations consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,2014			December 31,2013
Senior unsecured notes due 2019	$	—		$	607,750
Senior unsecured notes due 2022	750,000			—
Senior secured term loan due 2018 (4.00% at September 30, 2014 and December 31, 2013)	1,292,917			1,302,945
Discount on senior secured term loan	(3,567		)	(4,217		)
ABL Facility	—			—
Notes due at various dates from 2014 to 2022 with interest rates from 6% to 10%	731			852
Capital lease obligations due at various dates from 2014 to 2018	1,249			369
Total	2,041,330			1,907,699
Less current portion	(12,235		)	(12,318		)
Total long-term debt and capital lease obligations	$	2,029,095		$	1,895,381

XML

Related Party Transactions (Details) (USD $)	3 Months Ended	9 Months Ended		0 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013 CD&R	Sep. 30, 2014 CD&R	Sep. 30, 2013 CD&R	Nov. 25, 2008 The Hertz Corporation	Sep. 30, 2014 The Hertz Corporation	Sep. 30, 2014 The Hertz Corporation Maximum	Sep. 30, 2013 The Hertz Corporation Maximum	Sep. 30, 2014 The Hertz Corporation Maximum	Sep. 30, 2013 The Hertz Corporation Maximum	Sep. 30, 2014 Condition one CD&R Minimum	Sep. 30, 2014 Condition two CD&R Minimum	Sep. 30, 2014 Condition two CD&R Maximum	Sep. 30, 2014 Condition three CD&R Minimum	Sep. 30, 2014 Condition three CD&R Maximum	Sep. 30, 2014 Condition four CD&R Minimum	Sep. 30, 2014 Condition four CD&R Maximum	Sep. 30, 2014 Condition five CD&R Minimum	Sep. 30, 2014 Condition five CD&R Maximum	Sep. 30, 2014 Additional condition CD&R Minimum
Related party transactions
Percentage of outstanding shares of common stock owned		27.70%								50.00%	40.00%	50.00%	30.00%	40.00%	20.00%	30.00%	5.00%	20.00%	30.00%
Percentage of total number of directors comprising the board of directors											40.00%		30.00%		20.00%		5.00%
Annual fee		$ 5,000,000
Annual management fee			2,500,000
Payment made in connection with the termination of a consulting agreement	20,000,000
Minimum agreed amount per year to be spend for rental of cars				460,000
Amount spent under contract						$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000
Term of the corporate account agreement					1 year

XML

Insurance Collateral (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Insurance collateral
Available-for-sale securities	$ 24,998,000	$ 13,227,000
Insurance receivable	1,796,000	1,300,000
Cash deposits and other	9,768,000	27,808,000
Total insurance collateral	36,562,000	42,335,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities
Cost Basis	25,612,000	12,847,000
Gross Unrealized Gains	13,000	563,000
Gross Unrealized Losses	(627,000)	(183,000)
Fair Value	24,998,000	13,227,000
U.S. Treasuries
Insurance collateral
Available-for-sale securities	1,198,000	2,100,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities
Cost Basis	1,191,000	2,064,000
Gross Unrealized Gains	10,000	37,000
Gross Unrealized Losses	(3,000)	(1,000)
Fair Value	1,198,000	2,100,000
Corporate bonds / Fixed income
Insurance collateral
Available-for-sale securities	8,426,000	6,372,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities
Cost Basis	8,439,000	6,384,000
Gross Unrealized Gains	3,000	26,000
Gross Unrealized Losses	(16,000)	(38,000)
Fair Value	8,426,000	6,372,000
Contractual maturities of available-for-sale securities
Within one year	1,700,000
Longer than one year through five years	7,400,000
Longer than five years through ten years	500,000
Corporate equity
Insurance collateral
Available-for-sale securities	15,374,000	4,755,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities
Cost Basis	15,982,000	4,399,000
Gross Unrealized Gains		500,000
Gross Unrealized Losses	(608,000)	(144,000)
Fair Value	$ 15,374,000	$ 4,755,000

XML

Restructuring Charges (Tables)

9 Months Ended

Sep. 30, 2014

Restructuring Charges

Schedule of restructuring charges

	AMR
	Lease and
	other contract
	termination						EmCare			EVHC
	costs			Severance			Severance			Severance			Total
							(in thousands)
Balance as of January 1, 2013	$	8,122		$	3,015		$	773		$	408		$	12,318
Incurred	1,876			2,890			913			20			5,699
Paid	(6,989		)	(3,765		)	(1,204		)	(377		)	(12,335		)
Balance as of December 31, 2013	$	3,009		$	2,140		$	482		$	51		$	5,682
Incurred	3,265			512			729			400			4,906
Paid	(1,712		)	(1,296		)	(929		)	(451		)	(4,388		)
Balance as of September 30, 2014	$	4,562		$	1,356		$	282		$	—		$	6,200

XML

Variable Interest Entities (Tables)

9 Months Ended

Sep. 30, 2014

UHS-EmCare JV

Variable Interest Entities

Summary of the variable interest entity assets and liabilities which are included in the Company's consolidated financial statements

The following table summarizes the UHS-EmCare JV assets and liabilities as of September 30, 2014, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,
	2014
Current assets	$	18,021
Current liabilities	8,773

HCA-EmCare JV

Variable Interest Entities

Summary of the variable interest entity assets and liabilities which are included in the Company's consolidated financial statements

The following table summarizes the HCA-EmCare JV assets and liabilities as of September 30, 2014 and December 31, 2013, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,		December 31,
	2014		2013
Current assets	$	137,992	$	88,479
Current liabilities	31,294		22,005

XML

Basic and Diluted Net Income (Loss) Per Share

9 Months Ended

Sep. 30, 2014

Basic and Diluted Net Income (Loss) Per Share

Basic and Diluted Net Income (Loss) Per Share

3. Basic and Diluted Net Income (Loss) Per Share

The Company presents both basic earnings per share (“EPS”) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing “Net income (loss) attributable to Envision Healthcare Holdings, Inc.” by the “Weighted-average common shares outstanding” for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised. The potential dilution from stock awards was computed using the treasury stock method based on the average market value of the Company’s common stock. The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation (in thousands, except share and per share amounts).

	Three months endedSeptember 30,					Nine months endedSeptember 30,
	2014		2013			2014		2013
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776	$	(7,663	)	$	75,609	$	(1,913	)
Weighted-average common shares outstanding — common stock:
Basic	182,564,837		157,282,885			181,502,232		139,969,940
Dilutive impact of stock awards outstanding	7,619,486		—			8,205,377		—
Diluted	190,184,323		157,282,885			189,707,609		139,969,940
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic	$	0.29	$	(0.05	)	$	0.42	$	(0.01	)
Diluted	$	0.28	$	(0.05	)	$	0.40	$	(0.01	)

The Company had a net loss for the three and nine months ended September 30, 2013; therefore, the effect of stock awards to purchase common stock of 6,088,252 and 8,663,107, respectively, is excluded from the computations of diluted loss per share since the effect is anti-dilutive. As of September 30, 2014 and 2013, there were no stock awards of common stock outstanding excluded from the weighted-average common shares outstanding above.

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2014

Segment Information

Schedule of the Company's operating segment results

The Company’s operating segment results were as follows (in thousands):

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
Facility-Based Physician Services
Net revenue	$	748,080	$	605,105	$	2,082,661	$	1,729,158
Income from operations	81,246		55,706		201,325		156,802
Adjusted EBITDA	99,726		82,032		258,179		218,767
Healthcare Transportation Services
Net revenue	$	402,249	$	350,783	$	1,157,206	$	1,014,309
Income from operations	32,655		7,782		74,033		35,339
Adjusted EBITDA	52,507		39,623		138,223		109,843
Segment Totals
Net revenue	$	1,150,329	$	955,888	$	3,239,867	$	2,743,467
Income from operations	113,901		63,488		275,358		192,141
Adjusted EBITDA	152,233		121,655		396,402		328,610

Schedule of reconciliation of net income (loss) to Adjusted EBITDA

A reconciliation of net income (loss) to Adjusted EBITDA (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
Add-back of non-operating expense (income):
Interest expense, net	25,742			46,772			84,793			148,526
Income tax expense (benefit)	34,437			(4,949		)	49,700			3,932
Loss on early debt extinguishment	—			29,519			66,397			29,641
Realized losses (gains) on investments	466			(158		)	(648		)	(276		)
Interest income from restricted assets	(175		)	(2		)	(507		)	(634		)
Equity in earnings of unconsolidated subsidiary	(72		)	(68		)	(185		)	(230		)
Other expense (income), net	660			52			3,432			13,022
Corporate operating expense	—			(15		)	—			73
Income from operations — segment totals	113,901			63,488			275,358			192,141
Add-back of operating expense (income):
Depreciation and amortization expense	36,796			35,175			108,786			104,552
Restructuring charges	366			1,319			4,906			4,988
Net loss (income) attributable to noncontrolling interest	(67		)	—			3,233			—
Interest income from restricted assets	175			2			507			634
Equity-based compensation expense	1,062			1,062			3,612			3,186
Related party management fees	—			20,609			—			23,109
Adjusted EBITDA — segment totals	152,233			121,655			396,402			328,610
Corporate operating expense	—			15			—			(73		)
Adjusted EBITDA	$	152,233		$	121,670		$	396,402		$	328,537

XML

Summary of Significant Accounting Policies (Details 6) (USD $)										9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Level 1 Available-for-sale securities (insurance collateral)	Dec. 31, 2013 Level 1 Available-for-sale securities (insurance collateral)	Dec. 31, 2013 Level 2 Available-for-sale securities (insurance collateral)	Sep. 30, 2014 Level 2 Fuel hedge	Dec. 31, 2013 Level 2 Fuel hedge	Sep. 30, 2014 Level 2 Interest rate swap	Dec. 31, 2013 Level 2 Interest rate swap	Sep. 30, 2014 Level 3 Contingent consideration	Dec. 31, 2013 Level 3 Contingent consideration	Sep. 30, 2014 Total Available-for-sale securities (insurance collateral)	Dec. 31, 2013 Total Available-for-sale securities (insurance collateral)	Sep. 30, 2014 Total Fuel hedge	Dec. 31, 2013 Total Fuel hedge	Sep. 30, 2014 Total Contingent consideration	Dec. 31, 2013 Total Contingent consideration	Sep. 30, 2014 Total Interest rate swap	Dec. 31, 2013 Total Interest rate swap
Fair Value Measurement
Assets			$ 24,998,000	$ 12,710,000	$ 517,000		$ 672,000					$ 24,998,000	$ 13,227,000		$ 672,000
Liabilities						22,000		1,991,000	3,135,000	2,000,000	7,734,000			22,000		2,000,000	7,734,000	1,991,000	3,135,000
Decrease in a level 3 liability of the contingent consideration										5,700,000
Payments related to new acquisitions which offset the contingent consideration										2,000,000
Transfers in assets from Level 1 to level 2 fair value measurements	0	0
Transfers in assets from Level 2 to level 1 fair value measurements	0	0
Transfers in liabilities from Level 1 to level 2 fair value measurements	0	0
Transfers in liabilities from Level 2 to level 1 fair value measurements	$ 0	$ 0

XML

Restructuring Charges (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Restructuring Charges
Incurred	$ 366	$ 1,319	$ 4,906	$ 4,988	$ 5,699
Paid			(4,388)		(12,335)
Accrued restructuring liability	6,200		6,200		5,682	12,318
Lease & Other Contract Termination Costs | AMR
Restructuring Charges
Incurred			3,265		1,876
Paid			(1,712)		(6,989)
Accrued restructuring liability	4,562		4,562		3,009	8,122
Severance
Restructuring Charges
Incurred			400		20
Paid			(451)		(377)
Accrued restructuring liability					51	408
Severance | AMR
Restructuring Charges
Incurred			512		2,890
Paid			(1,296)		(3,765)
Accrued restructuring liability	1,356		1,356		2,140	3,015
Severance | EmCare
Restructuring Charges
Incurred			729		913
Paid			(929)		(1,204)
Accrued restructuring liability	$ 282		$ 282		$ 482	$ 773

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 247,170	$ 204,712
Insurance collateral	27,899	29,619
Trade and other accounts receivable, net	913,413	801,146
Parts and supplies inventory	23,983	23,376
Prepaids and other current assets	51,950	23,430
Total current assets	1,264,415	1,082,283
Non-current assets:
Property, plant and equipment, net	203,405	194,715
Intangible assets, net	543,226	513,698
Insurance collateral	8,663	12,716
Goodwill	2,536,156	2,435,670
Other long-term assets	38,629	60,935
Total assets	4,594,494	4,300,017
Current liabilities:
Accounts payable	52,072	52,588
Accrued liabilities	413,685	350,936
Current deferred tax liabilities	36,383	35,487
Current portion of long-term debt and capital lease obligations	12,235	12,318
Total current liabilities	514,375	451,329
Long-term debt and capital lease obligations	2,029,095	1,895,381
Long-term deferred tax liabilities	151,225	151,130
Insurance reserves	167,628	175,427
Other long-term liabilities	16,707	16,997
Total liabilities	2,879,030	2,690,264
Commitments and contingencies
Equity:
Common stock ($0.01 par value; 2,000,000,000 shares authorized, 183,381,792 and 180,382,885 issued and outstanding as of September 30, 2014 and December 31, 2013, respectively)	1,834	1,804
Preferred stock ($0.01 par value; 200,000,000 shares authorized, none issued and outstanding as of September 30, 2014 and December 31, 2013)
Additional paid-in capital	1,609,244	1,575,417
Retained earnings	93,950	18,341
Accumulated other comprehensive income (loss)	(1,611)	(839)
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723
Noncontrolling interest	12,047	15,030
Total equity	1,715,464	1,609,753
Total liabilities and equity	$ 4,594,494	$ 4,300,017

XML

Insurance Collateral (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Insurance collateral
Securities available-for-sale, Fair Value, Total	$ 23,372,000		$ 23,372,000		$ 7,631,000
Securities available-for-sale, Unrealized Loss, Total	(627,000)		(627,000)		(183,000)
Realized net losses on the sale and maturities of available-for-sale securities	500,000
Realized net gains on the sale and maturities of available-for-sale securities		200,000	600,000	300,000
U.S. Treasuries
Insurance collateral
Securities available-for-sale, Less than 12 months, Fair Value					132,000
Securities available-for-sale, 12 months or more, Fair Value	132,000		132,000
Securities available-for-sale, Less than 12 months, Unrealized Loss					(1,000)
Securities available-for-sale, 12 months or more, Unrealized Loss	(3,000)		(3,000)
Corporate bonds / Fixed income
Insurance collateral
Securities available-for-sale, Less than 12 months, Fair Value	6,531,000		6,531,000		2,768,000
Securities available-for-sale, 12 months or more, Fair Value	1,335,000		1,335,000		2,178,000
Securities available-for-sale, Less than 12 months, Unrealized Loss	(13,000)		(13,000)		(18,000)
Securities available-for-sale, 12 months or more, Unrealized Loss	(3,000)		(3,000)		(20,000)
Corporate equity
Insurance collateral
Securities available-for-sale, Less than 12 months, Fair Value	15,374,000		15,374,000
Securities available-for-sale, 12 months or more, Fair Value					2,553,000
Securities available-for-sale, Less than 12 months, Unrealized Loss	(608,000)		(608,000)
Securities available-for-sale, 12 months or more, Unrealized Loss					$ (144,000)

XML

General

9 Months Ended

Sep. 30, 2014

General

General

1. General

Basis of Presentation of Financial Statements

Envision Healthcare Holdings, Inc., formerly known as CDRT Holding Corporation, is organized as a holding company that operates through various subsidiaries.  Envision Healthcare Corporation, formerly known as Emergency Medical Services Corporation, (“Corporation”) is a wholly-owned subsidiary of the Company.

The accompanying interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) to reflect the consolidated financial position, results of operations and cash flows of the Company for interim reporting, and accordingly, do not include all of the disclosures required for annual financial statements.

In the opinion of management, the consolidated financial statements of the Company include all normal recurring adjustments necessary for a fair presentation of the periods presented. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.  For further information on the Company’s significant accounting policies and other information, see the Company’s consolidated financial statements, including the accounting policies and notes thereto for the year ended December 31, 2013, which includes all disclosures required by GAAP, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

On July 29, 2013, the Company effected a 9.3 for 1.0 stock split of its common stock, resulting in 132,082,885 shares of common stock issued, not including 504,197 treasury shares. The accompanying consolidated financial statements give retroactive effect to the stock split for all periods presented.

On August 13, 2013, the Company’s registration statement (the “Registration Statement”) for an initial public offering of its common stock, par value $0.01 per share (“Common Stock”) was declared effective.  On February 5, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $30.50 per share.  On July 10, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $34.00 per share.  On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company.  The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices.  See Note 2 for further information on the Company’s public offerings and its equity.

The Company’s business is conducted primarily through two operating subsidiaries, EmCare Holdings, Inc. (“EmCare”), its facility-based and post-acute care physician services segment, and American Medical Response, Inc. (“AMR”), its healthcare transportation services segment.

XML

Segment Information (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Reconciliation of net income (loss) to Adjusted EBITDA
Net income (loss)	$ 52,843	$ (7,663)	$ 72,376	$ (1,913)
Add-back of non-operating expense (income):
Interest expense, net	25,742	46,772	84,793	148,526
Income tax expense (benefit)	34,437	(4,949)	49,700	3,932
Loss on early debt extinguishment		29,519	66,397	29,641
Realized (losses) gains on investments	466	(158)	(648)	(276)
Equity in earnings of unconsolidated subsidiary	(72)	(68)	(185)	(230)
Other expense (income), net	660	52	3,432	13,022
Income from operations	113,901	63,503	275,358	192,068
Add-back of operating expense (income):
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988	5,699
Net loss (income) attributable to noncontrolling interest	67		(3,233)
Interest income from restricted assets	(175)	(2)	(507)	(634)
Equity-based compensation expense	1,100	1,100	3,612	3,186
Adjusted EBITDA	152,233	121,670	396,402	328,537
Segment
Reconciliation of net income (loss) to Adjusted EBITDA
Net income (loss)	52,843	(7,663)	72,376	(1,913)
Add-back of non-operating expense (income):
Interest expense, net	25,742	46,772	84,793	148,526
Income tax expense (benefit)	34,437	(4,949)	49,700	3,932
Loss on early debt extinguishment		29,519	66,397	29,641
Realized (losses) gains on investments	466	(158)	(648)	(276)
Interest income from restricted assets	(175)	(2)	(507)	(634)
Equity in earnings of unconsolidated subsidiary	(72)	(68)	(185)	(230)
Other expense (income), net	660	52	3,432	13,022
Income from operations	113,901	63,488	275,358	192,141
Add-back of operating expense (income):
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988
Net loss (income) attributable to noncontrolling interest	(67)		3,233
Interest income from restricted assets	175	2	507	634
Equity-based compensation expense	1,062	1,062	3,612	3,186
Related party management fees		20,609		23,109
Adjusted EBITDA	152,233	121,655	396,402	328,610
Corporate
Add-back of operating expense (income):
Corporate operating expense		$ 15		$ (73)

XML

Summary of Significant Accounting Policies (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Insurance Collateral
Reinsurance receivable	$ 1,796	$ 1,300
Trade and Other Accounts Receivable, net
Gross trade accounts receivable	4,691,710	3,841,672
Allowance for contractual discounts	(2,525,606)	(2,002,704)
Allowance for uncompensated care	(1,252,719)	(1,038,833)
Trade accounts receivable, net	913,385	800,135
Other receivables, net	28	1,011
Trade and other accounts receivable, net	$ 913,413	$ 801,146
Period after which look-back analysis is performed to review and adjust overage or deficit in accounts receivable allowances	15 months
EmCare
Trade and Other Accounts Receivable, net
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables		87.00%
AMR
Trade and Other Accounts Receivable, net
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables		89.00%

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Consolidation

Consolidation

The consolidated financial statements of the Company include all of its wholly-owned subsidiaries, including Corporation, EmCare and AMR and their respective subsidiaries and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

Insurance Collateral

Insurance Collateral

Insurance collateral is comprised of investments in U.S. Treasuries and marketable equity and debt securities held by the Company’s captive insurance subsidiary that supports the Company’s insurance program and reserves, as well as cash deposits with third parties. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. These investments are designated as available-for-sale and reported at fair value with the related temporary unrealized gains and losses reported as a separate component of accumulated other comprehensive income, net of deferred income tax. Declines in the fair value of a marketable investment security which are determined to be other-than-temporary are recognized in the statements of operations, thus establishing a new cost basis for such investment. Investment income earned on these investments is reported as interest income from restricted assets in the statements of operations.

Realized gains and losses are determined based on an average cost basis.

Insurance collateral also includes a receivable from insurers of $1.8 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively, for liabilities in excess of the Company’s self-insured retention.

Trade and Other Accounts Receivable, net

Trade and Other Accounts Receivable, net

The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee-for-service charges as of December 31, 2013 was equal to approximately 87% and 89% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014			December 31, 2013
Gross trade accounts receivable	$	4,691,710		$	3,841,672
Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
Trade accounts receivable, net	913,385			800,135
Other receivables, net	28			1,011
Trade and other accounts receivable, net	$	913,413		$	801,146

Other receivables primarily represent employee advances and other miscellaneous receivables.

Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. The Company continuously compares actual cash collected on a date of service basis to the revenue recorded for that period and records any  adjustment necessary for an overage or deficit in these allowances based on actual collections.

AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated based on historical write-off experience.

Business Combinations

Business Combinations

Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

Insurance Reserves

Insurance Reserves

Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first one million dollars to three million dollars of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims are discounted at a rate of 1.5%.

The Company’s most recent actuarial valuation was completed in September 2014. As a result of this and previous actuarial valuations, the Company recorded a decrease in its provision for insurance liabilities of $0.7 million and an increase in its provision for insurance liabilities of $6.6 million during the three and nine months ended September 30, 2014, respectively, as compared to increases of $1.6 million and $1.2 million for the three and nine months ended September 30, 2013, related to reserves for losses in prior years.

The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively.

Equity Structure and Public Offerings

Equity Structure and Public Offerings

On August 13, 2013, the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “SEC”) for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 per share, for an aggregate offering price of $1,110.9 million, and the offering terminated. At the closing, the Company received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with the Company (“Consulting Agreement”) which was recorded in the third quarter of 2013 to selling, general and administrative expenses in the statements of operations (see Note 13).

Net proceeds from the initial public offering were used to (i) redeem in full the Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million of aggregate principal amount of the senior unsecured notes due 2019 and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

On February 5, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by investment funds sponsored by, or affiliated with, CD&R (the “CD&R Affiliates”) to the underwriters pursuant to their option to purchase additional shares at $30.50 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

On July 10, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by the CD&R Affiliates to the underwriters pursuant to their option to purchase additional shares at $34.00 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company.  The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices.  The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders.

Financial Instruments and Concentration of Credit Risk

Financial Instruments and Concentration of Credit Risk

The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, long-term debt and other long-term liabilities constitute financial instruments. Based on management’s estimates, the carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value as of September 30, 2014 and December 31, 2013. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2014 and 2013, the Company derived approximately 31% and 28%, respectively, of its revenue from Medicare and Medicaid, 66% and 68%, respectively, from insurance providers and contracted payors, and 3% and 4%, respectively, directly from patients.

The Company estimates the fair value of its fixed rate senior notes based on an analysis in which the Company evaluates market conditions, related securities, various public and private offerings, and other publicly available information (Level 2, as defined below). The estimated fair value of the senior notes as of September 30, 2014 was approximately $738.8 million with a carrying amount of $750.0 million.

Fair Value Measurement

Fair Value Measurement

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include corporate bonds and derivatives.

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	24,998	$	—	$	—	$	24,998
Liabilities:
Contingent consideration	—		—		2,000		2,000
Fuel hedge	—		22		—		22
Interest rate swap	—		1,991		—		1,991

	December 31, 2013
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	12,710	$	517	$	—	$	13,227
Fuel hedge	—		672		—		672
Liabilities:
Contingent consideration	—		—		7,734		7,734
Interest rate swap	—		3,135		—		3,135

The contingent consideration balance classified as a Level 3 liability has decreased by $5.7 million since December 31, 2013 primarily due to payments made, offset by an increase of $2.0 million from recent acquisitions.

During the nine months ended September 30, 2014 and 2013, there were no transfers in and out of Level 1 and Level 2 fair value measurements.

Revenue Recognition

Revenue Recognition

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies at EmCare and fees for stand-by services, special event services and community subsidies at AMR.

The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within its care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

The Company has historically reported Medicare and Medicaid managed care in the line “Commercial insurance and managed care”. Medicare managed care and Medicaid managed care have been reclassified into the Medicare and Medicaid lines in the current period and all prior periods have been conformed to current period presentation.  Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Fee-for-service revenue, net of contractual discounts:
Medicare	$	265,300		$	231,517		$	816,040		$	732,153
Medicaid	70,343			52,089			236,784			196,952
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
Self-pay	728,598			644,141			2,205,326			1,961,170
Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
Subsidies and fees	189,116			171,481			554,653			446,679
Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate decreased the contractual discount and uncompensated care provisions (increased net revenue) by approximately $1.1 million for the three months ended September 30, 2014 and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $2.7 million for the nine months ended September 30, 2014, and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $1.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards.  ASU 2014-09 is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period.  Early application is not permitted.  The Company has not yet determined the effects, if any, that adoption of ASU 2014-09 may have on its consolidated financial position or results of operations.

XML

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Insurance Reserves
Discount rate for claims other than general liability claims (as a percent)			1.50%
Increase (decrease) in provisions for insurance liabilities for prior year losses	$ (700,000)	$ 1,600,000	$ 6,600,000	$ 1,200,000
Long-term portion of insurance reserves	167,628,000		167,628,000		175,427,000
Minimum
Insurance Reserves
Liability exposure in instances where third-party insurance coverage is obtained			1,000,000
Maximum
Insurance Reserves
Liability exposure in instances where third-party insurance coverage is obtained			$ 3,000,000

XML

Basic and Diluted Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2014

Basic and Diluted Net Income (Loss) Per Share

EPS amounts and the basic and diluted weighted-average shares outstanding used in the calculation

The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation (in thousands, except share and per share amounts).

	Three months endedSeptember 30,					Nine months endedSeptember 30,
	2014		2013			2014		2013
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776	$	(7,663	)	$	75,609	$	(1,913	)
Weighted-average common shares outstanding — common stock:
Basic	182,564,837		157,282,885			181,502,232		139,969,940
Dilutive impact of stock awards outstanding	7,619,486		—			8,205,377		—
Diluted	190,184,323		157,282,885			189,707,609		139,969,940
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic	$	0.29	$	(0.05	)	$	0.42	$	(0.01	)
Diluted	$	0.28	$	(0.05	)	$	0.40	$	(0.01	)

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Consolidation

The consolidated financial statements of the Company include all of its wholly-owned subsidiaries, including Corporation, EmCare and AMR and their respective subsidiaries and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

Insurance Collateral

Insurance collateral is comprised of investments in U.S. Treasuries and marketable equity and debt securities held by the Company’s captive insurance subsidiary that supports the Company’s insurance program and reserves, as well as cash deposits with third parties. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. These investments are designated as available-for-sale and reported at fair value with the related temporary unrealized gains and losses reported as a separate component of accumulated other comprehensive income, net of deferred income tax. Declines in the fair value of a marketable investment security which are determined to be other-than-temporary are recognized in the statements of operations, thus establishing a new cost basis for such investment. Investment income earned on these investments is reported as interest income from restricted assets in the statements of operations.

Realized gains and losses are determined based on an average cost basis.

Insurance collateral also includes a receivable from insurers of $1.8 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively, for liabilities in excess of the Company’s self-insured retention.

Trade and Other Accounts Receivable, net

The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee-for-service charges as of December 31, 2013 was equal to approximately 87% and 89% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014			December 31, 2013
Gross trade accounts receivable	$	4,691,710		$	3,841,672
Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
Trade accounts receivable, net	913,385			800,135
Other receivables, net	28			1,011
Trade and other accounts receivable, net	$	913,413		$	801,146

Other receivables primarily represent employee advances and other miscellaneous receivables.

Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. The Company continuously compares actual cash collected on a date of service basis to the revenue recorded for that period and records any  adjustment necessary for an overage or deficit in these allowances based on actual collections.

AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated based on historical write-off experience.

Business Combinations

Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

Insurance Reserves

Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first one million dollars to three million dollars of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims are discounted at a rate of 1.5%.

The Company’s most recent actuarial valuation was completed in September 2014. As a result of this and previous actuarial valuations, the Company recorded a decrease in its provision for insurance liabilities of $0.7 million and an increase in its provision for insurance liabilities of $6.6 million during the three and nine months ended September 30, 2014, respectively, as compared to increases of $1.6 million and $1.2 million for the three and nine months ended September 30, 2013, related to reserves for losses in prior years.

The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively.

Equity Structure and Public Offerings

On August 13, 2013, the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “SEC”) for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 per share, for an aggregate offering price of $1,110.9 million, and the offering terminated. At the closing, the Company received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with the Company (“Consulting Agreement”) which was recorded in the third quarter of 2013 to selling, general and administrative expenses in the statements of operations (see Note 13).

Net proceeds from the initial public offering were used to (i) redeem in full the Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million of aggregate principal amount of the senior unsecured notes due 2019 and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

On February 5, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by investment funds sponsored by, or affiliated with, CD&R (the “CD&R Affiliates”) to the underwriters pursuant to their option to purchase additional shares at $30.50 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

On July 10, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by the CD&R Affiliates to the underwriters pursuant to their option to purchase additional shares at $34.00 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company.  The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices.  The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders.

Financial Instruments and Concentration of Credit Risk

The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, long-term debt and other long-term liabilities constitute financial instruments. Based on management’s estimates, the carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value as of September 30, 2014 and December 31, 2013. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2014 and 2013, the Company derived approximately 31% and 28%, respectively, of its revenue from Medicare and Medicaid, 66% and 68%, respectively, from insurance providers and contracted payors, and 3% and 4%, respectively, directly from patients.

The Company estimates the fair value of its fixed rate senior notes based on an analysis in which the Company evaluates market conditions, related securities, various public and private offerings, and other publicly available information (Level 2, as defined below). The estimated fair value of the senior notes as of September 30, 2014 was approximately $738.8 million with a carrying amount of $750.0 million.

Fair Value Measurement

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include corporate bonds and derivatives.

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	24,998	$	—	$	—	$	24,998
Liabilities:
Contingent consideration	—		—		2,000		2,000
Fuel hedge	—		22		—		22
Interest rate swap	—		1,991		—		1,991

	December 31, 2013
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	12,710	$	517	$	—	$	13,227
Fuel hedge	—		672		—		672
Liabilities:
Contingent consideration	—		—		7,734		7,734
Interest rate swap	—		3,135		—		3,135

The contingent consideration balance classified as a Level 3 liability has decreased by $5.7 million since December 31, 2013 primarily due to payments made, offset by an increase of $2.0 million from recent acquisitions.

During the nine months ended September 30, 2014 and 2013, there were no transfers in and out of Level 1 and Level 2 fair value measurements.

Revenue Recognition

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies at EmCare and fees for stand-by services, special event services and community subsidies at AMR.

The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within its care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

The Company has historically reported Medicare and Medicaid managed care in the line “Commercial insurance and managed care”. Medicare managed care and Medicaid managed care have been reclassified into the Medicare and Medicaid lines in the current period and all prior periods have been conformed to current period presentation.  Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Fee-for-service revenue, net of contractual discounts:
Medicare	$	265,300		$	231,517		$	816,040		$	732,153
Medicaid	70,343			52,089			236,784			196,952
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
Self-pay	728,598			644,141			2,205,326			1,961,170
Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
Subsidies and fees	189,116			171,481			554,653			446,679
Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate decreased the contractual discount and uncompensated care provisions (increased net revenue) by approximately $1.1 million for the three months ended September 30, 2014 and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $2.7 million for the nine months ended September 30, 2014, and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $1.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards.  ASU 2014-09 is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period.  Early application is not permitted.  The Company has not yet determined the effects, if any, that adoption of ASU 2014-09 may have on its consolidated financial position or results of operations.

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	183,381,792	180,382,885
Common stock, shares outstanding	183,381,792	180,382,885
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies

Commitments and Contingencies

12. Commitments and Contingencies

Lease Commitments

The Company leases various facilities and equipment under operating lease agreements. Rental expense incurred under these leases was $11.3 million and $11.3 million for the three months ended September 30, 2014 and 2013, respectively and $34.0 million and $33.6 million for the nine months ended September 30, 2014 and 2013, respectively.

The Company also records certain leasehold improvements and vehicles under capital leases. Assets under capital leases are capitalized using inherent interest rates at the inception of each lease. Capital leases are collateralized by the underlying assets.

Services

The Company is subject to the Medicare and Medicaid fraud and abuse laws which prohibit, among other things, any false claims, or any bribe, kickback or rebate in return for the referral of Medicare and Medicaid patients. Violation of these prohibitions may result in civil and criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Management has implemented policies and procedures that management believes will assure that the Company is in substantial compliance with these laws and regulations but there can be no assurance the Company will not be found to have violated certain of these laws and regulations. From time to time, the Company receives requests for information from government agencies pursuant to their regulatory or investigational authority. Such requests can include subpoenas or demand letters for documents to assist the government agencies in audits or investigations. The Company is cooperating with the government agencies conducting these investigations and is providing requested information to the government agencies. Other than the proceedings described below, management believes that the outcome of any of these investigations would not have a material adverse effect on the Company.

Letters of Credit

As of September 30, 2014 and December 31, 2013, the Company had $130.2 million and $129.9 million, respectively, in outstanding letters of credit.

Other Legal Matters

In December 2006, AMR received a subpoena from the U.S. Department of Justice (“DOJ”). The subpoena requested copies of documents for the period from January 2000 through the present. The subpoena required AMR to produce a broad range of documents relating to the operations of certain AMR affiliates in New York. The Company produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited the Company to respond to the identified areas of concern. The Company reviewed the information provided by the government and provided its response. On May 20, 2011, AMR entered into a settlement agreement with the DOJ and a Corporate Integrity Agreement (“CIA”) with the Office of Inspector General of the Department of Health and Human Services (“OIG”) in connection with this matter. Under the terms of the settlement, AMR paid $2.7 million to the federal government. In connection with the settlement, the Company entered into a CIA with a five-year period beginning May 20, 2011. Pursuant to this CIA, the Company is required to maintain a compliance program, which includes, among other elements, the appointment of a compliance officer and committee, training of employees nationwide, safeguards for its billing operations as they relate to services provided in New York, including specific training for operations and billing personnel providing services in New York, review by an independent review organization and reporting of certain reportable events. The Company entered into the settlement in order to avoid the uncertainties of litigation, and has not admitted any wrongdoing. In May 2013, a subsidiary of the Company entered into an agreement to divest substantially all the assets underlying AMR’s services in New York, although the obligations of the Company’s compliance program will remain in effect following the expected divestiture. The divesture was completed on July 1, 2013.

Four different putative class action lawsuits have been filed against AMR and certain subsidiaries in California alleging violations of California wage and hour laws.  On April 16, 2008, Laura Bartoni commenced a suit in the Superior Court for the State of California, County of Alameda; on July 8, 2008, Vaughn Banta filed suit in the Superior Court of the State of California, County of Los Angeles; on January 22, 2009, Laura Karapetian filed suit in the Superior Court of the State of California, County of Los Angeles: and on March 11, 2010, Melanie Aguilar filed suit in Superior Court of the State of California, County of Los Angeles.  The Banta, Aguilar and Karapetian cases have been coordinated in the Superior Court for the State of California, County of Los Angeles, and the Aguilar and Karapetian cases have subsequently been consolidated into a single action.  In these cases, the plaintiffs allege principally that the AMR entities failed to pay wages, including overtime wages, in compliance with California law, and failed to provide required meal breaks, rest breaks or pay premium compensation for missed breaks.  The plaintiffs sought to certify classes on these claims and are seeking lost wages, various penalties, and attorneys’ fees under California law.  The Court has certified classes in the consolidated Karapetian /Aguilar case on claims alleging that AMR has not provided meal periods in compliance with the law as to dispatchers and call takers, that AMR has an unlawful time round policy, and that AMR has an unlawful practice of setting rates for those employees; the Court denied certification of the rest period claims of these employees.  In Banta, the Court denied certification of the meal and rest period claims as to EMTs and paramedics, a decision that is being appealed; the Court indicated that it would certify a class on overtime claims, but plaintiff’s counsel have indicated that they intend to dismiss that claim as AMR’s policy complies with a recent Court of Appeal decision.  In Bartoni, the Court denied certification on the meal and rest period claims, but certified a class on the overtime claims, as to which the Company intends to seek summary judgment. The Company is unable at this time to estimate the amount of potential damages, if any in any of these actions.

Merion Capital, L.P. (“Merion”), a former stockholder of Corporation, filed an action in the Delaware Court of Chancery on June 20, 2011 seeking to exercise its right to appraisal of its holdings in Corporation prior to the merger of Corporation with a wholly-owned subsidiary of the Company (the “Merger”) on May 25, 2011. During the first quarter of 2013, the Company expensed $8.4 million of legal settlement costs and $1.9 million of interest. On April 15, 2013, the Company paid $52.1 million in a settlement of Merion’s appraisal action, in which Merion agreed to release its claims against the Company.

On August 7, 2012, EmCare received a subpoena from the OIG requesting copies of documents for the period from January 1, 2007 through the present that appears to primarily be focused on EmCare’s contracts for services at hospitals that are affiliated with Health Management Associates, Inc. (“HMA”). The Company has been cooperating with the government during its investigation and, as such, continues to gather responsive documents. During the months of December 2013 and January 2014, several lawsuits filed by whistleblowers on behalf of the federal and certain state governments against HMA have been unsealed; the Company is a named defendant in two of these lawsuits. Although the federal government intervened in these lawsuits in connection with certain of the allegations against HMA, the federal government has not, at this time, disclosed whether it will intervene in these matters as they relate to the Company. The Company continues to engage in meaningful dialogue with the relevant government representatives and, at this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

On February 14, 2013, EmCare received a subpoena from the OIG requesting documents and other information relating to EmCare’s relationship with Community Health Services, Inc. (“CHS”). The Company is cooperating with the government during its investigation, has provided responsive documents, and is engaged in a meaningful dialogue with the relevant government representatives regarding additional requests. At this time, the Company is unable to determine the potential impact, if any, that will result from these investigations.

In November 2013, AMR received a subpoena from the New Hampshire Department of Insurance directed to American Medical Response of Massachusetts, Inc. The subpoena requested documents relating to ambulance services provided to approximately 150 patients residing in the state of New Hampshire who had been involved in motor vehicle accidents and who were ultimately transported by AMR. In addition, the subpoena requested information relating to any agreements for reimbursement between AMR and Progressive Insurance. We cooperated with the Department and, in March 2014, we were notified that the investigation was concluded and closed.

The Company is involved in other litigation arising in the ordinary course of business. Management believes the outcome of these legal proceedings will not have a material adverse impact on its financial condition, results of operations or liquidity.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information
Entity Registrant Name	Envision Healthcare Holdings, Inc.
Entity Central Index Key	0001578318
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		183,524,958
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

XML

Related Party Transactions

9 Months Ended

Sep. 30, 2014

Related Party Transactions

Related Party Transactions

13. Related Party Transactions

CD&R Affiliates

Stockholders Agreement

In connection with the Company’s initial public offering, the Company entered into a stockholders agreement (“Stockholders Agreement”) with CD&R Affiliates. Under the Stockholders Agreement, CD&R Affiliates were granted the right to designate for nomination for election a number of CD&R-designated directors equal to: (i) at least a majority of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 50% of the outstanding shares of Common Stock, (ii) at least 40% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 40% but less than 50% of the outstanding shares of Common Stock, (iii) at least 30% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 30% but less than 40% of the outstanding shares of Common Stock, (iv) at least 20% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 20% but less than 30% of the outstanding shares of Common Stock, and (v) at least 5% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 5% but less than 20% of the outstanding shares of Common Stock. Additionally, a CD&R-designated director will serve as the Chairman of the board of directors as long as the CD&R Affiliates own at least 30% of the outstanding shares of Common Stock. As of September 30, 2014, the CD&R Affiliates owned approximately 27.7% of the outstanding shares of Common Stock.

Consulting Agreement

The Company was party to the Consulting Agreement, dated May 25, 2011 (the “Consulting Agreement”), with CD&R pursuant to which CD&R provided the Company and its subsidiaries with financial, investment banking, management, advisory and other services in exchange for an annual fee of $5.0 million. The Company expensed $2.5 million for the nine months ended September 30, 2013, respectively, for this fee.

During the third quarter of 2013, the Company made a $20.0 million payment to CD&R with proceeds received from the initial public offering of Common Stock of the Company to terminate the Consulting Agreement.

Registration Rights Agreement

In connection with the closing of the Merger, the Company entered into a registration rights agreement (“Registration Rights Agreement”) with the CD&R Affiliates which grants the CD&R Affiliates specified demand and piggyback registration rights with respect to the Company’s Common Stock. Under the Registration Rights Agreement, if the Company registers Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), holders of the Common Stock, including CD&R Affiliates, have the right to require the Company’s to use reasonable best efforts to include in the Company’s registration statement shares of Common Stock held by them, subject to certain limitations and at the expense of the Company.

Indemnification Agreements

In connection with the closing of the Merger, the Company and the Company entered into separate indemnification agreements with CD&R and CD&R Affiliates (the “CD&R Entities”). Under the indemnification agreement with the CD&R Entities, Holding and the Company, subject to certain limitations, jointly and severally agreed to indemnify the CD&R Entities and certain of their affiliates against certain liabilities arising out of performance of the Consulting Agreement and certain other claims and liabilities.

Other

On November 25, 2008, the Company entered into a corporate account agreement with The Hertz Corporation pursuant to which it agreed to spend a minimum total amount of $460,000 per year for the rental of cars from The Hertz Corporation and its subsidiaries and licensees. For each of the three and nine months ended September 30, 2014 and 2013, we spent less than $1.0 million under this contract. The agreement had an initial one-year term, and renews automatically until terminated by either party. Investment funds associated with CD&R had been affiliated with Hertz Global Holdings.

Other Transactions

In connection with the closing of the Merger, Holding and Corporation entered into separate indemnification agreements with each of Richard J. Schnall, Ronald A. Williams, William A. Sanger, and Kenneth A. Giuriceo as the directors of Holding and Corporation. Under the indemnification agreements with the directors of Holding and Corporation, Holding and Corporation, subject to certain limitations, jointly and severally agreed to indemnify the directors against certain liabilities arising out of service as a director.

The executive employment agreements include indemnification provisions whereby the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

In connection with the Company’s initial public offering, the Company entered into new indemnification agreements with each of its directors. On November 11, 2013, the Company entered into an indemnification agreement with Mark V. Mactas. Under these agreements, the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue, net of contractual discounts	$ 1,989,957	$ 1,691,208	$ 5,802,153	$ 4,986,261
Provision for uncompensated care	(839,628)	(735,320)	(2,562,286)	(2,242,794)
Net revenue	1,150,329	955,888	3,239,867	2,743,467
Compensation and benefits	819,353	677,797	2,330,021	1,963,546
Operating expenses	129,535	110,387	364,885	313,145
Insurance expense	27,527	26,974	90,091	78,647
Selling, general and administrative expenses	22,851	40,733	65,820	86,521
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988
Income from operations	113,901	63,503	275,358	192,068
Interest income from restricted assets	175	2	507	634
Interest expense, net	(25,742)	(46,772)	(84,793)	(148,526)
Realized gains (losses) on investments	(466)	158	648	276
Other income (expense), net	(660)	(52)	(3,432)	(13,022)
Loss on early debt extinguishment		(29,519)	(66,397)	(29,641)
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	(12,680)	121,891	1,789
Income tax benefit (expense)	(34,437)	4,949	(49,700)	(3,932)
Income (loss) before equity in earnings of unconsolidated subsidiary	52,771	(7,731)	72,191	(2,143)
Equity in earnings of unconsolidated subsidiary	72	68	185	230
Net income (loss)	52,843	(7,663)	72,376	(1,913)
Less: Net (income) loss attributable to noncontrolling interest	(67)		3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	(7,663)	75,609	(1,913)
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
Basic (in dollars per share)	$ 0.29	$ (0.05)	$ 0.42	$ (0.01)
Diluted (in dollars per share)	$ 0.28	$ (0.05)	$ 0.40	$ (0.01)
Weighted-average common shares outstanding:
Basic (in shares)	182,564,837	157,282,885	181,502,232	139,969,940
Diluted (in shares)	190,184,323	157,282,885	189,707,609	139,969,940
Comprehensive income (loss):
Net income (loss)	52,843	(7,663)	72,376	(1,913)
Other comprehensive income (loss), net of tax:
Unrealized holding gains (losses) during the period	(310)	(133)	(1,012)	(582)
Unrealized gains (losses) on derivative financial instruments	(74)	236	240	(42)
Total other comprehensive income (loss), net of tax	(384)	103	(772)	(624)
Comprehensive income (loss)	52,459	(7,560)	71,604	(2,537)
Less: Comprehensive (income) loss attributable to noncontrolling interest	(67)		3,233
Comprehensive income (loss) attributable to Envision Healthcare Holdings, Inc.	$ 52,392	$ (7,560)	$ 74,837	$ (2,537)

XML

Debt and Capital Lease Obligations

9 Months Ended

Sep. 30, 2014

Debt and Capital Lease Obligations

Debt and Capital Lease Obligations

7. Debt and Capital Lease Obligations

Senior Unsecured Notes due 2019

On May 25, 2011, Corporation issued $950 million of senior unsecured notes due 2019 (“2019 Notes”). During the second quarter of 2012, the Company’s captive insurance subsidiary purchased $15.0 million of the 2019 Notes through an open market transaction and currently holds none of the 2019 Notes subsequent to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014.

On December 30, 2013, the Company redeemed $332.5 million in aggregate principal amount of the 2019 Notes of which $5.2 million was held by the Company’s captive insurance subsidiary at a redemption price of 108.125%, plus accrued and unpaid interest of $2.2 million. During the fourth quarter of 2013, the Company recorded a loss on early debt extinguishment of $38.7 million related to premiums and unamortized debt issuance costs from the partial redemption of the 2019 Notes.

On June 18, 2014, the Company redeemed $617.5 million in aggregate principal amount of the 2019 Notes of which $9.8 million was held by the Company’s captive insurance subsidiary at a redemption price of 106.094%, plus accrued and unpaid interest of $2.4 million. During the second quarter of 2014, the Company recorded a loss on early debt extinguishment of $66.4 million related to premiums, financing fees paid to the creditors of the unsecured senior notes due 2022, and unamortized debt issuance costs from the redemption of the 2019 Notes.

Senior Secured Credit Facilities

On May 25, 2011, Corporation entered into $1.8 billion of senior secured credit facilities (“Senior Secured Credit Facilities”) that consisted of a $1.44 billion senior secured term loan facility due 2018 (the “Term Loan Facility”) and a $350 million asset-backed revolving credit facility due 2016 (the “ABL Facility”). The Senior Secured Credit Facilities are secured by substantially all of the assets of the Company.

Term Loan Facility

Prior to February 7, 2013, loans under the Term Loan Facility bore interest at the Company’s election at a rate equal to (i) the highest of (x) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“Term Loan LIBOR”) and (y) 1.50%, plus, in each case, 3.75%, or (ii) the base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month Term Loan LIBOR (adjusted for maximum reserves) plus 1.00% per annum and (x) 2.50%, plus, in each case, 2.75%.

On February 7, 2013, Corporation, the borrower under the Term Loan Facility, entered into a First Amendment (the “Term Loan Amendment”) to the credit agreement governing the Term Loan Facility (as amended, the “Term Loan Credit Agreement”). Under the Term Loan Amendment, the Company incurred an additional $150 million in incremental borrowings under the Term Loan Facility, the proceeds of which were used to pay down the ABL Facility. In addition, the rate at which the loans under the Term Loan Credit Agreement bear interest was amended to equal (i) the higher of (x) the rate for deposits in U.S. dollars in the London Interbank Market (adjusted for maximum reserves) for the applicable interest period (“LIBOR”) and (y) 1.00%, plus, in each case, 3.00% (with a step-down to 2.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00), or (ii) the alternate base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% and (z) 2.00%, plus, in each case, 2.00% (with a step-down to 1.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00). The Company recorded a loss on early debt extinguishment of $0.1 million related to unamortized debt issuance costs as a result of this modification.

The credit agreement governing the Term Loan Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on the incurrence of debt, liens, fundamental changes, restrictions on subsidiary distributions, transactions with affiliates, further negative pledge, asset sales, restricted payments, investments and acquisitions, repayment of certain junior debt (including the senior notes) or amendments of junior debt documents related thereto and line of business. The negative covenants are subject to the customary exceptions.

ABL Facility

Prior to February 27, 2013, loans under the ABL Facility bore interest at the Company’s election at a rate equal to (i) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“ABL LIBOR”), plus an applicable margin that ranges from 2.25% to 2.75% based on the average available loan commitments, or (ii) the base rate, which is the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) the overnight federal funds rate plus 0.5% and (z) the one-month ABL LIBOR plus 1.0% per annum, plus, in each case, an applicable margin that ranges from 1.25% to 1.75% based on the average available loan commitments.

On February 27, 2013, Corporation entered into a First Amendment (the “ABL Amendment”) to the credit agreement governing the ABL Facility (as amended, the “ABL Credit Agreement”), under which the Company increased its commitments under the ABL Facility to $450 million and extended the term to 2018. In addition, the rate at which the loans under the ABL Credit Agreement bear interest was amended to equal (i) LIBOR plus, (x) 2.00% in the event that average daily excess availability is less than or equal to 33% of availability, (y) 1.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (z) 1.50% in the event that average daily excess availability is greater than 66% of availability, or (ii) the alternate base rate, which will be the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) 0.50% in excess of the overnight federal funds rate and (z) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% plus, in each case, (A) 1.00% in the event that average daily excess availability is less than or equal to 33% of availability, (B) 0.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (C) 0.50% in the event that average daily excess availability is greater than 66% of availability.

The ABL Facility bears a commitment fee that ranges from 0.500% to 0.375%, payable quarterly in arrears, based on the utilization of the ABL Facility. The ABL Facility also bears customary letter of credit fees.

As of September 30, 2014, letters of credit outstanding which impact the available credit under the ABL Facility were $130.2 million and the maximum available under the ABL Facility was $319.8 million.

The credit agreement governing the ABL Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on indebtedness, dividends and distributions, investments, acquisitions, prepayments or redemptions of junior indebtedness, amendments of junior indebtedness, transactions with affiliates, asset sales, mergers, consolidations and sales of all or substantially all assets, liens, negative pledge clauses, changes in fiscal periods, changes in line of business and hedging transactions. The negative covenants are subject to the customary exceptions and also permit the payment of dividends and distributions, investments, permitted acquisitions and payments or redemptions of junior indebtedness upon satisfaction of a “payment condition.” The payment condition is deemed satisfied upon 30-day average excess availability exceeding agreed upon thresholds and, in certain cases, the absence of specified events of default and compliance with a fixed charge coverage ratio of 1.0 to 1.0.

In the second quarter of 2013, the Company recorded $5.0 million of debt issuance expense related to the Term Loan Amendment and ABL Amendment.

Senior PIK Toggle Notes

On October 1, 2012, the Company issued $450 million of Senior PIK Toggle Notes due 2017 (the “PIK Notes”) and used the proceeds from the offering to pay an extraordinary dividend to its stockholders, pay debt issuance costs and make certain payments to members of management with rollover options in the Company.

On August 30, 2013, the Company redeemed all of the PIK Notes at a redemption price equal to 102.75% of the aggregate principal amount of the PIK Notes, plus accrued and unpaid interest of $17.2 million. During the third quarter of 2013, the Company recorded a loss on early debt extinguishment of $29.5 million related to premiums and unamortized debt issuance costs from the redemption of the PIK Notes.

Senior Unsecured Notes due 2022

On June 18, 2014, Corporation issued $750.0 million of senior unsecured notes due 2022 (“2022 Notes”) the proceeds of which were used to redeem the 2019 Notes and for other general corporate purposes. The Company paid $9.4 million in financing fees to the creditors of the 2022 Notes which was recorded to loss on early debt extinguishment in the second quarter of 2014.

The 2022 Notes have a fixed interest rate of 5.125%, payable semi-annually on January 1 and July 1 with the principal due at maturity on July 1, 2022. The 2022 Notes are general unsecured obligations of the Company and are guaranteed by each of the Company’s domestic subsidiaries, except for any of the Company’s subsidiaries subject to regulation as an insurance company, including the Company’s captive insurance subsidiary.

The Company may redeem the 2022 Notes, in whole or in part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus the applicable make-whole premium. The Company may redeem the 2022 Notes, in whole or in part, at any time (i) on and after July 1, 2017 and prior to July 1, 2018, at a price equal to 103.844% of the principal amount of the 2022 Notes, (ii) on or after July 1, 2018 and prior to July 1, 2019, at a price equal to 102.563% of the principal amount of the 2022 Notes, (iii) on or after July 1, 2019 and prior to July 1, 2020, at a price equal to 101.281% of the principal amount of the 2022 Notes, and (iv) on or after July 1, 2020, at a price equal to 100.000% of the principal amount of the 2022 Notes, in each case, plus accrued and unpaid interest, if any, to the redemption date. In addition, at any time prior to July 1, 2017, the Company at its option may redeem up to 40% of the aggregate principal amount of the 2022 Notes with the proceeds of certain equity offerings at a redemption price of 105.125%, plus accrued and unpaid interest, if any, to the applicable redemption date.

The indenture governing the 2022 Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: incur additional indebtedness or issue certain preferred shares; pay dividends on, redeem or repurchase stock or make other distributions in respect of its capital stock; repurchase, prepay or redeem subordinated indebtedness; make investments; create restrictions on the ability of the Company’s restricted subsidiaries to pay dividends to the Company or make other intercompany transfers; create liens; transfer or sell assets; consolidate, merge or sell or otherwise dispose of all or substantially all of its assets; enter into certain transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries. Upon the occurrence of certain events constituting a change of control, the Company is required to make an offer to repurchase all of the 2022 Notes (unless otherwise redeemed) at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any to the repurchase date. If the Company sells assets under certain circumstances, it must use the proceeds to make an offer to purchase the 2022 Notes at a price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to the date of purchase.

Debt and capital lease obligations consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,2014			December 31,2013
Senior unsecured notes due 2019	$	—		$	607,750
Senior unsecured notes due 2022	750,000			—
Senior secured term loan due 2018 (4.00% at September 30, 2014 and December 31, 2013)	1,292,917			1,302,945
Discount on senior secured term loan	(3,567		)	(4,217		)
ABL Facility	—			—
Notes due at various dates from 2014 to 2022 with interest rates from 6% to 10%	731			852
Capital lease obligations due at various dates from 2014 to 2018	1,249			369
Total	2,041,330			1,907,699
Less current portion	(12,235		)	(12,318		)
Total long-term debt and capital lease obligations	$	2,029,095		$	1,895,381

XML

Accrued Liabilities

9 Months Ended

Sep. 30, 2014

Accrued Liabilities

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities were as follows as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Accrued wages and benefits	$	186,983	$	161,398
Accrued paid time-off	30,115		25,713
Current portion of self-insurance reserves	73,719		73,738
Accrued restructuring	6,200		5,682
Current portion of compliance and legal	3,928		2,000
Accrued billing and collection fees	3,057		2,954
Accrued incentive compensation	33,297		19,570
Accrued income taxes	8,015		—
Accrued interest	12,812		6,898
Other	55,559		52,983
Total accrued liabilities	$	413,685	$	350,936

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Schedule of accounts receivable and allowances

The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014			December 31, 2013
Gross trade accounts receivable	$	4,691,710		$	3,841,672
Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
Trade accounts receivable, net	913,385			800,135
Other receivables, net	28			1,011
Trade and other accounts receivable, net	$	913,413		$	801,146

Summary of the valuation of the Company's financial instruments by the fair value hierarchy levels

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	24,998	$	—	$	—	$	24,998
Liabilities:
Contingent consideration	—		—		2,000		2,000
Fuel hedge	—		22		—		22
Interest rate swap	—		1,991		—		1,991

	December 31, 2013
Description	Level 1		Level 2		Level 3		Total
Assets:
Available-for-sale securities (insurance collateral)	$	12,710	$	517	$	—	$	13,227
Fuel hedge	—		672		—		672
Liabilities:
Contingent consideration	—		—		7,734		7,734
Interest rate swap	—		3,135		—		3,135

Schedule of net revenue

  Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Fee-for-service revenue, net of contractual discounts:
Medicare	$	265,300		$	231,517		$	816,040		$	732,153
Medicaid	70,343			52,089			236,784			196,952
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
Self-pay	728,598			644,141			2,205,326			1,961,170
Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
Subsidies and fees	189,116			171,481			554,653			446,679
Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

XML

Variable Interest Entities

9 Months Ended

Sep. 30, 2014

Variable Interest Entities

Variable Interest Entities

14. Variable Interest Entities

GAAP requires the assets, liabilities, noncontrolling interests and activities of Variable Interest Entities (“VIE”) to be consolidated if an entity’s interest in the VIE has specific characteristics including: voting rights not proportional to ownership and the right to receive a majority of expected income or absorb a majority of expected losses. In addition, the entity exposed to the majority of the risks and rewards associated with the VIE is deemed its primary beneficiary and must consolidate the entity.

UHS-EmCare JV

EmCare entered into an agreement in 2014 with Universal Health Services, Inc. to form an entity which would provide physician services to various healthcare facilities (“UHS-EmCare JV”).  UHS-EmCare JV began providing services to healthcare facilities during the second quarter of 2014 and meets the definition of a VIE.  The Company determined that, although EmCare holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

· EmCare provides management services to UHS-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of UHS-EmCare JV’s activities involve EmCare; and

· as payment for management services, EmCare is entitled to receive a base management fee from UHS-EmCare JV.

The following table summarizes the UHS-EmCare JV assets and liabilities as of September 30, 2014, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,
	2014
Current assets	$	18,021
Current liabilities	8,773

HCA-EmCare JV

EmCare entered into an agreement in 2011 with an indirect wholly-owned subsidiary of HCA Holdings Inc. to form an entity which would provide physician services to various healthcare facilities (“HCA-EmCare JV”). HCA-EmCare JV began providing services to healthcare facilities during the first quarter of 2012 and meets the definition of a VIE. The Company determined that, although EmCare only holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

· EmCare provides management services to HCA-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of HCA-EmCare JV’s activities involve EmCare; and

· as payment for management services, EmCare is entitled to receive a base management fee from HCA-EmCare JV as well as a bonus management fee.

The following table summarizes the HCA-EmCare JV assets and liabilities as of September 30, 2014 and December 31, 2013, which are included in the Company’s consolidated financial statements (in thousands):

	September 30,		December 31,
	2014		2013
Current assets	$	137,992	$	88,479
Current liabilities	31,294		22,005

XML

Restructuring Charges

9 Months Ended

Sep. 30, 2014

Restructuring Charges

Restructuring Charges

10. Restructuring Charges

The Company recorded restructuring charges of $0.4 million and $4.9 million during the three and nine months ended September 30, 2014, respectively, and $1.3 million and $5.0 million during the three and nine months ended September 30, 2013, respectively, related primarily to continuing efforts to re-align AMR’s operations and billing functions.  Payments currently under this plan are expected to be complete by March 2015.

	AMR
	Lease and
	other contract
	termination						EmCare			EVHC
	costs			Severance			Severance			Severance			Total
							(in thousands)
Balance as of January 1, 2013	$	8,122		$	3,015		$	773		$	408		$	12,318
Incurred	1,876			2,890			913			20			5,699
Paid	(6,989		)	(3,765		)	(1,204		)	(377		)	(12,335		)
Balance as of December 31, 2013	$	3,009		$	2,140		$	482		$	51		$	5,682
Incurred	3,265			512			729			400			4,906
Paid	(1,712		)	(1,296		)	(929		)	(451		)	(4,388		)
Balance as of September 30, 2014	$	4,562		$	1,356		$	282		$	—		$	6,200

XML

Consolidating Financial Information (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 247,170	$ 204,712	$ 575,761	$ 57,832
Insurance collateral	27,899	29,619
Trade and other accounts receivable, net	913,413	801,146
Parts and supplies inventory	23,983	23,376
Prepaids and other current assets	51,950	23,430
Total current assets	1,264,415	1,082,283
Property, plant, and equipment, net	203,405	194,715
Intangible assets, net	543,226	513,698
Insurance collateral	8,663	12,716
Goodwill	2,536,156	2,435,670
Other long-term assets	38,629	60,935
Total assets	4,594,494	4,300,017
Current liabilities:
Accounts payable	52,072	52,588
Accrued liabilities	413,685	350,936
Current deferred tax liabilities	36,383	35,487
Current portion of long-term debt and capital lease obligations	12,235	12,318
Total current liabilities	514,375	451,329
Long-term debt and capital lease obligations	2,029,095	1,895,381
Long-term deferred tax liabilities	151,225	151,130
Insurance reserves	167,628	175,427
Other long-term liabilities	16,707	16,997
Total liabilities	2,879,030	2,690,264
Equity:
Common stock	1,834	1,804
Additional paid-in capital	1,609,244	1,575,417
Retained earnings	93,950	18,341
Accumulated other comprehensive income (loss)	(1,611)	(839)		(213)
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723
Noncontrolling interest	12,047	15,030
Total equity	1,715,464	1,609,753
Total liabilities and equity	4,594,494	4,300,017
Consolidating Adjustments
Current assets:
Prepaids and other current assets	(29,568)	(27,355)
Total current assets	(29,568)	(27,355)
Long-term deferred tax assets	(128)	(128)
Investment in wholly owned subsidiary	(1,677,128)	(1,486,129)
Total assets	(1,706,824)	(1,513,612)
Current liabilities:
Accrued liabilities	(9,256)	(7,043)
Current deferred tax liabilities	(20,312)	(20,312)
Total current liabilities	(29,568)	(27,355)
Long-term deferred tax liabilities	(128)	(128)
Total liabilities	(29,696)	(27,483)
Equity:
Additional paid-in capital	(1,516,383)	(1,402,861)
Retained earnings	(162,356)	(84,107)
Accumulated other comprehensive income (loss)	1,611	839
Total Envision Healthcare Holdings, Inc. equity	(1,677,128)	(1,486,129)
Total equity	(1,677,128)	(1,486,129)
Total liabilities and equity	(1,706,824)	(1,513,612)
EVHC (excluding Corporation)
Current assets:
Cash and cash equivalents	5	81,722	481,722	281
EVHC (excluding Corporation) | Reportable legal entity
Current assets:
Cash and cash equivalents	5	81,722
Prepaids and other current assets	27,273	26,860
Total current assets	27,278	108,582
Long-term deferred tax assets	128	128
Investment in wholly owned subsidiary	1,677,128	1,486,129
Total assets	1,704,534	1,594,839
Current liabilities:
Accounts payable	1,117	116
Total current liabilities	1,117	116
Total liabilities	1,117	116
Equity:
Common stock	1,834	1,804
Additional paid-in capital	1,609,244	1,575,417
Retained earnings	93,950	18,341
Accumulated other comprehensive income (loss)	(1,611)	(839)
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723
Total equity	1,703,417	1,594,723
Total liabilities and equity	1,704,534	1,594,839
Corporation and Subsidiaries
Current assets:
Cash and cash equivalents	247,165	122,990	94,039	57,551
Corporation and Subsidiaries | Reportable legal entity
Current assets:
Cash and cash equivalents	247,165	122,990
Insurance collateral	27,899	29,619
Trade and other accounts receivable, net	913,413	801,146
Parts and supplies inventory	23,983	23,376
Prepaids and other current assets	54,245	23,925
Total current assets	1,266,705	1,001,056
Property, plant, and equipment, net	203,405	194,715
Intangible assets, net	543,226	513,698
Insurance collateral	8,663	12,716
Goodwill	2,536,156	2,435,670
Other long-term assets	38,629	60,935
Total assets	4,596,784	4,218,790
Current liabilities:
Accounts payable	50,955	52,472
Accrued liabilities	422,941	357,979
Current deferred tax liabilities	56,695	55,799
Current portion of long-term debt and capital lease obligations	12,235	12,318
Total current liabilities	542,826	478,568
Long-term debt and capital lease obligations	2,029,095	1,895,381
Long-term deferred tax liabilities	151,353	151,258
Insurance reserves	167,628	175,427
Other long-term liabilities	16,707	16,997
Total liabilities	2,907,609	2,717,631
Equity:
Additional paid-in capital	1,516,383	1,402,861
Retained earnings	162,356	84,107
Accumulated other comprehensive income (loss)	(1,611)	(839)
Total Envision Healthcare Holdings, Inc. equity	1,677,128	1,486,129
Noncontrolling interest	12,047	15,030
Total equity	1,689,175	1,501,159
Total liabilities and equity	$ 4,596,784	$ 4,218,790

XML

Derivative Instruments and Hedging Activities

9 Months Ended

Sep. 30, 2014

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

8. Derivative Instruments and Hedging Activities

The Company manages its exposure to changes in fuel prices and interest rates and, from time to time, uses highly effective derivative instruments to manage well-defined risk exposures. The Company monitors its positions and the credit ratings of its counterparties and does not anticipate non-performance by the counterparties. The Company does not use derivative instruments for speculative purposes.

At September 30, 2014, the Company was party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.63 to $3.76 per gallon. The Company purchases the diesel fuel at the market rate and periodically settles with its counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 0.6 million gallons, which represents approximately 25.2% of the Company’s total estimated usage during the periods hedged, through December 2014. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability and an asset associated with the fair value of the fuel hedge in the amount of less than $0.1 million and $0.7 million, respectively, as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify less than $0.1 million of deferred loss from accumulated other comprehensive income as the related fuel hedge transactions mature. Settlement of hedge agreements are included in operating expenses and resulted in net receipts from the counterparty of $0.1 million for each of the three months ended September 30, 2014 and 2013, respectively, and $0.4 million for each of the nine months ended September 30, 2014 and 2013, respectively.

In October 2011, the Company entered into interest rate swap agreements which mature on August 31, 2015. The swap agreements are with major financial institutions and effectively convert a total of $400 million in variable rate debt to fixed rate debt with an effective rate of 4.49%. The Company will continue to make interest payments based on the variable rate associated with the debt (based on LIBOR, but not less than 1.0%) and will periodically settle with its counterparties for the difference between the rate paid and the fixed rate. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability associated with the fair value of the interest rate swap in the amount of $2.0 million and $3.1 million as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify $2.0 million of deferred loss from accumulated other comprehensive income to interest expense as the related interest rate swap transactions mature. Settlement of interest rate swap agreements are included in interest expense and resulted in net payments to the counterparties of $0.5 million for each of the three months ended September 30, 2014 and 2013, respectively, and $1.5 million for each of the nine months ended September 30, 2014 and 2013, respectively.

XML

Changes in Accumulated Other Comprehensive Income (Loss) by Component

9 Months Ended

Sep. 30, 2014

Changes in Accumulated Other Comprehensive Income (Loss) by Component

Changes in Accumulated Other Comprehensive Income (Loss) by Component

9. Changes in Accumulated Other Comprehensive Income (Loss) by Component

The following table summarizes the changes in the Company’s accumulated other comprehensive income (loss) (“AOCI”) by component as of September 30, 2014 and December 31, 2013 (in thousands).  All amounts are after tax.

	Fuel hedge			Interest rate swap			Unrealized holding gains on available-for-sale securities			Total
Balance as of January 1, 2013	$	1,057		$	(2,861	)	$	1,591		(213		)
Other comprehensive income (loss) before reclassifications	(396		)	(336		)	(598		)	(1,330		)
Amounts reclassified from accumulated other comprehensive income (loss)	(241		)	1,239			(294		)	704
Net current-period other comprehensive income (loss)	(637		)	903			(892		)	(626		)
Balance as of December 31, 2013	$	420		$	(1,958	)	$	699		$	(839	)
Other comprehensive income (loss) before reclassifications	(501		)	38			(608		)	(1,071		)
Amounts reclassified from accumulated other comprehensive income (loss)	(226		)	929			(404		)	299
Net current-period other comprehensive income (loss)	(727		)	967			(1,012		)	(772		)
Balance as of September 30, 2014	$	(307	)	$	(991	)	$	(313	)	$	(1,611	)

The following table shows the line item on the statements of operations affected by reclassifications out of AOCI (in thousands):

	Amount reclassified from AOCI
	Three months endedSeptember 30,						Nine months endedSeptember 30,
Details about AOCI components	2014			2013			2014			2013			Statements of Operations
Gains and losses on cash flow hedges:
Fuel Hedge	$	86		$	106		$	362		$	326		Operating expenses
Interest rate swap	(496		)	(502		)	(1,489		)	(1,489		)	Interest expense, net
	(410		)	(396		)	(1,127		)	(1,163		)	Total before tax
	153			149			424			437			Tax benefit (expense)
	$	(257	)	$	(247	)	$	(703	)	$	(726	)	Net of tax
Unrealized holding gains on available-for-sale securities	$	(466	)	$	158		$	648		$	276		Realized gains (losses) on investments
	(466		)	158			648			276			Total before tax
	176			(59		)	(244		)	(104		)	Tax benefit (expense)
	$	(290	)	$	99		$	404		$	172		Net of tax

XML

Equity Based Compensation

9 Months Ended

Sep. 30, 2014

Equity Based Compensation

Equity Based Compensation

11. Equity Based Compensation

Upon completion of the Company’s initial public offering, the previous stock compensation plan (“Stock Compensation Plan”) terminated and the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (“Omnibus Incentive Plan”) was adopted pursuant to which options and awards with respect to a total of 16,708,289 shares of Common Stock are available for grant. As of September 30, 2014, a total of 16,539,527 shares remained available for grant under the Omnibus Incentive Plan. Awards under the Omnibus Incentive Plan include both performance and non-performance based awards. As of September 30, 2014, no grants of performance based awards under the Omnibus Incentive Plan had been made. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. No participant may be granted in any calendar year awards covering more than 2.5 million shares of Common Stock or 1.5 million performance awards up to a maximum dollar value of $5.0 million. Non-performance based awards have time-based vesting and performance-based awards vest upon achievement of certain company-wide objectives. All options have 10 year terms.

Awards previously granted under the Stock Compensation Plan were unaffected by the termination of the Stock Compensation Plan; however no future grants will be made under the Stock Compensation Plan.

A compensation charge of $1.1 million and $1.1 million was recorded for the three months ended September 30, 2014 and 2013, respectively, and $3.6 million and $3.2 million was recorded for the nine months ended September 30, 2014 and 2013, respectively.

XML

General (Details) (USD $)	0 Months Ended				9 Months Ended
	Sep. 23, 2014	Jul. 10, 2014	Feb. 05, 2014	Jul. 29, 2013	Sep. 30, 2014 item	Dec. 31, 2013	Aug. 13, 2013
Basis of Presentation of Financial Statements
Stock split ratio				9.3
Shares of common stock issued				132,082,885
Treasury shares issued				504,197
Common stock, par value (in dollars per share)					$ 0.01	$ 0.01	$ 0.01
Shares of common stock issued	17,500,000	31,625,000	31,625,000
Public offering price (in dollars per share)	$ 34.97	$ 34.00	$ 30.50
Number of operating subsidiaries					2

XML

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Changes in the company's AOCI by component, after tax
Balance at the beginning of the period			$ (839)	$ (213)	$ (213)
Other comprehensive income (loss) before reclassifications			(1,071)		(1,330)
Amounts reclassified from accumulated other comprehensive income (loss)			299		704
Total other comprehensive income (loss), net of tax	(384)	103	(772)	(624)	(626)
Balance at the end of the period	(1,611)		(1,611)		(839)
Unrealized holding gains on available-for-sale securities
Changes in the company's AOCI by component, after tax
Balance at the beginning of the period			699	1,591	1,591
Other comprehensive income (loss) before reclassifications			(608)		(598)
Amounts reclassified from accumulated other comprehensive income (loss)			(404)		(294)
Total other comprehensive income (loss), net of tax			(1,012)		(892)
Balance at the end of the period	(313)		(313)		699
Fuel hedge | Gains and losses on cash flow hedges
Changes in the company's AOCI by component, after tax
Balance at the beginning of the period			420	1,057	1,057
Other comprehensive income (loss) before reclassifications			(501)		(396)
Amounts reclassified from accumulated other comprehensive income (loss)			(226)		(241)
Total other comprehensive income (loss), net of tax			(727)		(637)
Balance at the end of the period	(307)		(307)		420
Interest rate swap | Gains and losses on cash flow hedges
Changes in the company's AOCI by component, after tax
Balance at the beginning of the period			(1,958)	(2,861)	(2,861)
Other comprehensive income (loss) before reclassifications			38		(336)
Amounts reclassified from accumulated other comprehensive income (loss)			929		1,239
Total other comprehensive income (loss), net of tax			967		903
Balance at the end of the period	$ (991)		$ (991)		$ (1,958)

XML

Consolidating Financial Information

9 Months Ended

Sep. 30, 2014

Consolidating Financial Information

Consolidating Financial Information

16. Consolidating Financial Information

Pursuant to the indenture governing the 2022 Notes, so long as any of the 2022 Notes are outstanding, the Company is required to provide condensed consolidating financial information with a separate column for (i) the Company and its subsidiaries (other than Corporation and its subsidiaries) on a combined basis, (ii) Corporation and its subsidiaries, (iii) consolidating adjustments on a combined basis, and (iv) the total consolidated amount. The consolidating adjustments column represents the elimination of any intercompany activity between EVHC (excluding Corporation and its subsidiaries) and Corporation.

Consolidating Balance Sheet

As of September 30, 2014

(in thousands, unaudited)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	5		$	247,165		$	—		$	247,170
Insurance collateral	—			27,899			—			27,899
Trade and other accounts receivable, net	—			913,413			—			913,413
Parts and supplies inventory	—			23,983			—			23,983
Prepaids and other current assets	27,273			54,245			(29,568		)	51,950
Total current assets	27,278			1,266,705			(29,568		)	1,264,415
Property, plant, and equipment, net	—			203,405			—			203,405
Intangible assets, net	—			543,226			—			543,226
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			8,663			—			8,663
Goodwill	—			2,536,156			—			2,536,156
Other long-term assets	—			38,629			—			38,629
Investment in wholly owned subsidiary	1,677,128			—			(1,677,128		)	—
Total assets	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494
Liabilities and Equity
Current liabilities:
Accounts payable	$	1,117		$	50,955		$	—		52,072
Accrued liabilities	—			422,941			(9,256		)	413,685
Current deferred tax liabilities	—			56,695			(20,312		)	36,383
Current portion of long-term debt and capital lease obligations	—			12,235			—			12,235
Total current liabilities	1,117			542,826			(29,568		)	514,375
Long-term debt and capital lease obligations	—			2,029,095			—			2,029,095
Long-term deferred tax liabilities	—			151,353			(128		)	151,225
Insurance reserves	—			167,628			—			167,628
Other long-term liabilities	—			16,707			—			16,707
Total liabilities	1,117			2,907,609			(29,696		)	2,879,030
Equity:
Common stock	1,834			—			—			1,834
Preferred stock	—			—			—			—
Additional paid-in capital	1,609,244			1,516,383			(1,516,383		)	1,609,244
Retained earnings	93,950			162,356			(162,356		)	93,950
Accumulated other comprehensive loss	(1,611		)	(1,611		)	1,611			(1,611		)
Total Envision Healthcare Holdings, Inc. equity	1,703,417			1,677,128			(1,677,128		)	1,703,417
Noncontrolling interest	—			12,047			—			12,047
Total equity	1,703,417			1,689,175			(1,677,128		)	1,715,464
Total liabilities and equity	$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494

Consolidating Balance Sheet

As of December 31, 2013

(in thousands)

	EVHC (excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Assets
Current assets:
Cash and cash equivalents	$	81,722		$	122,990		—			$	204,712
Insurance collateral	—			29,619			—			29,619
Trade and other accounts receivable, net	—			801,146			—			801,146
Parts and supplies inventory	—			23,376			—			23,376
Prepaids and other current assets	26,860			23,925			(27,355		)	23,430
Total current assets	108,582			1,001,056			(27,355		)	1,082,283
Property, plant, and equipment, net	—			194,715			—			194,715
Intangible assets, net	—			513,698			—			513,698
Long-term deferred tax assets	128			—			(128		)	—
Insurance collateral	—			12,716			—			12,716
Goodwill	—			2,435,670			—			2,435,670
Other long-term assets	—			60,935			—			60,935
Investment in wholly owned subsidiary	1,486,129			—			(1,486,129		)	—
Total assets	$	1,594,839		$	4,218,790		(1,513,612		)	$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable	$	116		$	52,472		—			$	52,588
Accrued liabilities	—			357,979			(7,043		)	350,936
Current deferred tax liabilities	—			55,799			(20,312		)	35,487
Current portion of long-term debt and capital lease obligations	—			12,318			—			12,318
Total current liabilities	116			478,568			(27,355		)	451,329
Long-term debt and capital lease obligations	—			1,895,381			—			1,895,381
Long-term deferred tax liabilities	—			151,258			(128		)	151,130
Insurance reserves	—			175,427			—			175,427
Other long-term liabilities	—			16,997			—			16,997
Total liabilities	116			2,717,631			(27,483		)	2,690,264
Equity:
Common stock	1,804			—			—			1,804
Preferred stock	—			—			—			—
Additional paid-in capital	1,575,417			1,402,861			(1,402,861		)	1,575,417
Retained earnings	18,341			84,107			(84,107		)	18,341
Accumulated other comprehensive loss	(839		)	(839		)	839			(839		)
Total Envision Healthcare Holdings, Inc. equity	1,594,723			1,486,129			(1,486,129		)	1,594,723
Noncontrolling interest	—			15,030			—			15,030
Total equity	1,594,723			1,501,159			(1,486,129		)	1,609,753
Total liabilities and equity	$	1,594,839		$	4,218,790		$	(1,513,612	)	$	4,300,017

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2014
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	1,150,329		$	—		$	1,150,329
Compensation and benefits	—			819,353			—			819,353
Operating expenses	—			129,535			—			129,535
Insurance expense	—			27,527			—			27,527
Selling, general and administrative expenses	—			22,851			—			22,851
Depreciation and amortization expense	—			36,796			—			36,796
Restructuring charges	—			366			—			366
Income (loss) from operations	—			113,901			—			113,901
Interest income from restricted assets	—			175			—			175
Interest expense, net	—			(25,742		)	—			(25,742		)
Realized gains (losses) on investments	—			(466		)	—			(466		)
Other income (expense), net	(1,433		)	773			—			(660		)
Loss on early debt extinguishment	—			—			—			—
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(1,433		)	88,641			—			87,208
Income tax benefit (expense)	697			(35,134		)	—			(34,437		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(736		)	53,507			—			52,771
Equity in net income (loss) of subsidiary	53,512			—			(53,512		)	—
Equity in earnings of unconsolidated subsidiary	—			72			—			72
Net income (loss)	52,776			53,579			(53,512		)	52,843
Less: Net (income) loss attributable to noncontrolling interest	—			(67		)	—			(67		)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776		$	53,512		$	(53,512	)	$	52,776

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Three months ended September 30, 2013
	EVHC(excluding Corporation)			Corporationand Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	955,888		$	—		$	955,888
Compensation and benefits	—			677,797			—			677,797
Operating expenses	(17		)	110,404			—			110,387
Insurance expense	—			26,974			—			26,974
Selling, general and administrative expenses	2			40,731			—			40,733
Depreciation and amortization expense	—			35,175			—			35,175
Restructuring charges	—			1,319			—			1,319
Income from operations	15			63,488			—			63,503
Interest income from restricted assets	—			2			—			2
Interest expense, net	(7,641		)	(39,131		)	—			(46,772		)
Realized gains (losses) on investments	—			158			—			158
Other income (expense), net	—			(52		)	—			(52		)
Loss on early debt extinguishment	(29,519		)	—			—			(29,519		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(37,145		)	24,465			—			(12,680		)
Income tax benefit (expense)	14,765			(9,816		)	—			4,949
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(22,380		)	14,649			—			(7,731		)
Equity in net income (loss) of subsidiary	14,717			—			(14,717		)	—
Equity in earnings of unconsolidated subsidiary	—			68			—			68
Net income (loss)	(7,663		)	14,717			(14,717		)	(7,663		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(7,663	)	$	14,717		$	(14,717	)	$	(7,663	)

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	3,239,867		$	—		$	3,239,867
Compensation and benefits	—			2,330,021			—			2,330,021
Operating expenses	—			364,885			—			364,885
Insurance expense	—			90,091			—			90,091
Selling, general and administrative expenses	—			65,820			—			65,820
Depreciation and amortization expense	—			108,786			—			108,786
Restructuring charges	—			4,906			—			4,906
Income from operations	—			275,358			—			275,358
Interest income from restricted assets	—			507			—			507
Interest expense, net	—			(84,793		)	—			(84,793		)
Realized gains (losses) on investments	—			648			—			648
Other income (expense), net	(4,232		)	800			—			(3,432		)
Loss on early debt extinguishment	—			(66,397		)	—			(66,397		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(4,232		)	126,123			—			121,891
Income tax benefit (expense)	1,592			(51,292		)	—			(49,700		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(2,640		)	74,831			—			72,191
Equity in net income (loss) of subsidiary	78,249			—			(78,249		)	—
Equity in earnings of unconsolidated subsidiary	—			185			—			185
Net income (loss)	75,609			75,016			(78,249		)	72,376
Less: Net (income) loss attributable to noncontrolling interest	—			3,233			—			3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	75,609		$	78,249		$	(78,249	)	$	75,609

Condensed Consolidating Statements of Operations

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Consolidating Adjustments			Total
Net revenue	$	—		$	2,743,467		$	—		$	2,743,467
Compensation and benefits	—			1,963,546			—			1,963,546
Operating expenses	70			313,075			—			313,145
Insurance expense	—			78,647			—			78,647
Selling, general and administrative expenses	3			86,518			—			86,521
Depreciation and amortization expense	—			104,552			—			104,552
Restructuring charges	—			4,988			—			4,988
Income from operations	(73		)	192,141			—			192,068
Interest income from restricted assets	—			634			—			634
Interest expense, net	(30,567		)	(117,959		)	—			(148,526		)
Realized gains (losses) on investments	—			276			—			276
Other income (expense), net	—			(13,022		)	—			(13,022		)
Loss on early debt extinguishment	(29,519		)	(122		)	—			(29,641		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary	(60,159		)	61,948			—			1,789
Income tax benefit (expense)	23,850			(27,782		)	—			(3,932		)
Income before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary	(36,309		)	34,166			—			(2,143		)
Equity in net income (loss) of subsidiary	34,396			—			(34,396		)	—
Equity in earnings of unconsolidated subsidiary	—			230			—			230
Net income (loss)	(1,913		)	34,396			(34,396		)	(1,913		)
Less: Net (income) loss attributable to noncontrolling interest	—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	(1,913	)	$	34,396		$	(34,396	)	$	(1,913	)

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2014
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(859	)	$	194,863		$	194,004
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(52,654		)	(52,654		)
Sales and maturities of available-for-sale securities	—			40,425			40,425
Purchase of property, plant and equipment	—			(55,659		)	(55,659		)
Proceeds from sale of property, plant and equipment	—			2,299			2,299
Acquisition of businesses, net of cash received	—			(199,261		)	(199,261		)
Net change in insurance collateral	—			2,021			2,021
Other investing activities	—			(1,774		)	(1,774		)
Net cash provided by (used in) investing activities	—			(264,603		)	(264,603		)
Cash Flows from Financing Activities
Borrowings under the ABL Facility	—			50,000			50,000
Proceeds from issuance of senior notes	—			740,625			740,625
Repayments of the Term Loan	—			(6,686		)	(6,686		)
Repayments of the ABL Facility	—			(50,000		)	(50,000		)
Repayments of PIK Notes and senior notes	—			(607,750		)	(607,750		)
Payment for debt extinguishment premiums	—			(37,630		)	(37,630		)
Debt issuance costs	—			(2,221		)	(2,221		)
Proceeds from stock options exercised	—			7,405			7,405
Excess tax benefits from equity-based compensation	—			38,520			38,520
Shares repurchased for tax withholdings	—			(14,430		)	(14,430		)
Proceeds from noncontrolling interest	—			250			250
Other financing activities	859			(5,885		)	(5,026		)
Net intercompany borrowings (payments)	(81,717		)	81,717			—
Net cash provided by (used in) financing activities	(80,858		)	193,915			113,057
Change in cash and cash equivalents	(81,717		)	124,175			42,458
Cash and cash equivalents, beginning of period	81,722			122,990			204,712
Cash and cash equivalents, end of period	$	5		$	247,165		$	247,170

Condensed Consolidating Statement of Cash Flows

(in thousands, unaudited)

	Nine months ended September 30, 2013
	EVHC(excluding Corporation)			Corporation and Subsidiaries			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities	$	(38,375	)	$	64,000		$	25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities	—			(2,615		)	(2,615		)
Sales and maturities of available-for-sale securities	—			7,616			7,616
Purchase of property, plant and equipment	—			(45,493		)	(45,493		)
Proceeds from sale of property, plant and equipment	—			396			396
Acquisition of businesses, net of cash received	—			(27,358		)	(27,358		)
Net change in insurance collateral	—			(2,121		)	(2,121		)
Other investing activities	—			(456		)	(456		)
Net cash provided by (used in) investing activities	—			(70,031		)	(70,031		)
Cash Flows from Financing Activities
Issuance of common stock	1,110,900			1,117			1,112,017
Borrowings under the Term Loan	—			150,000			150,000
Borrowings under the ABL Facility	—			345,440			345,440
Repayments of the Term Loan	—			(10,028		)	(10,028		)
Repayments of the ABL Facility	—			(470,440		)	(470,440		)
Repayments of PIK Notes and senior notes	(450,000		)	—			(450,000		)
Payment for debt extinguishment premiums	(12,386		)	—			(12,386		)
Dividend paid	20,813			(20,813		)	—
Debt issuance costs	(4		)	(5,007		)	(5,011		)
Equity issuance costs	(63,420		)	—			(63,420		)
Excess tax benefits from equity-based compensation	—			3,168			3,168
Payment of dissenting shareholder settlement	—			(38,336		)	(38,336		)
Net change in bank overdrafts	—			1,686			1,686
Other financing activities	—			(355		)	(355		)
Net intercompany borrowings (payments)	(86,087		)	86,087			—
Net cash provided by (used in) financing activities	519,816			42,519			562,335
Change in cash and cash equivalents	481,441			36,488			517,929
Cash and cash equivalents, beginning of period	281			57,551			57,832
Cash and cash equivalents, end of period	$	481,722		$	94,039		$	575,761

XML

Insurance Collateral (Tables)

9 Months Ended

Sep. 30, 2014

Insurance Collateral

Schedule of insurance collateral

Insurance collateral consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Available-for-sale securities:
U.S. Treasuries	$	1,198	$	2,100
Corporate bonds /Fixed income	8,426		6,372
Corporate equity	15,374		4,755
Total available-for-sale securities	24,998		13,227
Insurance receivable	1,796		1,300
Cash deposits and other	9,768		27,808
Total insurance collateral	$	36,562	$	42,335

Schedule of amortized cost basis and aggregate fair value of the entity's available-for-sale securities

Amortized cost basis and aggregate fair value of the Company’s available-for-sale securities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	1,191	$	10	$	(3	)	$	1,198
Corporate bonds /Fixed income	8,439		3		(16		)	8,426
Corporate equity	15,982		—		(608		)	15,374
Total available-for-sale securities	$	25,612	$	13	$	(627	)	$	24,998

	December 31, 2013
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	2,064	$	37	$	(1	)	$	2,100
Corporate bonds /Fixed income	6,384		26		(38		)	6,372
Corporate equity	4,399		500		(144		)	4,755
Total available-for-sale securities	$	12,847	$	563	$	(183	)	$	13,227

Schedule of the entity's temporarily impaired investment securities available-for-sale

The Company’s temporarily impaired investment securities available-for-sale as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014					December 31, 2013
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
U.S. Treasuries:
Less than 12 months	$	—	$	—		$	132	$	(1	)
12 months or more	132		(3		)	—		—
Corporate bonds /Fixed income:
Less than 12 months	6,531		(13		)	2,768		(18		)
12 months or more	1,335		(3		)	2,178		(20		)
Corporate equity:
Less than 12 months	15,374		(608		)	—		—
12 months or more	—		—			2,553		(144		)
Total	$	23,372	$	(627	)	$	7,631	$	(183	)

XML

Debt and Capital Lease Obligations (Details 3) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Long-Term Debt
Total debt	$ 2,041,330	$ 1,907,699
Less current portion	(12,235)	(12,318)
Total long-term debt and capital lease obligations	2,029,095	1,895,381
Senior unsecured notes due 2019
Long-Term Debt
Total debt		607,750
Senior unsecured notes due 2022
Long-Term Debt
Total debt	750,000
Senior secured term loan due 2018
Long-Term Debt
Total debt	1,292,917	1,302,945
Discount on debt	(3,567)	(4,217)
Interest rate (as a percent)	4.00%	4.00%
Notes due at various dates from 2014 to 2022
Long-Term Debt
Total debt	731	852
Interest rate, minimum (as a percent)	6.00%	6.00%
Interest rate, maximum (as a percent)	10.00%	10.00%
Capital lease obligations due at various dates from 2014 to 2018
Long-Term Debt
Total debt	$ 1,249	$ 369

XML

Summary of Significant Accounting Policies (Details 7) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue Recognition
Fee-for-service revenue, net of contractual discounts:	$ 1,800,841,000	$ 1,519,727,000	$ 5,247,500,000	$ 4,539,582,000
Subsidies and fees	189,116,000	171,481,000	554,653,000	446,679,000
Revenue, net of contractual discounts	1,989,957,000	1,691,208,000	5,802,153,000	4,986,261,000
Provision for uncompensated care	(839,628,000)	(735,320,000)	(2,562,286,000)	(2,242,794,000)
Net revenue	1,150,329,000	955,888,000	3,239,867,000	2,743,467,000
Revenue Recognition
(Increase) decrease in contractual discount or uncompensated care provisions	1,100,000	1,100,000	(2,700,000)	200,000
Medicare
Revenue Recognition
Fee-for-service revenue, net of contractual discounts:	265,300,000	231,517,000	816,040,000	732,153,000
Medicaid
Revenue Recognition
Fee-for-service revenue, net of contractual discounts:	70,343,000	52,089,000	236,784,000	196,952,000
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)
Revenue Recognition
Fee-for-service revenue, net of contractual discounts:	736,600,000	591,980,000	1,989,350,000	1,649,307,000
Self-pay
Revenue Recognition
Fee-for-service revenue, net of contractual discounts:	$ 728,598,000	$ 644,141,000	$ 2,205,326,000	$ 1,961,170,000
Minimum | Self-pay
Revenue Recognition
Treatment period			30 days
Bills and notifications period			90 days
Maximum | Self-pay
Revenue Recognition
Treatment period			60 days
Bills and notifications period			120 days

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities
Net income (loss)	$ 72,376	$ (1,913)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	116,133	118,683
(Gain) loss on disposal of property, plant and equipment	(2,094)	(55)
Equity-based compensation expense	3,612	3,186
Excess tax benefits from equity-based compensation	(38,520)	(3,168)
Loss on early debt extinguishment	66,397	29,641
Equity in earnings of unconsolidated subsidiary	(185)	(230)
Dividends received	430	556
Deferred income taxes	1,456	4,319
Payment of dissenting shareholder settlement		(13,717)
Changes in operating assets/liabilities, net of acquisitions:
Trade and other accounts receivable, net	(92,537)	(126,506)
Parts and supplies inventory	(574)	(489)
Prepaids and other current assets	(10,959)	(8,997)
Accounts payable and accrued liabilities	85,008	22,520
Insurance accruals	(6,539)	1,795
Net cash provided by (used in) operating activities	194,004	25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities	(52,654)	(2,615)
Sales and maturities of available-for-sale securities	40,425	7,616
Purchases of property, plant and equipment	(55,659)	(45,493)
Proceeds from sale of property, plant and equipment	2,299	396
Acquisition of businesses, net of cash received	(199,261)	(27,358)
Net change in insurance collateral	2,021	(2,121)
Other investing activities	(1,774)	(456)
Net cash provided by (used in) investing activities	(264,603)	(70,031)
Cash Flows from Financing Activities
Issuance of common stock		1,112,017
Borrowings under the Term Loan		150,000
Borrowings under the ABL Facility	50,000	345,440
Proceeds from issuance of senior notes	740,625
Repayments of the Term Loan	(6,686)	(10,028)
Repayments of the ABL Facility	(50,000)	(470,440)
Repayments of PIK Notes and senior notes	(607,750)	(450,000)
Payment for debt extinguishment premiums	(37,630)	(12,386)
Debt issuance costs	(2,221)	(5,011)
Equity issuance costs		(63,420)
Proceeds from stock options exercised	7,405
Excess tax benefits from equity-based compensation	38,520	3,168
Shares repurchased for tax withholdings	(14,430)
Proceeds from noncontrolling interest	250
Payment of dissenting shareholder settlement		(38,336)
Net change in bank overdrafts		1,686
Other financing activities	(5,026)	(355)
Net cash provided by (used in) financing activities	113,057	562,335
Change in cash and cash equivalents	42,458	517,929
Cash and cash equivalents, beginning of period	204,712	57,832
Cash and cash equivalents, end of period	$ 247,170	$ 575,761

XML

Insurance Collateral

9 Months Ended

Sep. 30, 2014

Insurance Collateral

Insurance Collateral

5. Insurance Collateral

Insurance collateral consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Available-for-sale securities:
U.S. Treasuries	$	1,198	$	2,100
Corporate bonds /Fixed income	8,426		6,372
Corporate equity	15,374		4,755
Total available-for-sale securities	24,998		13,227
Insurance receivable	1,796		1,300
Cash deposits and other	9,768		27,808
Total insurance collateral	$	36,562	$	42,335

Amortized cost basis and aggregate fair value of the Company’s available-for-sale securities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	1,191	$	10	$	(3	)	$	1,198
Corporate bonds /Fixed income	8,439		3		(16		)	8,426
Corporate equity	15,982		—		(608		)	15,374
Total available-for-sale securities	$	25,612	$	13	$	(627	)	$	24,998

	December 31, 2013
Description	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
U.S. Treasuries	$	2,064	$	37	$	(1	)	$	2,100
Corporate bonds /Fixed income	6,384		26		(38		)	6,372
Corporate equity	4,399		500		(144		)	4,755
Total available-for-sale securities	$	12,847	$	563	$	(183	)	$	13,227

As of September 30, 2014, available-for-sale securities included U.S. Treasuries and corporate bonds /fixed income securities of $1.7 million with contractual maturities within one year, $7.4 million with contractual maturities extending longer than one year through five years and $0.5 million with contractual maturities extending longer than five years through and including ten years. Actual maturities may differ from contractual maturities as a result of the Company’s ability to sell these securities prior to maturity.

The Company’s temporarily impaired investment securities available-for-sale as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

	September 30, 2014					December 31, 2013
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
U.S. Treasuries:
Less than 12 months	$	—	$	—		$	132	$	(1	)
12 months or more	132		(3		)	—		—
Corporate bonds /Fixed income:
Less than 12 months	6,531		(13		)	2,768		(18		)
12 months or more	1,335		(3		)	2,178		(20		)
Corporate equity:
Less than 12 months	15,374		(608		)	—		—
12 months or more	—		—			2,553		(144		)
Total	$	23,372	$	(627	)	$	7,631	$	(183	)

The Company evaluates the investment securities available-for-sale on a quarterly basis to determine whether declines in the fair value of these securities are other-than-temporary.  This quarterly evaluation consists of reviewing the fair value of the security compared to the carrying amount, the historical volatility of the price of each security, and any industry and company specific factors related to each security.

The Company is not aware of any specific factors indicating that the underlying issuers of the U.S. Treasuries and corporate bonds /fixed income securities would not be able to pay interest as it becomes due or repay the principal amount at maturity.  Therefore, the Company believes that the changes in the estimated fair values of these debt securities are related to temporary market fluctuations.  Additionally, the Company is not aware of any specific factors which indicate the unrealized losses on the investments in corporate equity securities are due to anything other than temporary market fluctuations.

The Company realized net losses of $0.5 million and net gains of $0.6 million on the sale and maturities of available-for-sale securities for the three and nine months ended September 30, 2014, respectively, and net gains of $0.2 million and $0.3 million on the sale and maturities of available-for-sale securities for both the three and nine months ended September 30, 2013, respectively.

XML

Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 item	Sep. 30, 2013
Segment Information
Number of separately managed business units			2
Segment Information
Net revenue	$ 1,150,329	$ 955,888	$ 3,239,867	$ 2,743,467
Income from operations	113,901	63,503	275,358	192,068
Adjusted EBITDA	152,233	121,670	396,402	328,537
Segment
Segment Information
Net revenue	1,150,329	955,888	3,239,867	2,743,467
Income from operations	113,901	63,488	275,358	192,141
Adjusted EBITDA	152,233	121,655	396,402	328,610
Segment | Facility-Based Physician Services
Segment Information
Net revenue	748,080	605,105	2,082,661	1,729,158
Income from operations	81,246	55,706	201,325	156,802
Adjusted EBITDA	99,726	82,032	258,179	218,767
Segment | Healthcare Transportation Services
Segment Information
Net revenue	402,249	350,783	1,157,206	1,014,309
Income from operations	32,655	7,782	74,033	35,339
Adjusted EBITDA	$ 52,507	$ 39,623	$ 138,223	$ 109,843

XML

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2014

Accrued Liabilities

Schedule of accrued liabilities

Accrued liabilities were as follows as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30,		December 31,
	2014		2013
Accrued wages and benefits	$	186,983	$	161,398
Accrued paid time-off	30,115		25,713
Current portion of self-insurance reserves	73,719		73,738
Accrued restructuring	6,200		5,682
Current portion of compliance and legal	3,928		2,000
Accrued billing and collection fees	3,057		2,954
Accrued incentive compensation	33,297		19,570
Accrued income taxes	8,015		—
Accrued interest	12,812		6,898
Other	55,559		52,983
Total accrued liabilities	$	413,685	$	350,936

XML

Summary of Significant Accounting Policies (Details 4) (Net revenue, Customer concentration risk)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Medicare and Medicaid
Concentration of Credit Risk
Percentage of concentration risk	31.00%	28.00%
Insurance providers and contracted payors
Concentration of Credit Risk
Percentage of concentration risk	66.00%	68.00%
Patients
Concentration of Credit Risk
Percentage of concentration risk	3.00%	4.00%

XML

Segment Information

9 Months Ended

Sep. 30, 2014

Segment Information

Segment Information

15. Segment Information

The Company is organized around two separately managed business units: facility-based and post-acute care physician services and healthcare transportation services, which have been identified as operating segments. The facility-based and post-acute care physician services reportable segment provides physician services to hospitals primarily for emergency department, anesthesiology, hospitalist/inpatient, radiology, teleradiology and surgery services. It also offers physician-led care management solutions outside the hospital. The healthcare transportation services reportable segment focuses on providing a full range of medical transportation services from basic patient transit to the most advanced emergency care and pre-hospital assistance. The Chief Executive Officer has been identified as the chief operating decision maker (the “CODM”) as he assesses the performance of the business units and decides how to allocate resources to the business units.

Net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, related party management fees, restructuring charges, and depreciation and amortization expense (“Adjusted EBITDA”) is the measure of profit and loss that the CODM uses to assess performance and make decisions. Adjusted EBITDA is not considered a measure of financial performance under GAAP and the items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the Company’s financial statements as an indicator of financial performance. Since Adjusted EBITDA is not a measure determined to be in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Pre-tax income from continuing operations represents net revenue less direct operating expenses incurred within the operating segments. The accounting policies for reported segments are the same as for the Company as a whole (see Note 2).

The Company’s operating segment results were as follows (in thousands):

	Three months endedSeptember 30,				Nine months endedSeptember 30,
	2014		2013		2014		2013
Facility-Based Physician Services
Net revenue	$	748,080	$	605,105	$	2,082,661	$	1,729,158
Income from operations	81,246		55,706		201,325		156,802
Adjusted EBITDA	99,726		82,032		258,179		218,767
Healthcare Transportation Services
Net revenue	$	402,249	$	350,783	$	1,157,206	$	1,014,309
Income from operations	32,655		7,782		74,033		35,339
Adjusted EBITDA	52,507		39,623		138,223		109,843
Segment Totals
Net revenue	$	1,150,329	$	955,888	$	3,239,867	$	2,743,467
Income from operations	113,901		63,488		275,358		192,141
Adjusted EBITDA	152,233		121,655		396,402		328,610

A reconciliation of net income (loss) to Adjusted EBITDA (in thousands):

	Three months endedSeptember 30,						Nine months endedSeptember 30,
	2014			2013			2014			2013
Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
Add-back of non-operating expense (income):
Interest expense, net	25,742			46,772			84,793			148,526
Income tax expense (benefit)	34,437			(4,949		)	49,700			3,932
Loss on early debt extinguishment	—			29,519			66,397			29,641
Realized losses (gains) on investments	466			(158		)	(648		)	(276		)
Interest income from restricted assets	(175		)	(2		)	(507		)	(634		)
Equity in earnings of unconsolidated subsidiary	(72		)	(68		)	(185		)	(230		)
Other expense (income), net	660			52			3,432			13,022
Corporate operating expense	—			(15		)	—			73
Income from operations — segment totals	113,901			63,488			275,358			192,141
Add-back of operating expense (income):
Depreciation and amortization expense	36,796			35,175			108,786			104,552
Restructuring charges	366			1,319			4,906			4,988
Net loss (income) attributable to noncontrolling interest	(67		)	—			3,233			—
Interest income from restricted assets	175			2			507			634
Equity-based compensation expense	1,062			1,062			3,612			3,186
Related party management fees	—			20,609			—			23,109
Adjusted EBITDA — segment totals	152,233			121,655			396,402			328,610
Corporate operating expense	—			15			—			(73		)
Adjusted EBITDA	$	152,233		$	121,670		$	396,402		$	328,537